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AGM: Aorto-Gonado-Mesonephron  
ANG: Angiopoietin 
Angpt2: Angiopoietin2 
APC: Antigen Presenting Cells 
Arg1: Arginase1 
B220: Leukocyte common antigen (CD45) receptor 
CCR: C-C chemokine Receptor 
CD: Cluster of differentiation 
CD3ε: CD3g Molecule, Gamma (CD3-TCR Complex) 
CD11b: Mac-1 α (integrin αM chain) 
CD11c: Integrin, alpha X (complement component 3 receptor 4 subunit) 
CD45: Leukocyte common antigen 
CD16/CD32: Fc gamma RII/RIII 
CD31: Platelet endothelial cell adhesion molecule (PECAM-1) 
CD64: Fc Fragment of IgG, high affinity Ia, receptor 
CD68: Macrosialin / Scavenger Receptor Class D 
CD163: Hemoglobin Scavenger Receptor 
CDH5: Cadherin 5 
CMP: Common Myeloid Progenitor 
COX2: Cyclooxygenase 2 
CRMs: Cardiac Resident Macrophages 
CSF-1: Colony-Stimulating Factor 1 (MCSF) 
CSF-1R: Colony Stimulating Factor 1 Receptor 
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CX3CL1: Chemokine (C-X3-C motif) Ligand 1 (Fractalkine) 
CX3CR1: Chemokine (C-X3-C motif) Receptor 1 
DCs: Dendritic Cells 
EC: Endothelial Cell 
EGFP: Enhanced Green Fluorescent Protein 
Epas1: Endothelial PAS Domain Protein 1 (HIF2A) 
F4/80: Egf-like module containing, mucin-like, Hormone receptor-Like 1  
FACS: Fluorescence-Activated Cell Sorting 
FLT3-ligand: Fms-Like Tyrosine kinase 3 ligand 
FLT1: Vascular Endothelial Growth Factor Receptor 1 
FLT4: Vascular Endothelial Growth Factor Receptor 3 
GFP: Green Fluorescent Protein 
GM-CSF: Granulocyte Macrophage Colony-Stimulating Factor 
HBBS: Hank´s Balanced Salt Solution 
HSC: Hematopoietic Stem Cell 
Igf1: Insulin growth factor 1 
IL: Interleukin 
IBD: Inflammatory Bowel Disease 
IM: Infarto de Miocardio 
IFN𝛾: Interferon 𝛾 
IRF: Interferon Regulatory Factor 
KEGG: Kyoto Encyclopedia of Genes and Genomes  
KDR: Vascular Endothelial Growth Factor Receptor 2 (FLK1) 
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LAD: Left Anterior Descendent coronary artery 
LAD-ligation: Permanent Left Anterior Descendent coronary artery ligation 
LPS: Lipopolysaccharide 
LVEF: Left Ventricle Ejection Fraction 
Ly6C: Lymphocyte antigen 6C 
Ly6G: Lymphocyte antigen 6G 
LYVE1: Lymphatic vessel endothelial hyaluronan receptor 1 
MaFIA: Macrophage Fas-Induced Apoptosis 
MDP: Macrophage/dendritic cell progenitor 
MerTK: MER Receptor Tyrosine Kinase 
MHCII: Major Histocompatibility Complex, class II 
MI: Myocardial Infarction 
MMP13: Matrix Metallopeptidase 13 (collagenase 3) 
MPS: Macrophage mononuclear system 
MRC1: Mannose Receptor, C type 1 
MSC: Mesenchymal Stromal Cell 
NFКB: Nuclear Factor КB 
NG2: Chondroitin Sulfate Proteoglycan 4 
NO: Nitric Oxide 
NOS2: Nitric Oxide Synthetase (iNOS) 
PBS: Phosphate Buffered Saline 
PHD2: Egl-9 Family Hypoxia-Inducible Factor 1 
OCT: Optimum Cutting temperature 
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PFA: Paraformaldehyde 
Pparg: Peroxisome proliferator-activated receptor gamma 
PT MP: Peritoneal macrophages 
Q-PCR (RT-qPCR): Real Time quantitative Reverse Transcritption 
Retnla: Resistin-like molecule-𝛼 (FIZZ1) 
RNA-seq: RNA sequencing analysis 
ROS: Reactive oxygen species 
RSEM: RNA-Seq by Expectation-Maximization 
STAB1: Stabilin 1 
STAT: Signal Transducer and Activator of Transcription 
SMA: Smooth Muscle Actin 
SP MP: Splenic macrophages 
TAMs: Tumor-associated macrophages 
Tie2: Endothelial Tyrosine Kinase (Tk) 
TEMs: Tie2-expressing monocytes/macrophages 
Tg: Transgenic 
Tgfb: Transforming growth factor, beta   
Th: T helper 
Tlr: Toll like receptor 
VEGFA: Vascular Endothelial Growth Factor A 
YM1: Chitinase-3- like protein-3 (Chi3l3) 
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Recent studies show that macrophages are present in the healthy myocardium 
and can also be recruited in response to myocardial infarction (MI). However, the 
specific contribution of these cells to either cardiac homeostasis or cardiac repair 
following injury is not fully understood. In our study, we focus on macrophages 
present in the heart and examine their subsets, phenotype and functional properties 
in the steady state and after MI. For the analysis, we developed two different mouse 
models of MI: cryoinjury and left anterior descending coronary artery ligation (LAD-
ligation), and we used in vivo tracing flow cytometry, state-of-the-art confocal 
microscopy, transcriptional and ecocardiography analysis. We identified a population 
of cardiac resident macrophages located in close proximity with endothelial cells and  
that exhibit an M2-like/tissue-homeostatic signature consistent with anti-inflammatory 
and pro-angiogenic activity. These findings suggest that cardiac resident 
macrophages found in the healthy myocardium might have a role in maintaining 
cardiac homeostasis and coronary vasculature integrity. After MI, we found two 
distinct subsets of monocytes and macrophages that sequentially appeared in the 
infarcted myocardium and that showed different gene expression profiles. Ly6Chi 
cells found soon after myocardial injury correspond to pro-inflammatory 
monocytes/macrophages, whereas Ly6Clo cells found at later stages represent 
macrophages exhibiting anti-inflammatory and pro-angiogenic activity. Notably, the 
gene expression profile of these cells had features of pro-angiogenic Tie2-expressing 
macrophages (TEMs), which are also present in tumors and ischemic tissues. We 
examined the presence of TEMs in the ischemic myocardium and found that these 
cells are recruited in response to injury and exhibit pro-angiogenic properties. These 
results indicate that TEMs might be involved in the revascularization of the ischemic 
myocardium following MI.  
Our findings suggest that modulation of macrophage activation in both 
homeostasis and cardiac disease might help to develop novel therapeutic 
approaches to avoid adverse cardiac remodeling and improve cardiac repair.
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El corazón alberga poblaciones de macrófagos tanto en condiciones 
fisiológicas, como en respuesta al daño cardíaco por infarto de miocardio (IM). No 
obstante, la contribución específica de estas poblaciones al mantenimiento de la 
homeostasis y a la reparación cardíaca de corazón adulto no ha sido completamente 
dilucidada. Nuestro estudio se centra en la caracterización de las distintas 
subpoblaciones de macrófagos presentes en el corazón en homeostasis y en 
respuesta al IM. Para ello, se han desarrollado dos modelos distintos de inducción 
de IM: la criolesión y la ligación permanente coronaria y se han llevado a cabo 
estudios in vivo por citometría de flujo, microscopía confocal, ecocardiografía y 
análisis de la expresión génica. Se ha identificado la existencia de una población de 
macrófagos residentes cardíacos cuya localización es cercana a los pequeños y 
grandes vasos sanguíneos de la vasculatura coronaria. Estos macrófagos exhiben 
un perfil génico anti-inflamatorio caracterizado por la expresión de marcadores 
homeostáticos y pro-angiogénicos, lo que sugiere una función de estas células en el 
mantenimiento de la homeostasis cardíaca y de la integridad vascular. En respuesta 
al IM, se ha identificado la presencia de dos subpoblaciones de monocitos y 
macrófagos que aparecen de forma secuencial en el corazón y muestran distintos 
perfiles de expresión. La subpoblación celular Ly6Chi se compone de monocitos y 
macrófagos con carácter pro-inflamatorio, que se hallan presentes en fases 
tempranas tras el IM. En fases más tardías, se encuentra un subpoblación de 
macrófagos Ly6Clo que exhiben propiedades anti-inflamatorias y pro-angiogénicas 
similares a las mostradas por poblaciones de macrófagos Tie2+ (TEMs), previamente 
descritos en distintos procesos isquémicos. De acorde a este hallazgo, se ha llevado 
a cabo el estudio de la presencia de TEMs tras el IM. Se ha demostrado que estas 
células corresponden a subpoblaciones de macrófagos presentes en el miocardio 
dañado, que exhiben un patrón de expresión altamente pro-angiogénico y son 
distintas de los macrófagos Ly6Clo.  
Los resultados obtenidos en este estudio sugieren que en el contexto tanto de 
homeostasis como de enfermedad cardíaca, la modulación de la activación del 
macrófago puede servir como herramienta útil para el desarrollo de nuevas terapias 
enfocadas a la mejora de la función cardíaca.
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1. THE MONONUCLEAR PHAGOCYTE SYSTEM AND 
MACROPHAGE DEVELOPMENT. 
1.1 Macrophage overview: function and definition. 
The concept of macrophage system was originally introduced by Ilya Ilyich 
Mechnikov, who was the first to describe the process of phagocytosis in the late 19th 
century. After this feature, macrophages were named as “big eaters” (from ancient 
Greek, makros “large” + phagein “eat”). The older literature classified macrophages 
as part of the reticuloendothelial system which grouped macrophages and 
endothelial cells together (Sabin 1925). However, emerging functional and 
morphological differences between both cell types led to the conclusion that 
reticuloendothelial system did not accurately represent their cell lineage. 
In 1968 Ralph van Furth and Zanvil Cohn demonstrated that major population 
of macrophages arises from blood monocytes (van Furth and Cohn 1968). This 
finding allowed to establish the concept of the mononuclear phagocyte system 
(MPS), a linear model proposing that bone marrow committed precursors give rise to 
circulating monocytes, from which tissue-resident macrophages derived (van Furth 
and Cohn 1968).  However, recent works showing different origins of macrophages 
independently from their bone marrow source, have led to the redefinition of this 
model (Davies, Jenkins et al, 2013).  
 Macrophages are large myeloid cells that display stellate morphology and are 
characterized by the presence of pseudopodia, non-specific esterases and 
phagocytic granules, which give them a 'foamy' appearance. Macrophages have 
roles in almost every aspect of an organism’s biology; from development, 
homeostasis and repair, to immune responses against pathogens. In adult mammals, 
macrophages are found in all tissues where they display a wide anatomical and 
functional diversity. 
 Macrophages broadly consist of two classes: tissue-resident macrophages 
and infiltrating macrophages (Pollard 2009; Murray and Wynn 2011). Tissue-
resident macrophages regulate tissue homeostasis by acting as sentinels and 
responding to changes in physiology as well as challenges from external 
environment. In contrast, infiltrating macrophages are only found in inflammatory 
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responses induced by pathogens or tissue damage. These cells exhibit different 
phenotypes and can also be recruited from the monocyte reservoirs of blood, spleen 
and bone marrow, (van Furth, Cohn et al, 1972) and likely from resident tissue 
progenitors or through local proliferation (Davies, Jenkins et al, 2013). 
By virtue of their ability to acquire antigen and their expression of class II 
MHC, as well as production of regulatory cytokines, macrophages can also contribute 
to the adaptive arm of the immune system by influencing T cell behavior and thus, 
they play a critical role in protective immune responses. On the other hand, aberrant 
macrophage activity has been associated with many inflammatory conditions such as 
rheumatoid arthritis, atherosclerosis, inflammatory bowel disease (IBD), and 
diabetes-associated insulin resistance (Pollard 2009; Wynn, Chawla et al, 2013). 
 
1.2. Monocyte and macrophage development. 
The MPS is useful for classifying macrophages in adults but the origin of 
macrophages in embryos is more complex. It has been proposed a three-wave 
model for macrophage ontogeny, which takes place in the extra-embryonic yolk sac 
before the onset of definitive hematopoiesis (Bertrand, Jalil et al, 2005) (Figure 1). In 
mice, the first macrophages appear in the yolk sac very early during development, 
precisely at embryonic day E7.5, and have been reported to be of maternal origin. 
The second and third macrophage populations appear in the yolk sac between E8 
and E9, and are derived from monopotent and erythromyeloid macrophage precursor 
cells, respectively (Bertrand, Jalil et al, 2005). Starting from E8.5, macrophages can 
be readily identified in both extra-embryonic and embryonic tissues, including yolk 
sac, neural, inter-somitic and inter-digital tissues (Pucci, Venneri et al, 2009). 
Definitive hematopoiesis (i.e., the generation of hematopoietic cells from multipotent 
hematopoietic stem cells) starts at E9.5 - E10 in the Aorto-Gonado-Mesonephron 
(AGM) region of the embryo to continue in the fetal liver, spleen and bone marrow at 
later stages of development. Therefore, after birth, as the bony structures are formed 
the main site of hematopoiesis is the bone marrow; at this stage, the MPS is 
established (van Furth, Cohn et al, 1972).  
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Adult hematopoiesis in the bone marrow is the source of circulating 
monocytes. These cells differentiate from hematopoietic stem cells (HSC) through a 
number of morphologically distinct intermediate stages, from the common myeloid 
progenitor (CMP), to the macrophage/dendritic cell progenitor (MDP) (Auffray, Fogg 
et al, 2009). At each of these stages there is a progressive lineage commitment and 
cells gradually lose the potential to give rise to other cell types. The MDP gives rise 
to monocytes and macrophages, as well as pro-dendritic cells (pro-DC) which 
subsequently develop into DCs (Naik, Sathe et al, 2007) (Figure 2). The production 
of mononuclear phagocytes from progenitor cells is directed by colony-stimulating 
factors, to some extent lineage restricted and hierarchical in their actions.  They 
include macrophage colony-stimulating factor (CSF-1), granulocyte macrophage 
colony-stimulating factor (GM-CSF) and fms-like tyrosine kinase 3 ligand (Flt3-
ligand).  These growth factors instruct the common myeloid progenitor to adopt a 
macrophage fate (Onai, Obata-Onai et al, 2007; Stanley 2009). 
 Studies by Geissmann and colleagues have demonstrated that there may be 
at least two distinct monocyte subsets in mice (Geissmann, Jung et al, 2003; Auffray, 
Fogg et al, 2007) (Figure 2), an idea which has been long established in human 
(Yasaka, Mantich et al, 1981). In mouse, these subsets have been distinguished on 
the basis of differential expression of Ly6C (or Gr-1) and CX3CR1 (Geissmann, Jung 
et al, 2003). Monocytes expressing high levels of Ly6C and intermediate or low levels 
of CX3CR1 (referred to hereafter as Ly6C
hi monocytes), also express the chemokine 
receptor CCR2 and the adhesion molecule CD62L (L selectin). Ly6Chi monocytes, 
Figure 1 Developmental stages of macrophages. See the text. 
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also termed as 'inflammatory' monocytes, migrate to sites of inflammation, where 
they differentiate into inflammatory macrophages (M1), that participate in 
inflammatory responses and produce pro-inflammatory cytokines during infection or 
tissue damage  (Serbina and Pamer 2006; Dunay, Damatta et al, 2008; Getts, Terry 
et al, 2008). The second major monocyte subset in mice is defined by low expression 
of Ly6C, high levels of CX3CR1, but low or no expression of CCR2 and CD62L 
(referred to hereafter as Ly6Clo monocytes). These Ly6Clo cells have been 
denominated 'resident' or “non-classical” monocytes, as they were found in both 
healthy and inflamed tissues following adoptive transfer (Geissmann, Jung et al, 
2003). More recently, it has been reported that circulating “resident” monocytes 
exhibit patrolling behavior in the vasculature, where they crawl along the blood 
vessels in a process that is independent of blood flow and dependent upon the β2 
integrin and CX3CR1 (Auffray, Fogg et al, 2007). In this regard, Ly6C
lo monocytes 
have also been defined as “patrolling monocytes”. In response to damage these 
Ly6Clo cells extravasate into the tissue where they give rise to anti-inflammatory 
macrophages (M2) that facilitate tissue healing and revascularization (Auffray, Fogg 
et al, 2007; Nahrendorf, Swirski et al, 2007). However, it is still not clear whether 
there is a significant recruitment of Ly6Clo monocytes into the tissues after injury. 
Instead, emerging evidence points to a role for Ly6Clo cells, as patrolling monocytes 
that act to maintain vessel integrity and to detect pathogens while inflammatory 
monocytes are recruited predominantly to sites of infection or injury, or to tissues that 
have continuous cyclical recruitment of macrophages (Davies, Jenkins et al, 2013; 
Wynn, Chawla et al, 2013). 
In addition, recent studies have described the existence of a minor population 
of circulating Tie-2 expressing monocytes (TEMs) that are recruited into tissues 
where they differentiate into Tie2-expressing macrophages which are involved in 
angiogenic processes (De Palma, Venneri et al, 2005). 
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Although the ontogeny of macrophages during development has been well 
characterized, the precise origin of tissue-resident as well as inflammatory 
macrophages in adult tissues is still a matter of debate (Geissmann, Jung et al, 2003; 
Geissmann, Manz et al, 2010). A number of studies have provided evidences that 
precursors can develop and give rise to monocytes outside the bone marrow in a 
process called extramedullary monocytopoiesis (Leuschner, Rauch et al, 2012).  In 
addition, it has been reported that monocytes are not exclusively circulating cells, but 
can also reside in tissues as reservoirs for mobilization during inflammation (Swirski, 
Nahrendorf et al, 2009). Despite these findings, the major break from this model 
Figure 2 The Mononuclear Phagocyte System. See the text. 
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came from recent studies showing that in mouse, macrophages derived early in 
embryogenesis from the yolk sac can contribute to adult pool of tissue resident 
macrophages, independently of bone marrow supply (Ginhoux, Tacke et al, 2006; 
Chorro, Sarde et al, 2009; Schulz, Gomez Perdiguero et al, 2012; Hashimoto, Chow 
et al, 2013). In the MPS scheme, the dogma had remained that tissue-resident 
macrophages derived from Ly6Clo monocytes. Nonetheless, these novel findings 
have led to a redefinition of this model, including not just monocytes as major source 
of tissue-resident macrophages, but also highlighting the embryonic origin of many of 
these populations (Jenkins, Ruckerl et al, 2011).  
 
1.3. Macrophage activation states. 
Diversity and plasticity are hallmarks of monocytes and macrophages. In 
tissues, macrophages can adopt a myriad of phenotypes based on signals they 
receive from their environment. From in vitro studies a nomenclature was proposed, 
similar to the Th1–Th2 polarization of T cells, with M1 macrophages being known as 
classically activated macrophages and M2 being known as alternatively activated 
macrophages (Martinez, Sica et al, 2008; Mosser and Edwards 2008) (Figure 3).  
Classically activated or M1 macrophages develop after being exposed to IFN𝛾 
and TNF𝛼 or lipopolysaccharide (LPS), under the influence of the transcription factor 
interferon regulatory factor 5 (IRF5) (Krausgruber, Blazek et al, 2011). They mediate 
defense of the host from a variety of intracellular pathogens by generating reactive 
oxygen species (ROS) and nitric oxide (NO) through upregulation of inducible nitric 
oxide synthetase (iNOS) expression and by amplifying Th1 immune responses by 
producing pro-inflammatory cytokines like IL-12, IL-1𝛽, and TNF𝛼  (Biswas and 
Mantovani 2010). In addition, M1 macrophages show enhanced phagocytosis of 
microorganisms, and act as antigen presenting cells (APC) for T cells (Sica and 
Mantovani 2012). 
Macrophages exposed to Th2-type cytokines such as IL4 and IL13, undergo 
alternatively activated or M2 polarization state, a process controlled by the 
transcription factors IRF4, STAT6 and PPAR (Ohmori and Hamilton 1997; Satoh, 
Takeuchi et al, 2010). These M2 macrophages have a role in protection against 
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helminthes, and are considered wound-healing cells because of their association with 
physiological and pathological tissue remodeling (Mosser and Edwards 2008). They 
are characterized by their high phagocytic activity and upregulated expression of 
mannose receptor, Arginase-1, Chitinase-3- like protein-3 (Chi3l3, also known as 
Ym1), and Resistin-like molecule-𝛼 (Relm𝛼, also known as Retnla or FIZZ1) (Kreider, 
Anthony et al, 2007; Martinez, Sica et al, 2008).  
 
Although the M1 versus M2 model has been helpful in describing immune 
response during acute infections, allergies, asthma and obesity (Chinetti-Gbaguidi 
and Staels 2011), unlikely fully represents the complexity of the transitional states of 
macrophage activation, which is often fine-tuned in response to different 
microenvironments.  Results obtained in chronic diseases strongly suggest that the 
myeloid compartment has a much broader transcriptional repertoire depending on 
the signals received by the environment. Considering the plasticity of macrophages, 
it is difficult and controversial to define a specific marker to identify macrophage 
subtypes, since phenotypes exhibited by macrophages in different settings appear as 
a continuum rather than discrete entities (Mosser and Edwards 2008; Geissmann, 
Manz et al, 2010).  
 
 
 
Figure 3 Macrophage activated phenotypes. In response to IFN𝛾 TNF𝛼 or 
LPS, macrophages undergo M1 or classically-activated phenotype, releasing 
several pro-inflammatory cytokines. In contrast, macrophage polarization 
into M2 or alternatively activation takes place in response to IL-13 or IL-4 
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Figure 4 Populations of tissue-resident macrophages in the organism. Distinct 
populations of tissue-resident macrophages can be found in different organs and tissues 
where they perform specialized functions. 
2. MACROPHAGES IN TISSUE HOMEOSTASIS.  
2.1. Tissue resident macrophage diversity in the body. 
It is now clear that macrophages are not only big eaters of pathogens and 
dead cells, but also important components of the stromal architecture of several 
tissues and organs, where they regulate organ homeostasis and remodeling (Pollard 
2009). Various populations of mature tissue-resident macrophages are strategically 
located close to the body's epithelial surfaces where they perform tissue specific 
functions (Figure 4). These cells are extremely heterogeneous, exhibiting unique 
phenotypes which may reflect the influence of the tissue environment where they 
reside. Their functions range from the maintenance of tissue homeostasis through 
clearance of cellular debris and iron processing to wound healing after infection, 
injury and resolution of inflammation. In this regard, tissue-resident macrophages 
have been largely defined as sentinels for tissue protection. 
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At steady state, the traditional view has been that tissue-resident 
macrophages arise from circulating monocytes. However, now it is clear that a wide 
number of tissue-resident macrophages can have different origins during ontogeny 
that persists into adulthood by self-renewal and proliferation. Some clear examples 
are represented by microglia, kupffer cells and Langerhans cells, which are 
established prenatally, arise independently of the hematopoietic transcription factor 
Myb, and persevere throughout life (Ginhoux, Greter et al, 2010; Schulz, Gomez 
Perdiguero et al, 2012; Yona, Kim et al, 2013). Fate mapping studies using the pan 
macrophage marker CX3CR1 confirm the prenatal establishment of macrophages in 
almost all the tissues with the exception of intestinal CX3CR1
+ macrophages, which 
are continually replenished by blood Ly6Chi monocytes (Zigmond, Varol et al, 2012). 
In addition, it is becoming evident that most tissue-resident macrophages are 
maintained and can expand by in situ proliferation, a requirement for long-term 
maintenance of prenatal macrophages (Jenkins, Ruckerl et al, 2011; Davies, Rosas 
et al, 2013). Some studies point to M-CSF and its receptor (CSF1R) as candidates 
for supporting tissue-resident macrophage proliferation in adult tissues (Hume and 
MacDonald 2012). Despite these findings, it is evident that many tissues contain 
diverse populations of both local self-renewing and peripheral derived resident cells 
although it is unclear how functionally distinct are these populations (Yona, Kim et al, 
2013). Further investigations are needed to address the functional equivalence of 
prenatally derived tissue-resident macrophages with their monocyte-derived 
replacements. This will rely on markers for resident cell function that are more robust 
than the limited markers currently available. 
  According to the “M1/M2” standard classification, tissue-resident macrophages 
have been classified as “M2-like” macrophages, consistent with their role in tissue 
homeostasis, that correlates with the function of M2 macrophages in remodeling 
during fetal life and in selected tissues during adulthood as well as in resolution of 
inflammation (Mantovani, Sica et al, 2005; Rae, Woods et al, 2007; Klimchenko, Di 
Stefano et al, 2011; Mantovani, Biswas et al, 2013). However, this concept of M2-like 
phenotype of tissue-resident macrophages represents a rigid classification as it 
disregards the complexity and diversity of their function in distinct 
microenvironments. Further studies need to be performed to determine whether 
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discretely expressed transcription factors may regulate the functional diversity of 
tissue-resident macrophages in a tissue- specific or niche-specific manner. 
 
3. MACROPHAGE PHENOTYPES IN TISSUE INJURY AND 
INFLAMMATION. 
Following disruption of tissue homeostasis, macrophages contribute to repair 
and restoration of tissue integrity. The use of ablation models in different organs such 
as muscle, liver, heart, kidney, etc, has led to the consensus that macrophages 
present during tissue repair include a temporally regulated spectrum of activation 
states to orchestrate the various phases of healing rather than a single 
homogeneous population (Mirza, DiPietro et al, 2009; Novak and Koh 2013; Novak 
and Koh 2013).  
Inflammatory response after injury typically involves invasion of the injured site 
by infiltrating Ly6Chi monocytes that once recruited differentiate into M1 
macrophages (Willenborg, Lucas et al, 2012; Novak and Koh 2013; Novak and Koh 
2013). These cells participate in host defense, phagocytosis of necrotic tissue, and 
secretion of pro-inflammatory cytokines (Lucas, Waisman et al, 2010). However, 
uncontrolled number of pro-inflammatory macrophages can be detrimental leading to 
tissue damage due to the release of pro-inflammatory and cytotoxic mediators. To 
counteract the tissue-damaging potential of the inflammatory response, inflammatory 
macrophages undergo apoptosis or switch into an anti-inflammatory or suppressive 
phenotype that allows resolution of inflammation while facilitating wound healing 
(Moyer and Wagner 2011; Murray and Wynn 2011).These M2 macrophages possess 
anti-inflammatory functions, release a number of growth factors to orchestrate tissue 
healing processes and promote collagen deposition and neovascularization. It has 
been proposed that M2 macrophages arise from local M1 to M2 macrophage 
conversion (Mantovani, Sica et al, 2004; Titos, Rius et al, 2011; Uderhardt, Herrmann 
et al, 2012). Alternatively, M2 macrophages also may arise from either infiltrating 
Ly6Clo monocytes or through direct differentiation of Ly6Chi monocytes in a 
microenvironment that favors resolution (Hilgendorf, Gerhardt et al, 2014). 
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An unanswered question in macrophage biology is whether tissue-resident 
macrophages of a given organ sufficiently respond to tissue damage, or whether 
there is always a requirement for recruitment of inflammatory cells. During tissue 
repair and resolution of inflammation, infiltrating blood-derived 
monocytes/macrophages are often greater in number than tissue-resident 
macrophages and thus, the contribution of these cells has been neglected. However, 
some studies have reported that under certain inflammatory conditions, tissue-
resident macrophages are able to expand and accumulate in greater far number than 
those at homeostasis, in the absence of peripheral monocyte recruitment. (Jenkins, 
Ruckerl et al, 2011). Moreover, the importance of tissue-resident macrophages in 
initiating inflammatory response is illustrated by studies in which their depletion 
impairs chemokine production and neutrophil influx in experimental inflammation 
(Maus, Koay et al, 2002; Cailhier, Partolina et al, 2005).These findings suggest that 
tissue-resident macrophages might actively contribute to organ repair after injury 
exerting key functions aimed at restoring tissue homeostasis. 
 
 4. MACROPHAGE HETEROGENEITY IN THE HEART.  
4.1. Macrophages in the healthy myocardium. 
The existence of macrophages residing in the healthy heart as well as their 
distribution throughout the myocardium has been previously documented (Azzawi, 
Hasleton et al, 1997; Azzawi, Kan et al, 2005). Recent work using the CX3CR1GFP/+ 
transgenic mouse model, describes an abundant population of cardiac resident 
macrophages that appears within the normal myocardium in direct contact with 
endothelial cells and myocytes (Pinto, Paolicelli et al, 2012).These cells exhibit an 
alternative like phenotype in resting conditions. Furthermore, the existence of four 
different populations of cardiac resident macrophages has been recently 
demonstrated (Epelman, Lavine et al, 2014). It has been shown that these cells arise 
from yolk sac and fetal progenitors and that are maintained through local proliferation 
at steady state (Epelman, Lavine et al, 2014).       
Although these findings clearly improve our knowledge of macrophage biology 
in resting myocardium, it is currently unclear how cardiac resident macrophages 
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exactly contribute to myocardial homeostasis and how their actions may impact the 
physiology of the repair response following cardiac insult.  
 
4.2. Monocytes and macrophages in myocardial infarction. 
4.2.1. Myocardial infarction: causes and therapies. 
Myocardial infarction (MI) represents the most frequent cardiovascular event, 
being one of the main disability and mortality causes worldwide (Hellermann, 
Jacobsen et al, 2003; Hellermann, Jacobsen et al, 2005). The typical trigger of MI is 
plaque rupture in a coronary artery, resulting in an insufficient oxygen supply to the 
downstream myocardium that undergoes necrosis with the loss of cardiac muscle 
and fibrosis (Fishbein, Maclean et al, 1978; Frangogiannis, Smith et al, 2002). The 
short-term survival rate in post-MI patients is 90% due to improvements in 
emergency coronary reperfusion and current standard therapy with  blockers and 
angiotensin-converting enzyme inhibitors (Braunwald, Muller et al, 1983; Pfeffer and 
Braunwald 1990). However, a significant high number of MI patients will undergo 
adverse remodeling of the left ventricle leading to heart failure, which is an 
incapacitating disease with high morbidity and mortality worldwide as well as broad 
socioeconomic impact (Gaziano 2005; Chien, Domian et al, 2008). The adult human 
heart has limited regenerative capacity, so cardiomyocyte lost after MI is typically 
replaced by non-contractile scar tissue resulting in cardiac dysfunction (Jackson, 
Majka et al, 2001). Current medical management including device therapy, and most 
recently, stem cell therapy have been shown to partially ameliorate the extent and 
consequences of heart failure, but at present, cardiac transplantation represents the 
only means of replacing the lost muscle. However, whole-organ transplantation is 
limited by the inadequate supply of donor hearts and the need for subsequent 
immunosuppression. Moreover, cell-based therapy has entered the clinical area 
since 2000 as an alternate means of achieving cardiac repair (Bolli, Chugh et al, 
2011). Stem cell therapy through using multiple cell types to regenerate the injured 
heart has been tested in clinical trials. Nonetheless, its efficacy has several 
limitations, such as low cardiac engraftment of cells, and low cardiomyogenic 
potential of bone marrow cells as well as the necessity of optimizing more efficient 
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delivery methods (Tongers, Losordo et al, 2011). An exciting new avenue is in situ 
reprogramming of fibroblasts into myocytes (Song, Nam et al, 2012), but this 
technology is still in its infancy. This situation has led to clinicians and basic scientists 
to explore new therapeutic approaches to understand and to repair the failing heart.  
Improvement of intrinsic wound healing that takes place during the first 1 or 2 
weeks after MI, has emerged as a potential strategy to prevent heart failure. Healing 
of injured myocardium necessitates a balanced inflammatory response to avoid 
adverse remodeling after MI. However, strategies targeting the cardiac healing 
process are still lacking. Macrophages regulate multiple aspects of the post-MI 
wound healing response (Nahrendorf and Swirski 2013; Hilgendorf, Gerhardt et al, 
2014) and as such have emerged as likely candidates for investigation and 
intervention. 
 
 4.2.2. Monocyte and macrophage roles in myocardial infarction. 
Soon after MI, leukocytes are recruited into the myocardium. These cells are 
primarily composed of neutrophil and inflammatory Ly6Chi monocytes. Neutrophil 
tissue numbers peak 24 hours after onset of ischemia, whereas inflammatory 
monocytes peak around day 3 (Nahrendorf, Swirski et al, 2007). Nahrendorf and co-
workers showed that undifferentiated Ly6Chi monocytes are able to generate 
inflammatory cytokines and exhibit phagocytic and proteolytic functions. However, 
once recruited, these cells may differentiate into inflammatory macrophages (Frantz 
and Nahrendorf 2014). The main function of both, monocytes and macrophages is 
likely to remove debris, dead myocytes and apoptotic neutrophils, in order to prepare 
tissue for repair.  
Monocytes and macrophages initially accumulate in the infarct border zone 
(van der Laan, Ter Horst et al, 2014), probably because vascular access is still intact 
in this area. Presumably, over time, monocytes and macrophages migrate into the 
core of the infarct as demonstrated by human studies reporting an increase in 
monocyte number in the infarct core later than in the border zone (van der Laan, Ter 
Horst et al, 2014).  
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The initial inflammatory response (1-3 days) is followed by a proliferation 
phase (4-7 days) dominated by the anti-inflammatory Ly6Clo monocytes (Nahrendorf, 
Swirski et al, 2007). This phase is crucial to provide mechanical stability of the left 
ventricle through generation of new matrix and infarct scar. Ly6Clo cells express 
genes associated to M2 response as well as high levels of vascular endothelial 
growth factor (VEGF) and TGF beta, and thus, likely regulate angiogenesis and 
myofibroblast activity (Nahrendorf, Swirski et al, 2007; Nahrendorf, Pittet et al, 2010). 
  
 
Interestingly, it has been demonstrated that the spleen can contribute to 
extramedullary production of Ly6Chi monocytes that are recruited into the 
myocardium in response to MI (Swirski, Nahrendorf et al, 2009). Moreover, a recent 
study report profound alterations in splenic tissue niches in chronic heart failure that 
promotes the circulation and recruitment of pro-inflammatory monocytes into the 
myocardium where they regulate both chronic inflammation and the progression of 
pathological  left ventricle remodeling (van der Laan, Ter Horst et al, 2014). 
Figure 5 Biphasic monocyte response after myocardial infarction. Time 
course of monocyte subsets recruitment and their function depicted in the lower 
panel. Distinct phases of cardiac healing after MI are depicted in the upper panel. 
Adapted from Nahrendorf et al, 2007. 
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Despite these novel findings, the origin of monocyte subsets after cardiac 
injury still remains controversial. Some studies indicate that Ly6Clo monocytes act 
predominantly as vascular sentinels and infiltrate tissue at very low frequencies. 
Notably, in contrast to the biphasic monocyte response described by Nahrendorf, 
recent work from the same author suggests that Ly6Clo cells are actually 
macrophages derived from the local differentiation of Ly6Chi monocytes (Hilgendorf, 
Gerhardt et al, 2014). Dissecting the exact monocyte/macrophage lineage 
relationship during healing response in the ischemic myocardium may thus require 
the development of sophisticated lineage-tracing studies. 
A number of publications have described the functional role of monocytes and 
macrophages in infarct repair suggesting the use of these cells as therapeutic targets 
in heart failure (Lambert, Lopez et al, 2008). Clodronate liposome depletion targeting 
either the early Ly6Chi or the late Ly6Clo phase shows that both are essential for 
cardiac healing   (Nahrendorf, Swirski et al, 2007; van Amerongen, Harmsen et al, 
2007; van Amerongen, Harmsen et al, 2008; Frantz, Hofmann et al, 2013). 
Elimination of Ly6Chi phase results in larger areas of debris and necrotic tissue, 
whereas depletion of Ly6Clo phase  leads to decreased deposition of collagen and 
reduced numbers of new blood vessels (Nahrendorf, Swirski et al, 2007). 
Therapies aimed at modulating macrophage activation to a M2-polarized state 
have been found to improve cardiac repair through the control of the inflammatory 
phase and thus preventing cardiac damage after MI (Harel-Adar, Ben Mordechai et 
al, 2011). This strategy exploits the principle underlying the anti-inflammatory effects 
of M2 macrophages which are known to actively suppress inflammation and promote 
infarct repair (Nahrendorf, Swirski et al, 2007). Indeed, excessive inflammation is 
known to impair appropriate cardiac healing as demonstrated by a study in a murine 
model in which prolonged Ly6Chi monocytosis, early after MI onset impairs 
myocardial healing (Bouchentouf, Paradis et al, 2010; Panizzi, Swirski et al, 2010). 
Moreover, recent studies provide an insightful explanation of how mesenchymal 
stromal cell (MSC) injection could positively affect infarct healing by establishing a 
crosstalk between injected stem cells and macrophages (Dayan, Yannarelli et al, 
2011). In this study, MSC transplantation into the infarct increases the percentage of 
reparative M2 macrophages in the infarcted heart of mice supporting the concept that 
these cells are crucial for cardiac repair and cardiac function recovery. 
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Regeneration of myocardium is still a subject of intense debate ad 
investigation, whose ultimate goal is the regrowing myocardium lost after ischemia. 
Macrophages support tissue regeneration in many organs and thus, they have been 
proposed to have a role in cardiac regenerative process (Arnold, Henry et al, 2007; 
Ruckh, Zhao et al, 2012; Godwin, Pinto et al, 2013). There are some evidences for a 
macrophage´s role in forming regenerative niches. For instance, elimination of 
specialized CD169+ macrophages in the bone marrow impairs red blood cell 
regeneration pointing to macrophages as essential elements of the hematopoietic 
stem cell niche (Lucas, Scheiermann et al, 2013). Furthermore, salamander limb 
loses the ability to regenerate after systemic macrophage depletion and is able to 
regain the regenerative capacity when macrophage population is recovered (Godwin, 
Pinto et al, 2013). Therefore, it is tempting to speculate that macrophages may 
produce signals that inform the microenviroment and instruct tissue resident 
progenitors to regenerate the tissue. Despite these findings, the dogma prevails that 
cardiomyocytes in the adult mammalian heart are terminally differentiated cells and 
thus, are unable to proliferate. Indeed, to date, the evidence for a macrophage´s 
regenerative role in myocardium only applies to the neonatal myocardium, in which 
recent work shows that macrophage elimination leads to an impairment of heart 
regeneration following MI (Aurora, Porrello et al, 2014).  
 
4.2.3. Macrophages in myocardial angiogenesis 
 After MI, neovascularization in the border zone adjacent to the ischemic 
region is critical to supply the healing infarct with oxygen and nutrients and thus, to 
preserve cardiac function and attenuate adverse left ventricular remodeling 
(Frangogiannis 2012). Neovascularization is orchestrated by interactions between 
pro-angiogenic and anti-angiogenic factors, the extracellular matrix, and endothelial 
cells and pericytes at the border zone (Frangogiannis, Smith et al, 2002). The new 
blood vessels restore perfusion to ischemic areas through connecting patent and 
occluded arteries. Initially, new vessels only consist of endothelial cells but acquire a 
more mature morphology, including a pericyte coat, over time (Ren, Michael et al, 
2002). Enhancing blood supply to the infarct border through stimulation of 
angiogenesis, e.g. by injection of putative cell progenitors or pro-angiogenic factors 
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into the myocardium, reduces infarct expansion and remodeling, and improves heart 
function in experimental MI (Orlic, Kajstura et al, 2001). However, translation of this 
strategy to the clinic has had limited success to date (Meyer, Wollert et al, 2006; 
Lasala and Minguell 2009). An alternative approach is to manipulate endogenous 
mechanisms involved in infarct healing so that the associated angiogenic response is 
promoted.  
The contribution of macrophages to angiogenesis post MI events has been 
reported by a number of studies. Depletion of monocytes/macrophages after 
experimental model of ischemic cardiomyopathy results in impaired angiogenesis on 
the infarct border (Nahrendorf, Swirski et al, 2007; van Amerongen, Harmsen et al, 
2007). In contrast, enhancement of monocyte recruitment by overexpression of 
monocyte chemoattractant protein-1 (MCP-1) (Morimoto, Takahashi et al, 2006), or 
direct injection of activated macrophages into the heart (Leor, Rozen et al, 2006), 
increase vessel density on the infarct border and improves heart function. These 
findings encourage the identification of specific macrophage subsets that may 
account for the revascularization of the ischemic myocardium and thus, may be used 
as therapeutic targets for ischemic heart disease.   
 
 4.2. Role of Tie2 expressing macrophages in angiogenesis.  
Tie2-expressing monocytes/macrophages (TEMs) are major drivers of  
angiogenesis in tumors, developing organs and remodeling tissues (De Palma, 
Murdoch et al, 2007; Lewis, De Palma et al, 2007; Venneri, De Palma et al, 2007; 
Bacci, Capobianco et al, 2009; Coffelt, Tal et al, 2010; Fantin, Vieira et al, 2010). 
TEMs were originally identified in mouse tumor models as a small subpopulation 
within the total tumor infiltrating, CD11b+ myeloid cells, characterized by the 
expression of the angiopoietin receptor Tie2/Tek (De Palma, Venneri et al, 2005). 
Tie2, is a tyrosine kinase receptor broadly expressed by endothelial cells and It is 
essential for the maintenance of the hematopoietic stem within the bone marrow; it 
regulates angiogenesis and vascular morphogenesis both in development and 
adulthood through its interaction with angiopoietin (ANG) ligands, of which ANG1 and 
ANG2 are the best characterized (Augustin, Koh et al, 2009). Activated endothelial 
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cells (such as those of angiogenic blood vessels) secrete high levels of Tie2 ligands, 
which bind Tie2 both autocrinally on endothelial cells and paracrinally on TEMs. Such 
reciprocal signaling might regulate macrophage/endothelial cell interactions and 
facilitate macrophage-assisted vascular patterning in developing organs, tumors and 
ischemic tissues (Mazzieri, Pucci et al, 2011) (Figure 6). 
Tie2 is weakly expressed in circulating monocytes under non-pathological 
conditions, but is significantly upregulated in perivascular, tumor-associated (De 
Palma, Murdoch et al, 2007; Pucci, Venneri et al, 2009) or ischemia-associated 
(Hamm, Veschini et al, 2013; Patel, Smith et al, 2013) macrophages. Tie2-
expressing macrophages have features of M2-polarized tumor-associated 
macrophages (TAMs) (Pucci, Venneri et al, 2009; Sica and Mantovani 2012), but 
differ from them by their highly pro-angiogenic capacity and their preferential 
perivascular localization. In vitro studies have shown that endothelial cells can 
provide a selective niche for differentiation and functional polarization of 
macrophages into a M2-like phenotype, characterized by enhanced Tie2 expression 
and pro-angiogenic activity (He, Xu et al, 2012). These findings suggest that 
differentiation of TEMs might be mediated by cell-to-cell interactions with endothelial 
cells as these cells extravasate and localize in the vessel wall (He, Xu et al, 2012). 
According to this idea, studies in animal models point to a role for TEMs in providing 
paracrine support for angiogenesis by cross-talking with endothelial cells to aid tip-
cell fusion (Fantin, Vieira et al, 2010; Mazzieri, Pucci et al, 2011). 
The original identification of TEMs in tumors has been followed by a number of 
studies in human and animal models exploring their contribution to either pathological 
or therapeutic neovascularization. For instance, in mice that undergo hepatectomy 
some TEMs are found close to newly growing vessels, suggesting that they might 
also support angiogenesis during liver regeneration (Matsubara, Kanto et al, 2013). 
Moreover, Tie2+ cells distinct from endothelial cells participate in disease conditions 
characterized by aberrant vascular remodeling, such as arthritis (Shahrara, Volin et 
al, 2002), thrombus recanalization (Modarai, Burnand et al, 2005) and endometriosis 
(Bacci, Capobianco et al, 2009). 
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Notably, recent work shows that TEMs are present in the blood torrent and in 
the ischemic muscle of chronic limb ischemia patients and that they play a role in the 
revascularization of the ischemic limb in mice (Patel, Smith et al, 2013). These 
emerging evidences suggest the possibility that TEMs could mediate the reperfusion 
of ischemic muscles by promoting endothelial cell survival and exerting both pro-
angiogenic and pro-arteriogenic functions (Hamm, Veschini et al, 2013; Patel, Smith 
et al, 2013).  
 
Angiopoietins and their receptor Tie2 play critical roles in regulating 
angiogenic processes during development, homeostasis, tumorigenesis, 
inflammation and tissue repair (Augustin, Koh et al, 2009). Tie2 signaling is best 
characterized in endothelial cells, wherein ANG1 promotes cell-to-cell contacts and 
vessel stabilization, while ANG2 induces endothelial cell activation and angiogenesis 
(Augustin, Koh et al, 2009; Daly, Eichten et al, 2013). Previous results have shown 
that ANG2 regulates gene expression in TEMs and augments their pro-angiogenic 
functions in cancer and arthritis (Coffelt, Tal et al, 2010; Krausz, Garcia et al, 2012), 
and that ANG2-Tie2 signaling mediates cell-to-cell interaction between endothelial 
cells and TEMs in tumor angiogenesis. Furthermore, recent data show that 
macrophages recruited after femoral artery occlusion are skewed toward a pro-
arterogenic phenotype characterized by induced Tie2 expression (Hamm, Veschini et 
al, 2013). In this context, ANG1-Tie2 signaling in macrophages favours Tie2 
expression through Phd2 repression and canonical NfKb pathway activation overall 
leading to the accumulation of pro-arteriogenic macrophages which enhance 
Figure 5. Model for Tie2-expressing 
macrophage regulation of 
angiogenesis. In tumors or in ischemic 
tissues, endothelial cells (EC)- derived 
angiopoietin (Ang) binds to Tie2 in 
macrophages, promoting a pro-angiogenic 
and vascular remodeling program. 
INTRODUCTION 
 
36 
 
collateral vessels maturation (Hamm, Veschini et al, 2013). These findings suggest 
that, in angiogenesis, secretion of angiopoietins by endothelial cells might promote 
the recruitment of TEMs from circulation and locally enhance their pro-angiogenic 
activity. Similar to angiopoietin signaling in endothelial cells, it has been suggested 
that ANG1-Tie2 axis in macrophages promote vessel maturation, whereas ANG2-
Tie2 signaling is required for angiogenesis (Hamm, Veschini et al, 2013). 
Altogether, these observations raise the possibility that TEMs may be crucial 
in other pathologies in which angiogenesis is required to restore tissue perfusion, 
oxygenation and repair. It may be the case for cardiac healing following MI, in which 
angiogenesis occurring in the last phase of repair is a prerequisite for re-oxigenation 
and cardiac recovery. Although neovascularization of the ischemic myocardium has 
been associated with the presence of Ly6Clo cells, it is tempting to speculate that a 
small subset of highly pro-angiogenic TEM-like cells might exist within the 
macrophage population in the ischemic myocardium that function as the true 
executers of cardiac re-vascularization and repair.  
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1. SISTEMA FAGOCÍTICO MONONUCLEAR Y DESARROLLO DEL 
MACRÓFAGO. 
1.1 Macrófago: función y definición. 
El descubrimiento del macrófago (del griego, makros “grande” y phago 
“comer”) tuvo lugar gracias a los estudios llevados a cabo por Ilya Ilyich Metchnikoff 
a finales del siglo XIX, en los que describió por vez primera el proceso de 
fagocitosis.  Más tarde, en 1968, Ralph van Furth y Zanvil Cohn demostraron que los 
macrófagos derivan de los monocitos circulantes (van Furth and Cohn 1968), lo que 
supuso el establecimiento del sistema mononuclear fagocítico, según el cual existe 
una relación linear entre los precursores de médula ósea, los monocitos circulantes y 
los macrófagos de tejido (van Furth and Cohn 1968).  No obstante, diversos estudios 
realizados en los últimos años han demostrado el origen embrionario de muchas 
poblaciones de macrófagos, lo que ha dado lugar a la redefinición de este modelo 
(Davies, Jenkins et al, 2013).  
 Los macrófagos constituyen la primera línea de defensa del organismo, al 
detectar y eliminar partículas extrañas, actuando por tanto como reguladores 
esenciales de la inflamación y de la respuesta inmune innata. A su vez, los 
macrófagos son importantes en el mantenimiento de la homeostasis e integridad 
tisular. Para ello, participan en la resolución de la inflamación así como en los 
procesos de remodelación de la matriz extracelular, reparación tisular y 
angiogénesis (Wynn, Chawla et al, 2013).  
 Existen dos grupos principales de macrófagos: los macrófagos residentes 
de tejido y los macrófagos extravasados (Pollard 2009; Murray and Wynn 2011). 
Los macrófagos residentes de tejido son poblaciones de macrófagos órgano-
específicas que se encuentran en los tejidos en condiciones fisiológicas (ausencia 
de inflamación y/o infección), donde constituyen la primera barrera de defensa frente 
a posibles cambios o daños externos, manteniendo de esta forma la homeostasis 
tisular. Los macrófagos extravasados, por el contario, son aquellos macrófagos 
derivados de la diferenciación de monocitos circulantes, que son reclutados durante 
los procesos inflamatorios y/o infecciosos.  
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1.2. Desarrollo de los monocitos y macrófagos. 
En el adulto, el proceso de hematopoyesis que tiene lugar en la médula ósea 
constituye la principal fuente de monocitos circulantes, los cuales se forman a partir 
de diversos estados intermedios o precursores de médula ósea, derivados de las 
células madre hematopoyéticas (Figura 2) (Auffray, Fogg et al, 2009).  
 Los monocitos circulantes de sangre periférica son una población muy 
heterogénea que pueden distinguirse por la expresión diferencial de marcadores de 
superficie como Ly6C y CX3CR1 (Yasaka, Mantich et al, 1981; Geissmann, Jung et 
al, 2003; Auffray, Fogg et al, 2007). Los subpoblación de monocitos que expresan 
niveles elevados de Ly6C y niveles intermedios o bajos de CX3CR1 (monocitos 
Ly6Chi) se consideran monocitos pro-inflamatorios, ya que son capaces de migrar 
hacia el foco de inflamación, donde se diferencian en macrófagos clásicos o M1. Los 
macrófagos M1 se caracterizan por la producción de un número elevado de 
citoquinas pro-inflamatorias (IL6, Il1, Il12, TNFa) y por la activación de enzimas 
como iNOS, que permiten la eliminación del patógeno (Serbina and Pamer 2006; 
Dunay, Damatta et al, 2008; Getts, Terry et al, 2008). Por otra parte, se ha descrito 
la existencia de una subpoblación de monocitos circulantes “no clásicos”, que 
muestran una menor expresión de Ly6C y una expresión elevada de CX3CR1  y se 
conocen con el nombre de monocitos Ly6Clo. En respuesta a infecciones o daño 
tisular, los monocitos Ly6Clo son capaces de penetrar en los tejidos donde se 
diferencian en macrófagos alternativos o anti-inflamatorios (M2). Los macrófagos 
M2, están implicados en la resolución de la inflamación, y tienen un papel importante 
en la regulación de los procesos de angiogénesis, reparación y/o cicatrización tisular 
(Geissmann, Jung et al, 2003; Auffray, Fogg et al, 2007; Nahrendorf, Swirski et al, 
2007).  
Recientemente, se ha descrito la existencia de una subpoblación de 
monocitos circulantes anti-inflamatorios, que se caracterizan por la expresión del 
receptor Tie2 y que son conocidos con el nombre de “TEMs” (del inglés, “Tie2-
expressing monocytes”). Estos monocitos, son reclutados hacia el foco de 
inflamación, donde dan lugar a macrófagos Tie2+, implicados en los procesos de 
vasculogénesis y angiogénesis (De Palma, Venneri et al, 2005). 
Dentro del contexto del sistema fagocítico mononuclear, tradicionalmente se 
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ha considerado que los macrófagos residentes de tejido derivan de la diferenciación 
de monocitos circulantes, Ly6Clo. No obstante, diversos estudios llevados a cabo en 
la última década, han demostrado la existencia de poblaciones de macrófagos 
residentes de tejido, que se originan en la etapa embrionaria y que son capaces de 
prevalecer en los órganos a lo largo de la etapa adulta, mediante un proceso de 
auto-renovación y proliferación (Jenkins, Ruckerl et al, 2011).  
 
2. EL MACRÓFAGO EN LA HOMEOSTASIS TISULAR.  
2.1. Macrófagos residentes de tejidos. 
Los macrófagos son componentes importantes de la arquitectura de 
numerosos órganos y tejidos, donde desempeñan un papel esencial en la regulación 
de la homeostasis y remodelación tisular (Pollard 2009). Existen diversas 
poblaciones de macrófagos residentes de tejido, que se hayan distribuidas de forma 
estratégica a lo largo del  organismo (Davies, Jenkins et al, 2013). La 
heterogeneidad y plasticidad funcional de estas poblaciones son consecuencia de su 
especialización en las diferentes localizaciones anatómicas donde se encuentran 
(Figura 3). Algunos ejemplos de macrófagos residentes de tejido los constituyen las 
células Kupffer del hígado, los osteoclastos del hueso, los macrófagos alveolares en 
el pulmón etc..  
Diversos estudios han confirmado el origen embrionario de un gran número 
de macrófagos residentes de tejido, como las células kupffer, la microglia  en el 
cerebro y las células Langerhans en la piel. Se ha demostrado que estas 
poblaciones se establecen de forma prenatal y perduran en los respectivos órganos 
a lo largo de la vida del organismo, por lo que no dependen de la diferenciación a 
partir de monocitos derivados de medula ósea (Ginhoux, Greter et al, 2010; Schulz, 
Gomez Perdiguero et al, 2012; Yona, Kim et al, 2013). De hecho, trabajos recientes 
de mapeo génico con el marcador CX3CR1 han mostrado un origen prenatal para la 
amplia mayoría de macrófagos residentes de tejido, con la excepción de los 
macrófagos intestinales (Zigmond, Varol et al, 2012).  
La capacidad de proliferación y auto-perpetuación de los macrófagos 
residentes de tejido de origen embrionario son requisitos indispensables para su 
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permanencia en los tejidos a lo largo de la edad adulta (Jenkins, Ruckerl et al, 2011; 
Davies, Rosas et al, 2013). Algunos estudios apuntan al ligando M-CSF y a su 
receptor (CSF1R) como posibles candidatos responsables de los mecanismos de 
proliferación de estos macrófagos (Hume and MacDonald 2012).  
  Los macrófagos residentes de tejido han sido considerados tradicionalmente 
como macrófagos M2 de acuerdo a sus propiedades anti-inflamatorias, necesarias 
para el mantenimiento de la homeostasis, remodelado tisular y resolución de la 
inflamación durante el desarrollo fetal y durante la etapa adulta (Mantovani, Sica et 
al, 2005; Rae, Woods et al, 2007; Klimchenko, Di Stefano et al, 2011; Mantovani, 
Biswas et al, 2013). No obstante, esta clasificación es demasiado restrictiva, ya que 
los macrófagos residentes de tejido son altamente heterogéneos, mostrando 
fenotipos únicos, que van más allá del fenotipo M2 y que son consecuencia del 
microambiente que les rodea en cada uno de los órganos (Davies, Jenkins et al, 
2013).  
 
3. EL MACRÓFAGO EN RESPUESTA AL DAÑO TISULAR E 
INFLAMACIÓN. 
Tras la ruptura de la homeostasis tisular debida a procesos inflamatorios o 
infecciosos, los macrófagos llevan a cabo una serie de acciones recogidas en un 
amplio espectro de estados de activación, que tienen como objetivo último la 
reparación y restauración de la integridad del tejido (Mirza, DiPietro et al, 2009; 
Novak and Koh 2013; Novak and Koh 2013).  
La respuesta inflamatoria consecuente al daño o infección, viene dada por el 
reclutamiento de monocitos Ly6Chi, que se diferencian en macrófagos M1, los cuales 
tienen acciones microbicidas, mediadas por la secreción de citoquinas y 
quimioquinas pro-inflamatorias así como por la fagocitosis de los agentes infecciosos 
y del tejido necrosado (Lucas, Waisman et al, 2010; Willenborg, Lucas et al, 2012; 
Novak and Koh 2013; Novak and Koh 2013). No obstante, la presencia prolongada e 
incontrolada de los macrófagos M1, puede dar lugar a la liberación excesiva de 
citoquinas citotóxicas perjudiciales para el tejido. Con el objetivo de contrarrestar el 
daño potencial causado por los macrófagos M1, tiene lugar su muerte por apoptosis 
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o su transformación directa en macrófagos M2, que facilitan la resolución de la 
respuesta inflamatoria (Moyer and Wagner 2011; Murray and Wynn 2011). Los 
macrófagos M2 liberan un gran número de citoquinas anti-inflamatorias y factores de 
crecimiento que promueven los procesos de angiogénesis, remodelación y 
reparación tisular. Los macrófagos M2 pueden derivar de la conversión local a partir 
de macrófagos M1 (Mantovani, Sica et al, 2004; Titos, Rius et al, 2011; Uderhardt, 
Herrmann et al, 2012), así como de la diferenciación de monocitos Ly6Clo, reclutados 
de sangre periférica (Hilgendorf, Gerhardt et al, 2014).  
La contribución de los macrófagos residentes de tejido a la respuesta frente al 
daño tisular no está bien establecida. Algunos estudios de inflamación experimental 
apuntan a un papel de estos macrófagos en la iniciación de la respuesta 
inflamatoria, mediante el reclutamiento de neutrófilos (Maus, Koay et al, 2002; 
Cailhier, Partolina et al, 2005). No obstante, no está claro si en respuesta al daño 
tisular, la acción de los macrófagos residentes de tejido es suficiente para la defensa 
del órgano, o si por el contrario, se requiere siempre la presencia de macrófagos 
extravasados M1 y M2. 
 
 4. POBLACIONES DE MACRÓFAGOS EN EL CORAZÓN.  
4.1. Los macrófagos residentes de corazón.  
Estudios previos han demostrado la existencia de poblaciones de macrófagos 
que se hallan de forma fisiológica en el corazón (Azzawi, Hasleton et al, 1997; 
Azzawi, Kan et al, 2005). Mediante el uso del ratón transgénico CX3CR1
GFP/+, se ha 
descrito la presencia de macrófagos residentes cardíacos que se reconocen por su 
expresión de CX3CR1 y se caracterizan por poseer un perfil génico anti-inflamatorio 
y por su cercanía a células endoteliales y a los cardiomiocitos presentes en el 
miocardio (Pinto, Paolicelli et al, 2012). Por otra parte, recientemente se ha descrito 
la existencia de cuatro poblaciones de macrófagos residentes cardíacos, que se 
distinguen por su expresión de marcadores de superficie como Ly6C, MHCII y por su 
autofluorescencia (Epelman, Lavine et al, 2014). Se ha visto que estas poblaciones 
de macrófagos cardíacos derivan de poblaciones primitivas de macrófagos 
originados en el saco vitelino (Epelman, Lavine et al, 2014).       
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Aunque estos estudios han supuesto un avance en el conocimiento de la 
biología del macrófago en el corazón, actualmente se desconocen cuáles son los 
mecanismos mediante los cuales llevan a cabo el mantenimiento de la homeostasis 
cardíaca y la reparación frente al daño. 
 
4.2. Papel de los monocitos y macrófagos en la respuesta al infarto 
de miocardio. 
4.2.1. Infarto de miocardio: causas y terapias. 
El infarto de miocardio (IM) es la enfermedad cardiovascular más frecuente, 
constituyendo una de las principales causas de mortalidad en el mundo (Hellermann, 
Jacobsen et al, 2003; Hellermann, Jacobsen et al, 2005). El corazón adulto posee 
una capacidad regenerativa muy limitada, por lo que el proceso isquémico que tiene 
lugar tras el IM, trae como consecuencia la muerte de la célula 
cardíaca/cardiomiocito, que es reemplazada por tejido fibrótico no contráctil dando 
lugar a la disfunción y al fallo cardíaco (Jackson, Majka et al, 2001). 
Una de las estrategias emergentes para la prevención del fallo cardíaco en 
pacientes que han sufrido un infarto, consiste en la mejora de los mecanismos de 
reparación y cicatrización cardíaca que tienen lugar durante las dos primeras 
semanas tras el IM. Dichos procesos, requieren una respuesta inflamatoria 
equilibrada para evitar un remodelado excesivo y patológico del corazón tras el 
proceso isquémico.  
Recientemente, el estudio del macrófago ha despertado interés debido a su 
papel reparador en numerosos órganos y tejidos, emergiendo de esta forma como 
nuevo candidato para la investigación enfocada hacia la mejora de la reparación y 
función cardíaca tras el IM (Nahrendorf and Swirski 2013; Hilgendorf, Gerhardt et al, 
2014). 
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 4.2.2. Poblaciones de monocitos y macrófagos en respuesta al 
infarto de miocardio.  
Mediante el uso de modelos experimentales de IM, se ha descrito la 
presencia de dos subpoblaciones de monocitos que aparecen de forma secuencial 
en el miocardio infartado (Nahrendorf, Swirski et al, 2007). Tras el IM, tiene lugar una 
respuesta inflamatoria inicial, que es llevada a cabo por los monocitos Ly6Chi, los 
cuales producen numerosas citoquinas pro-inflamatorias para evitar la infección del 
tejido y llevan a cabo la fagocitosis de los restos celulares derivados de la apoptosis 
y necrosis celular (Nahrendorf, Swirski et al, 2007). Esta respuesta dura de 1 a 3 
días y  es seguida por una fase de proliferación, que se extiende de 4 a 7 días, en la 
que predominan los monocitos anti-inflamatorios Ly6Clo (Nahrendorf, Swirski et al, 
2007). Los monocitos Ly6Clo expresan un gran número de citoquinas anti-
inflamatorias, así como niveles elevados de factores inductores de la angiogénesis 
(VEGF) y de factores promotores de la actividad de los miofibroblastos (TGFβ) 
(Nahrendorf, Swirski et al, 2007; Nahrendorf, Pittet et al, 2010). Se cree que la 
actividad de los monocitos Ly6Clo es crucial para la generación de nueva matriz 
extracelular que permite la sustitución del miocardio dañado por una matriz de 
colágeno, necesaria para proporcionar la estabilidad mecánica del ventrículo 
izquierdo.  
Los estudios llevados a cabo por Nahrendorf y colaboradores, muestran una 
respuesta al IM llevada a cabo de forma exclusiva por monocitos, excluyendo por 
tanto la diferenciación de los mismos a macrófagos así como descartando la 
conversión local de monocitos Ly6Chi en monocitos Ly6Clo (Nahrendorf, Swirski et al, 
2007). No obstante, un trabajo reciente ha demostrado que la subpoblación de 
células Ly6Clo presentes durante la segunda fase de reparación cardíaca son 
realmente macrófagos, que derivan de la diferenciación de los monocitos Ly6Chi, 
presentes en la fase inflamatoria previa (Hilgendorf, Gerhardt et al, 2014). Estos 
hallazgos arrojan luz a la relación existente entre monocitos y macrófagos durante el 
proceso de reparación tras el infarto. No obstante, esta relación aún no está bien 
definida, así como tampoco se conoce la aportación de cada una de estas 
poblaciones a la reparación del miocardio. El hallazgo de marcadores específicos 
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que nos permitan discernir entre monocitos y macrófagos de forma clara, será 
necesario para dilucidar estas cuestiones.  
Varios estudios han puesto el foco de atención en el monocito/macrófago 
como células con potencial reparador del miocardio, indicando el posible uso de los 
mismos como dianas terapéuticas en la enfermedad cardiaca (Lambert, Lopez et al, 
2008). Mediante la eliminación de monocitos y macrófagos con clodronato, se ha 
visto que tanto la fase inicial inflamatoria llevada a cabo por la subpoblación de 
monocitos Ly6Chi así como la fase de proliferación mediada por las células Ly6Clo 
son esenciales para la correcta reparación del miocardio dañado tras el IM 
(Nahrendorf, Swirski et al, 2007; van Amerongen, Harmsen et al, 2007; van 
Amerongen, Harmsen et al, 2008; Frantz, Hofmann et al, 2013). De acorde a esto, la 
eliminación de la fase pro-inflamatoria da lugar a la formación de grandes áreas de 
restos necróticos, mientras que la ausencia de la fase de proliferación o anti-
inflamatoria conduce a una disminución de la deposición de colágeno así como a la 
reducción de la formación de nuevos vasos sanguíneos en la zona infartada 
(Nahrendorf, Swirski et al, 2007).  
Por otra parte, la modulación de la activación del macrófago hacia un fenotipo 
M2 parece ser efectiva en la mejora de la reparación cardiaca tras el IM (Harel-Adar, 
Ben Mordechai et al, 2011). Esta estrategia se basa en el principio fundamental que 
atribuye un papel anti-inflamatorio y reparador a los macrófagos M2 (Nahrendorf, 
Swirski et al, 2007). En línea con estos estudios, trabajos recientes han demostrado 
un efecto positivo en la función cardíaca tras la inyección de células madre 
mesenquimales (MSC) (Dayan, Yannarelli et al, 2011). Este efecto se atribuye a una 
relación directa entre las MSC y los macrófagos, que conlleva un aumento en el 
porcentaje de macrófagos M2 reparadores en la zona infartada (Dayan, Yannarelli et 
al, 2011).  
El estudio de la regeneración cardiaca constituye un objeto de intenso debate 
e investigación, cuya última finalidad es la recuperación del miocardio perdido tras el 
proceso isquémico consecuente al IM. Varios estudios han demostrado un papel 
regenerador del macrófago en distintos órganos y tejidos, lo que ha suscitado la idea 
de que estas células puedan tener una función en la regeneración del miocardio tras 
el infarto (Arnold, Henry et al, 2007; Ruckh, Zhao et al, 2012; Godwin, Pinto et al, 
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2013). No obstante, según el dogma establecido, los cardiomiocitos presentes en el 
corazón del mamífero adulto son células terminalmente diferenciadas sin capacidad 
de proliferación. De hecho, hasta la fecha, la única evidencia de una posible función 
regeneradora del macrófago en el corazón se ha visto en ratones recién nacidos o 
neonatos, los cuales poseen una ventana temporal en la cual el corazón es capaz de 
regenerar (Porrello, Mahmoud et al, 2011). En este contexto, se ha visto que la 
capacidad regenerativa del corazón de los neonatos tras el IM, se debe a la 
presencia del macrófago y a su actividad pro-angiogénica tras el infarto (Aurora, 
Porrello et al, 2014).  
  
4.2.3. Papel de los macrófagos en los procesos de angiogénesis 
consecuentes al infarto de miocardio. 
 Tras el IM, tiene lugar un proceso de formación de nuevos vasos o 
neovascularización en la zona adyacente al infarto, o zona isquémica  necesario 
para el suministro de oxígeno y nutrientes que permitan atenuar la remodelación 
excesiva del ventrículo y por tanto preservar la función cardíaca (Frangogiannis 
2012).  
Mediante el uso de modelos experimentales de infarto en ratón adulto, se ha 
demostrado una contribución del macrófago al proceso de angiogénesis posterior al 
daño cardíaco. Por una parte, se ha visto que la eliminación del macrófago impide la 
neovascularización del miocardio infartado (Nahrendorf, Swirski et al, 2007; van 
Amerongen, Harmsen et al, 2007). A su vez, se ha demostrado  que la inyección de 
macrófagos directamente en la región isquémica guarda una relación directa con un 
aumento en la densidad de vasos sanguíneos en la zona infartada, que se traduce 
en una mejora de la función cardíaca (Leor, Rozen et al, 2006). Muchos de estos 
trabajos apuntan a la población Ly6Clo, como responsable directa del proceso 
angiogénico tras el MI. No obstante, no está claro si es esta la única población que 
contribuye a este proceso, o si por el contrario, existen subpoblaciones pequeñas de 
macrófagos especializadas en la re-vascularización del miocardio.  
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4.2. Papel de los macrófagos Tie2+ en el proceso de angiogénesis.  
Los macrófagos/monocitos Tie2+ (TEMs) son poblaciones celulares 
inductoras de los procesos de angiogénesis que tienen lugar en tumores, órganos en 
desarrollo y durante la remodelación tisular (De Palma, Murdoch et al, 2007; Lewis, 
De Palma et al, 2007; Venneri, De Palma et al, 2007; Bacci, Capobianco et al, 2009; 
Coffelt, Tal et al, 2010; Fantin, Vieira et al, 2010). Los TEMs fueron originalmente 
identificados en tumores, donde se ha visto que constituyen una pequeña fracción 
de la población mieloide infiltrante asociada al tumor, y que se caracteriza por la 
expresión del receptor de angiopoyetina Tie2/Tek (De Palma, Venneri et al, 2005). 
Tie2, es el receptor de tirosina kinasa, que interacciona con sus ligandos, las 
angiopoyetinas (Ang), entre las cuales Ang1 y Ang2 son las mejor caracterizadas 
(Augustin, Koh et al, 2009). Tie2 se encuentra ampliamente expresado en las células 
endoteliales y está implicado en la regulación de los mecanismos de angiogénesis y 
morfología vascular durante el desarrollo embrionario y durante la etapa adulta 
(Augustin, Koh et al, 2009). Las células endoteliales activadas secretan altos niveles 
de Angs, que se unen a su receptor Tie2 bien de forma autocrina en la misma célula 
endotelial, o de forma paracrina en los TEMs. Dicha unión da lugar a una vía de 
señalización en los TEMs mediante la cual se activa un programa pro-angiogénico 
en estas células, que facilita el modelado vascular durante el desarrollo embrionario, 
en tumores y en tejidos isquémicos (Mazzieri, Pucci et al, 2011) (Figura 6). 
Los macrófagos Tie2+, exhiben características típicas de macrófagos M2 
asociados a tumor (TAMs) (Pucci, Venneri et al, 2009; Sica and Mantovani 2012), 
pero difieren de estos últimos por su alta capacidad pro-angiogénica, así como por 
su localización preferencialmente en zonas perivasculares. Estudios en modelos 
animales sugieren una interacción directa entre los TEMs y las células endoteliales, 
en la que los primeros proporcionan un soporte paracrino que permite la fusión de 
los extremos de los vasos de nueva formación, dando lugar al proceso de 
angiogénesis (Fantin, Vieira et al, 2010; Mazzieri, Pucci et al, 2011). 
Trabajos recientes han demostrado un papel de los TEMs en el proceso de 
re-vascularización del músculo esquelético durante la isquemia crónica muscular 
(Hamm, Veschini et al, 2013; Patel, Smith et al, 2013). Estos estudios muestran la 
contribución de los TEMs en funciones pro-angiogénicas y pro-arteriogénicas, que 
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promueven la formación de nuevos vasos así como el aumento del diámetro de los 
vasos prexistentes, necesario para la recuperación del tejido muscular dañado tras 
la isquemia.  
En conjunto, estos hallazgos suscitan la posibilidad de que los TEMs puedan 
ser cruciales en otras patologías en las que se requiere un  proceso de formación de 
nuevos vasos para la restauración del flujo sanguíneo tisular y la consiguiente 
reparación del tejido u órgano isquémico. Este podría ser el caso del miocardio 
dañado tras el infarto, en el que la neovascularización que tiene lugar en las últimas 
fases de reparación tisular, constituye un requisito indispensable para la re-
oxigenación y recuperación cardiaca. Es tentador especular con la idea de la 
existencia de subpoblaciones pro-angiogénicas de macrófagos Tie2+, que funcionen 
como promotores reales del proceso de re-vascularización del miocardio tras el MI.  
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Macrophages are crucial in development, in maintaining tissue homeostasis 
and in promoting tissue repair after injury in several organs. However, the specific 
function of these cells, or their subsets, in the heart is not well understood. Therefore, 
we sought to explore macrophage populations and their phenotypes in the heart in 
physiological state and upon injury. For that purpose, we used mouse models of 
myocardial injury/infarction such as cryoinjury and LAD-ligation.  
       To dissect the role of macrophages in both, the healthy heart and in response 
to myocardial infarction, we propose the following aims: 
1. To identify and characterize different macrophage populations residing in the 
heart in healthy conditions. 
 
2. To identify and characterize the distinct subsets of macrophages and their 
contribution to cardiac healing/repair upon myocardial infarction. 
 
3. To identify and characterize Tie2-expressing macrophages in the context of 
ischemic myocardium and to evaluate their possible role in cardiac 
healing/repair. 
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Mice 
The mouse strains used were the following: 
1. C57BL/6 wild type mice (Charles Rivers).  
2. Macrophage Fas-Induced Apoptosis (MaFIA) transgenic mice: 
  The generation of these mice has been previously described (Burnett, 
Kershen et al, 2004). Briefly, a Fas suicide/apoptotic construct (containing an IRES 
sequence and the intracellular domain region of the Fas gene) was inserted 
immediately downstream of the Enhanced Green Fluorescent Protein gene (EGFP). 
This entire construct was placed under the control of the mouse colony stimulating 
factor 1 receptor (Csf1r) promoter, which is specific for the monocyte/macrophage 
lineage. The resulting 11.1 kbp transgene (termed Macrophage Fas-Induced 
Apoptosis or MaFIA) was introduced into C57BL/6 donor eggs. The resulting 
transgenic mice were maintained in a C57BL/6 background.  
3. CX3CR1 
GFP/+ knock-in mice.  
These mice have been previously described (Jung, Aliberti et al, 2000).    
Briefly, a targeting vector containing an EGFP cDNA sequence, loxP-flanked 
neomycin resistance gene (neo), herpes simplex virus thymidine kinase gene, and 
SV40 polyadenylation site sequence was used to disrupt the first 390 bp of the gene 
encoding CX3CR1, the receptor for the chemokine fractalkine (CX3CL1). 
CX3CR1
+/GFP heterozygous mice maintained in C57BL/6 background were used for 
this study.  
4. Tie2-GFP transgenic mice. 
These mice were generated as previously described (Motoike, Loughna et al, 
2000). Briefly, a LacZ was replaced by GFP in the previously described Tie2-LacZ 
construct (Schlaeger, Bartunkova et al, 1997) resulting in transgenic mice containing 
the endothelial-specific receptor tyrosine kinase (Tek, formerly, Tie2) 
promoter/enhancer elements fused to GFP cDNA. Mice were maintained on an 
FVB/N background. 
All mice were used in a mix of males and females of 2-3 months old. 
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DNA extraction and mice genotyping 
Genotyping of the different genes was performed by PCR of genomic DNA 
extracted from tail snips. Total DNA was obtained using REDExtract-N-Amp Tissue 
PCR Kit, (Sigma). The following primers were used: 
 
-MaFIA: 
EGFP Forward:  5´-CCAGGAGCGCACCATCTTCTT-3´  
EGFP Reverse:  5´-GTAGTGGTTGTCGGGCAGCAG-3´   
  
-CX3CR1:  
Wild type Forward: 5´-TTCACGTTCGGTCTGGTGGG-3´ 
Common:                5´-GGTTCCTAGTGGAGCTAGGG-3´ 
Mutant Forward:     5´-GATCACTCTCGGCATGGACG-3 
 
-Tie2-GFP: 
 EGFP Forward:   5´-ATTCTCGTGGAACTGGATGG-3´ 
 EGFP Reverse: 5´-GGACAGGTAATGGTTGTCTGG-3´ 
 
Mice were maintained in a specific pathogen-free (SPF) environment and were 
fed standard mouse diet ad libitum. Animal studies were approved by the CNIC 
Animal Experimentation Ethics Committee. All animal procedures conformed to EU 
Directive 2010/526/EC regarding the protection of animals used for experimental and 
other specific purposes, enforced in Spanish law under Real Decreto 1201/2005. 
 
Mouse models of myocardial infarction 
1. Cryoinjury 
Cryoinjury was induced as described before (van Amerongen, Harmsen et al, 
2008). Briefly, mice were weighed, anesthetized with sevoflurane (4%), and intubated 
using a 24-gauge intravenous catheter with a blunt end. Mice were artificially 
ventilated with a mixture of O2 and air [1:1 (vol/vol)] using a rodent ventilator 
(minivent 845, Harvard) with 160 strokes/min in a total volume of 250μl. A 
thoracotomy was performed through the fourth left intercostal space, the pericardium 
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was opened, and the heart was exposed. Mice were placed on a heating pad to 
maintain body temperature at 37°C. Cryoinjury was induced by applying a 2 mm 
diameter cryoprobe, cooled to −196°C with liquid nitrogen to the anterior left ventricle 
free wall for 10 seconds. After this, the procedure was repeated three times. The 
exact position of the probe was carefully set using the left atrium and pulmonary 
artery as anatomic landmarks. Sham-operated mice underwent the same procedure, 
but a non-frozen probe was used. Control mice (day 0) were not subjected to any 
surgery. 
2. Left anterior descending coronary artery ligation (LAD-ligation)  
Ligation of the LAD coronary artery was performed as described previously 
(Salto-Tellez, Yung Lim et al, 2004). The same procedure as in cryoinjury was used. 
Briefly, mice were anesthetized and artificially ventilated. A thoracotomy was 
performed through the fourth left intercostal space, the pericardium was opened, and 
the heart was exposed. The proximal LAD coronary artery was localized and 
permanently ligated by passing a 7-0 silk suture mounted on a tapered needle 
around the artery. Sham animals underwent a thoracotomy without infarct induction. 
Control animals did not undergo any surgery. 
 
Echocardiographic analysis  
Transthoracic echocardiography was performed on mice subjected to 
cryoinjury or LAD-ligation. Mice were anesthetized by inhalation of isofluorane and 
oxygen (1.25% and 98.75%, respectively) and moved to a biofeedback warming 
station that maintained core body temperature. Ultrasound gel was applied to the 
chest of the animals, and echocardiography measurements were obtained using the 
VEVO 2100 software package and ultrasound system with a linear transducer 
MS400 18–38 MHz. (Visual Sonics, Toronto, Canada). Short-axis, long-axis, B-mode 
and two-dimensional M-mode views were obtained as described previously (Cruz-
Adalia, Jimenez-Borreguero et al, 2010). From these images, left ventricle ejection 
fraction was estimated by the ejection fraction obtained from the M-mode by a 
blinded echocardiography expert. For the ejection fraction measurements, a long- or 
short-axis view of the heart was selected to obtain an M-mode registration in a line 
perpendicular to the left ventricular septum and posterior wall at the level of the mitral 
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chordae tendinea. Ultrasounds were performed in collaboration with Dr. J. 
Borreguero and María Villalba (CNIC).  
 
Immunohistochemistry and confocal microscopy  
For Masson’s trichrome analysis, hearts were perfused with cold PBS, fixed in 
4% PFA overnight, embedded in paraffin and sectioned (10μm) with a manual 
microtome.  
 For immunofluorescence analysis, hearts were embedded in OCT/sucrose 
and sectioned (8μm) with an automatic cryostat.  OCT-embedded sections were 
permeabilized with 0.1% Triton X-100 (Sigma)/ PBS solution, and blocked in 1% 
goat-serum/ 0.1% Triton X-100/PBS for 1h. Cells were labeled with primary 
antibodies (4ºC, overnight) and with fluorescently labeled secondary antibodies (45 
min at room temperature). 
The antibodies used are listed in Table 1. Fluorescent microscopy images 
were obtained using a Zeiss LSM700 confocal microscope (Plan-Apochromat 10X, 
25X or 40X1.3 Oil DIC M27) and images were analyzed with ZEN software and 
IMARIS. 
 
Whole-mount staining 
Hearts were removed and fixed with 4% PFA/ 5% goat serum overnight at 4ºC 
and dehydrated in 25% sucrose. Fixed hearts were flat mounted and blocked in 2% 
BSA/PBS/0.3% Triton X-100 followed by overnight incubation with primary 
antibodies. The next day, the hearts were extensively washed with PBS and 
incubated with fluorescent-conjugated antibodies. Images were acquired with Zeiss 
LSM700 confocal microscope (Plan-Apochromat 10X, 25X or 65X1.4 Oil DIC M27) 
and were analyzed with ZEN and IMARIS software. 
 
Antibodies and FACS analysis  
For extraction of cardiac single cell suspensions, mice were euthanized by 
CO2 fixation and hearts were harvested and perfused with cold PBS through the apex 
in order to remove blood. For all the studies, the right and left atria were removed 
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and the rest of the heart was used for analysis. Hearts were minced with fine 
scissors, and placed into a cocktail of collagenase IV (0,1%) and protease (0,1%) in 
HBBS buffer and shaken at 37°C for 45 min. Cells were then triturated through nylon 
mesh of 100 μm and centrifuged (10 min, 1400 rpm, 4° C). The resulting single-cell 
suspensions were washed with PBS supplemented with 0.5% BSA, and red blood 
cell lysis was performed for 3 min using a commercial red blood cell lysis buffer. 
Single cell suspensions were blocked with Fc block for 15 min and were incubated 
with primary and secondary antibodies for 15 min. All the incubations were performed 
at room temperature, in PBS supplemented with 0.5% BSA. For CD206 (Mrc1) 
staining, cells were fixed and permeabilized by using a commercial kit (Fixation & 
Permeabilization, eBioscience). All flow cytometric analysis were done in a FACS 
Canto 3L using FACS Diva and FlowJo Software. All antibodies used in this study 
are listed in Table 1.  
 
Cell sorting 
To sort cardiac macrophages, cell suspensions were collected, washed and 
cell surface molecules were labeled as described above.  
To isolate splenic macrophages, spleens were removed, minced and triturated 
through 40 μm filters in HBSS. Red blood cells were lysed for 3 min and cell 
suspensions were washed in PBS supplemented with 10% FBS.  
Peritoneal cavity macrophages were isolated by lavage of mouse peritoneal 
cavities with 15 ml of cold PBS. Cell suspensions were centrifuged and the resulting 
cells were washed in PBS supplemented with 10% FBS. 
Cell sorting was performed using FACS-ARIA cell sorter (Becton Dickinson) 
and all samples were sorted directly into PBS supplemented with 10% FBS for RNA 
extraction. 
 
Quantitative Real Time PCR (Q-PCR) 
For relative quantification of expression, quantitative real-time PCR analysis 
was performed using the AB7900 FAST 384 Detection System (Applied Biosystems), 
according to the manufacturer´s instructions. Total RNA was isolated from FACS-
sorted cells using Quiagen RNA synthesis kit (RNeasy micro kit, Quiagen). DNaseI 
treatment and cDNA synthesis were performed with 500ng of total RNA by using 
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High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene 
expression values were normalized to the housekeeping genes 36b4 and cyclophilin, 
and expressed as relative mRNA level. Data were analyzed by qBASE program 
(Biogazelle, Zwijnaarde, Belgium) obtaining the Ct of the amplification products. 
Primer sequences are shown in Table 3. 
 
Gene clustering analysis 
Clustering analysis of signal intensity from Q-PCR data were performed using 
Genesis software (http://genome.tugraz.at). Genesis is a Java independent platform 
to visualize and analyze a whole set of expression patterns, generating a matrix of 
genes/proteins based on different similarity distance measurements and creating a 
hierarchical clustering and self-organizing map (Sturn, Quackenbush et al, 2002). 
 
RNA sequencing analysis 
Total RNA samples were isolated from three independent biological replicates 
using Zymo research RNA synthesis kit (Direct-zol RNA miniprep, Zymo research), 
and were analysed with a Bioanalyzer (Agilent Technologies) system for RNA quality. 
cDNA was amplified from total RNA (1-10 ng) using the Ovation® RNA-seq System 
v2 (NuGEN® Technologies, San Carlos CA). Amplified cDNA (1 ug) was sonicated to 
an average size of 200-300 bp and used with the TruSeq DNA Sample Preparation 
v2 Kit (Illumina, San Diego CA) to generate index-tagged sequencing libraries. 
Libraries were applied to an Illumina flow cell and sequence-by-synthesis single 
reads of 54 base length using the TruSeq SBS Kit v5 (Illumina) were generated on 
the Genome Analyzer IIx following the standard RNA sequencing protocol. Reads 
were further processed using the CASAVA package (Illumina). Read quality was 
determined by analyzing reads with the application FastQC 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc. The reads were then 
aligned using Bowtie version 0.12.7 and then mapped to the transcripts using the 
latest Ensembl transcript set using RSEM v1.16 (Li and Dewey 2011). Differentially 
expressed genes were detected using the statistical models implemented in edgeR 
package from bioconductor. Genes with an adjusted-p value lower than 0.05 were 
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considered differentially expressed. Gene Ontology analysis was performed using 
Ingenuity and Babelomics.   
 
Bioinformatic data analysis and Babelomics 
The Babelomics web tool (http://www.babelomics.org/) is an available program 
suited to analysis of large-scale experiments (microarray, proteomics) with functional 
annotation (Medina, Carbonell et al, 2010). The FatiGO module was used for 
enrichment analysis of selected genes (Al-Shahrour, Diaz-Uriarte et al, 2004) and for 
the analysis of KEGG pathways (Kanehisa, Goto et al, 2004). This functional profiling 
was performed by comparing two lists of genes; the first being the genes encoding 
the differentially expressed genes (DEGs) obtained in the RNA-seq analysis with 
adjusted P<0.05, and the second being the rest of the genome. 
 
Data analysis and statistical analysis 
Statistical comparisons were performed using the unpaired student’s t-test 
when comparing two groups. For comparisons of more than two groups, two-way 
ANOVA was used with Tukey´s post-test to adjust for multiple comparisons. All the 
experiments were performed at least in triplicate. Data are represented as mean 
value ± standard error of the mean (SEM). Differences were considered significant 
when p<0.05; *0.05>p>0.01, **0.01>p>0.001, ***p<0.0001. 
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MATERIALS AND REAGENTS 
Table 1. Antibodies 
CD16/CD32 (rat anti mouse) 553141, BD Biosciences 
CD45- PerCP-Cy5.5 (rat anti mouse) 550994, BD Pharmingen 
CD11b-PE Cy7 (rat anti mouse) 552850, BD Biosciences 
CD11b (biotin conjugated rat anti mouse) MCA74BT, AbD Serotec 
F4/80-PE (rat anti mouse) MCA497RT, AbD Serotec 
Ly6C-APC (rat anti mouse) 560595, BD Pharmingen 
Ly6C-FITC (rat anti mouse) 553104, AbD Serotec 
Ly6G-PE (rat anti mouse) 551461, BD Biosciences 
B220- PerCP-Cy5.5 (rat anti mouse) 561101, AbD Serotec 
CD11c-FITC (rat anti mouse) 110114, BD Biosciences 
CD3ε-FITC (rat anti mouse) 530031, BD Biosciences 
CD64-APC (rat anti mouse) 558539, AbD Serotec 
CD68- PerCP-Cy5.5 (rat anti mouse) 137010, BioLegend 
CD68 (purified rat anti mouse) MCA1957, AbD Serotec 
CD206-APC (rat anti mouse) MCA2235A647T, AbD Serotec 
CD206 (Mrc1) (rat anti mouse) MCA2235, AbD Serotec 
Lyve1 (rabbit anti mouse) sc-28190,Santa Cruz Biotechnology 
MHC-II (rat anti mouse) MCA1107FT, AbD Serotec 
MerTK (biotin-conjugated rat anti mouse) 108928, R&D systems 
GFP (chicken anti mouse) Ab13970, Abcam 
CD31 (PECAM-1) (hamster anti mouse) MAB1398Z, AbD Serotec 
CD31-APC 551262, BD Pharmingen 
NG2 (mouse anti mouse) Ab83508, Abcam 
SMA (mouse anti mouse) A5228, Sigma  
Alexa 647 conjugated secondary antibody (chicken 
anti rat) 
A21472, Invitrogen 
Cy3 conjugated secondary antibody (goat anti 
rabbit) 
112166062,Jackson Immunoresearch 
Cy3 conjugated secondary antibody (goat anti 
chicken) 
ab97145, Abcam 
FITC conjugated secondary antibody (goat anti rat) A11006, Invitrogen 
FITC conjugated secondary antibody (goat anti 
rabbit) 
A11034, Invitrogen 
Alexa 647 conjugated secondary antibody (goat 
anti hamster) 
A21451, Invitrogen 
Alexa 647 conjugated streptavidin  S32357, Invitrogen 
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Table 2. Reagents and buffers 
HBBS Hanks´balanced solution  H6648, Sigma 
Red blood cells lysis buffer  00433357, eBioscience 
Fixation and permeabilization kit 88882388, eBioscience 
Collagenase IV (528 Units/mg) C5138, Sigma 
Protease XIV (528 Units/mg) P5147, Sigma 
 
 
Table 3. Primers 
36b4 Forward 5´-GCGACCTGGAAGTCCAACTA-3´ 
Reverse 5´-ATCTGCTGCATCTGCTTGG-3´ 
Cyclophilin Forward 5´ -ACAGGTCCTGGCATCTTGTC-3´ 
Reverse 5´-CATGGCTTCCACAATGTTCA-3´ 
Cox2 Forward 5´-ATTCTTTGCCCAGCACTTCA-3´ 
Reverse 5´-GGGATACACCTCTCCACCAA-3´ 
Il1b Forward 5´-TGGGCCTCAAAGGAAAGAAT-3´  
Reverse 5´-CAGGCTTGTGCTCTGCTTGT-3´  
Il6 Forward 5´-CCAGAGATACAAAGAAATGATGG-3´  
Reverse 5´-ACTCCAGAAGACCAGAGGAAAT-3´ 
Nos2 Forward 5´-CAGCTGGGCTGTACAAACCTT-3´ 
Reverse 5´-CATTGGAAGTGAAGCGTTTCG-3´ 
Cd163 Forward 5´ -TCTTTGTTGTGGCTGTGAGC-3´ 
Reverse 5´ -CCCCACTTGTCATGGATCTT-3´ 
Cx3cr1 Forward 5´-AAGTTCCCTTCCCATCTGCT-3´ 
Reverse 5´-CGAGGACCACCAACAGATTT-3´ 
Igf1 Forward 5´-TGGATGCTCTTCAGTTCGTG-3´ 
Reverse 5´-GCAACACTCATCCACAATGC-3´ 
Mrc1 Forward 5´-ATGCCAAGTGGGAAAATCTG-3´ 
Reverse 5´-TGTAGCAGTGGCCTGCATAG-3´ 
Retnla Forward 5´-CCCTTCTCATCTGCATCTCC-3´ 
Reverse 5´-CAGTAGCAGTCATCCCAGCA-3´ 
Lyve1 Forward 5´-AGAATGGCAAAGGTGTCCCTG-3´ 
Reverse 5´-GTCCAACACGGGGTAAAATG-3´ 
Stab1 Forward 5´-CCCGGATACACTCAGCAAGA-3´ 
Reverse 5´-CTTTCCCATCTCCGTGGTAA-3´ 
Vegfa Forward 5´-GCGAGGCAGCTTGAGTTAAA-3´ 
Reverse 5´-TCTTTCCGGTGAGAGGTCTG-3´ 
F4/80 Forward 5´- CTTTGGCTATGGCTTCCAGTC-3´ 
Reverse 5´-GCAAGGAGGACAGAGTTTATCGTG-3´ 
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MerTK Forward 5´-GACTCCCTATCCCGGAGTTC-3´ 
Reverse 5´-CTGCAGCCTCAACACAGAGA-3´ 
Cd64 Forward 5´-GGGAAGACACCGCTACACAT-3´ 
Reverse 5´-CTGCAGCCTCAACACAGAGA-3´ 
Cd68 Forward 5´-ACCGCCATGTAGTCCAGGTA-3´ 
Reverse 5´-ATCCCCACCTGTCTCCTCTTCA-3´ 
Cd115 Forward5´ -AACACTGGGACCTACCGTTG-3´ 
Reverse5´ -GCCATGGCGAGAAGAAGTAG-3´ 
Mmp13 Forward5´ -ATCCTGGCCACCTTCTTCTT-3´ 
Reverse5´ -TTTCTCGGAGCCTGTCAACT-3´ 
Cdh5 Forward5´ -CAGGGAATGTGCTTGCCTAT-3´ 
Reverse5´ -TCACACGGATGACAGAGGTC-3´ 
Tk (Tie2) Forward5´ -CCTTCACCAGGCTGATTGTT-3´ 
Reverse5´ -ATAAACCCAGGAGGGAAAT-3´ 
Pecam1 (Cd31) Forward5´ -TGCACAGTGATGCTGAACAA-3´ 
Reverse5´ -CCATGAGCACAAAGTTCTCG-3´ 
Epas Forward5´ -TGAGTTGGCTCATGAGTTGC-3´ 
Reverse5´ -TTGCTGATGTTTTCCGACAG-3´ 
Angpt2 Forward5´ -ATGTGGTGCAGAACCAGACA-3´ 
Reverse5´ -TGGTCTGATCCAAAATCTGCT-3´ 
Pparg Forward5´ - AAGAGCTGACCCAATGGTTG-3´ 
Reverse5´ - GCATCCTTCACAAGCATGAA-3´ 
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Objective 1 Identification and characterization of different 
macrophage populations residing in the heart in healthy conditions. 
Our first aim was to identify the populations of macrophages present in the 
heart in homeostatic conditions and to explore their identity and functional properties. 
For that purpose, we used in vivo cell tracking approaches, immunofluorescence, 
and gene expression profile analysis.  
 
1.1. Characterization of cardiac resident macrophages in C57BL/6 
mice. 
To characterize cardiac macrophages we performed flow cytometry analysis 
(FACS) of cells isolated from digested C57BL/6 mouse hearts. We identified a 
population of leukocytes, recognized as CD45+ cells (Figure 1A, left), most of which 
were myeloid cells, as identified by CD11b staining (Figure 1A, right). The analysis 
of the macrophage and monocyte specific markers F4/80 and Ly6C revealed a 
population of F4/80+ / Ly6Clo cells within the myeloid gate (Figure 1B). These cells 
were found in high number, accounting for the ~65% of the total CD45+ gate (Figure 
1B and C).  
To ensure that this macrophage population was pure, we analyzed the 
expression of macrophage specific markers. F4/80+ / Ly6Clo cells stained positive for 
MerTK, CD64, CD68 and for the maturation/activation marker MHCII (IAb), confirming 
their macrophage identity (Figure 2A, top). MHCII staining gave rise to two subsets 
of MHCIIhi and MHCIIlo cells within the F4/80+ / Ly6Clo population. In addition, F4/80+ 
/ Ly6Clo cells showed positive labeling for the M2-like markers Mrc1 and Lyve1 
(Figure 2A, bottom).  
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Figure 1 Identification of cardiac resident macrophages in C57BL/6 mice. 
Cardiac single cell suspensions from healthy hearts of C57BL/6 mice were analyzed by 
FACS. (A) Dot plot depicting CD45
+
 leukocytes (after doublets exclusion by FSC-W versus 
FSC-A) (left) and CD11b
+
 myeloid cells within the CD45
+
 gate (right). (B) Dot plot showing 
F4/80
+
 / Ly6C
lo
 
cells within the myeloid gate. (C) Total number of leukocytes (CD45
+
 cells) 
and F4/80
+
 
/ Ly6C
lo
 cells per mg of tissue in the heart. Data represent the mean ± SEM of 5 
independent experiments with a pool of 4-5 mice per group. 
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 We further analyze the expression of distinct immune cell surface markers to 
distinguish F4/80+ / Ly6Clo cells from other myeloid and non-myeloid cells. No 
staining was detected for Ly6G and CD11c, which represent granulocyte and 
dendritic cell markers respectively (Figure 2B, top). In addition, no expression was 
shown for the lymphocyte markers B220 and CD3e (Figure 2B, bottom). These data 
indicate that F4/80+ / Ly6Clo cells within the mouse myocardium are macrophages 
and thus, we have denominated this population “cardiac resident macrophages” 
(CRMs). 
 
 
 
 
 
Figure 2 Immunophenotype of cardiac resident macrophages in C57BL/6 mice. 
F4/80
+
 / Ly6C
lo
 
cells from C57BL/6 mouse hearts were analyzed for the expression of the 
indicated antibodies. (A) Histograms for MerTK, CD64, CD68, MHC-II, Mrc1 and Lyve1 
expression detected within the F4/80
+
 / Ly6C
lo
 
population. (B) Histograms for granulocytes 
(Ly6G), dendritic cells (CD11c), B cells (B220) and T cells (CD3ε) related markers show 
negative expression in F4/80
+
 / Ly6C
lo
 cells. Controls represent cells labeled with the antibodies 
CD45, CD11b, F4/80 and Ly6C but not with the antibody of interest in each case (MerTK, 
CD64, CD68, MHC-II, Mrc1, Lyve1, Ly6G, CD11c, B220 or CD3ε). Histograms are 
representative of 3 independent experiments with mouse group sizes of 4-5 mice.  
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1.1.1. Distribution of cardiac resident macrophages in the heart. 
 We next sought to determine the distribution of CRMs and their localization in 
relation to the coronary vasculature. For that purpose, immunofluorescence analysis 
were conducted on heart sections after staining with CD68, Dapi (for the nuclei) and 
the pericyte and endothelial cell specific markers NG2 and CD31, respectively. 
Confocal analysis of adult left ventricular myocardium revealed a population of 
large extravascular CD68+ cells that were recognized as CRMs. These cells were 
found equally distributed along distinct cardiac areas, occupying interstitial spaces 
and exhibiting no preferential anatomic distribution (Figure 3A). CRMs were 
identified as mononuclear cells with ameboid cell body and stellate shaped 
morphology (Figure 3B). 
The heart is provided with an abundant network of small capillaries and big 
blood vessels essential for supplying the myocardium with oxygen and nutrients 
(Brutsaert 2003). Confocal analysis of heart sections stained with CD31 revealed an 
innermost layer of vascular endothelium underlying the myocardium and a dense 
network of small capillaries distributed throughout the cardiac muscle (Figure 3A and 
B). By NG2 staining, we identified pericyte-coated big blood vessels likely 
representing arteries and arterioles that were located within the myocardium (Figure 
3A and B). Notably, CRMs were found in close proximity to either CD31+ capillary 
endothelial cells (Figure 3B; 2 and 4), or with NG2+ pericytes (Figure 3B; 1 and 3) 
exhibiting a predominant perivascular position (Figure 3B). These findings were 
supported by three-dimensional reconstruction of stained sections showing the close 
proximity of CRMs to coronary vasculature, including big vessels (Figure 3C, 
middle) and small capillaries (Figure 3C, right). 
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Figure 3 Confocal analysis of cardiac resident macrophages in C57BL/6 mice. 
(A) Cross sectional image of C57BL/6 mouse heart left ventricle stained for nuclei (blue), CD68 
(red), CD31 (white) and NG2 (green). Left ventricle is indicated (LV). (B) Magnified projection view 
of regions from (A) highlighted in white shows CD68
+
 cells (white arrows) with perivascular 
position. Endothelial cells were stained with CD31 (yellow arrowheads) and pericytes were stained 
with NG2 (white arrowheads). (C) 3D reconstruction of heart sections stained for CD68 (red), 
CD31(white) and SMA (green) showing macrophages (CD68
+
 cells; white arrows) in close 
proximity to either big CD31
+ 
/ SMA
+ 
blood vessels (white arrowheads) or CD31
+
 small capillaries 
(yellow arrowheads). (D) Micrographs of adult C57BL/6 mouse heart sections stained for CD68 
(red), CD31(white) and Lyve1 (white) showing CD68
+
 / Lyve1
+
 (left, white arrows) and Lyve1
+ 
/ 
Mrc1
+ 
(right, white arrows). CRMs are found near to CD31
+
 endothelial cells (yellow arrowheads). 
White lines represent scale bars. Images are representative of at least 3 hearts.  
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Tissue-resident macrophages have been considered as “M2-like” cells 
consistent to their role in tissue homeostasis (Davies, Jenkins et al, 2013). We 
examined the expression of the typical M2-like genes Lyve1 and Mrc1 by CRMs. We 
found that CRMs co-expressed CD68 and Lyve1 (Figure 3D, left), and that Lyve1+ 
CRMs also exhibited positive labeling for Mrc1 (Figure 3D, right).  
These results demonstrate that the heart contains a population of 
macrophages that are associated with the coronary vasculature and show expression 
of anti-inflammatory markers.  
 
1.1.2. Gene expression profile of cardiac resident macrophages. 
To develop a gene signature for CRMs, we next identified genes that might 
distinguish CRMs from other tissue-resident macrophages. Splenic and peritoneal 
F4/80+ macrophages were selected for that purpose, since these cells have been 
previously characterized and accepted as bona fide tissue-resident macrophages 
(Gautier, Shay et al, 2012). After isolation of macrophages from heart, spleen and 
peritoneum of C57BL/6 mice (Figure 4A, B and C) we assessed the expression of 
typical M2-like genes by Q-PCR.  
The analysis revealed that CRMs expressed high levels of M2-like markers 
associated to tissue homeostasis such as Cd163, Cx3cr1 and Mrc1 compared to 
peritoneal and splenic macrophages (Figure 5A). In addition, CRMs differentially 
expressed some pro-angiogenic (Lyve1 and Stab1) and tissue-remodeling (Mmp13, 
Timp3) genes (Figure 5A). In contrast, Retnla was upregulated in peritoneal 
macrophages compared to CRMs and splenic cells. Moreover, splenic macrophages 
showed a slight upregulation of other M2-like genes such as Igf1 and Pparg 
compared to CRMs and peritoneal macrophages.  
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Figure 4 FACS-sorting isolation strategy of cardiac, splenic and peritoneal 
macrophages from C57BL/6 mice. 
 Dot plots depicting isolation of F4/80
+
 / Ly6C
lo
 CRMs from heart (A), CD11b
+
 / F4/80
+
  
macrophages from peritoneum (B) and CD11b
+
 / F4/80
+
. macrophages from spleen. (C). 
Images are representative of 3 independent experiments with mouse group sizes of 5-10 
mice. 
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Figure 5 Gene expression profile analysis of FACS-sorted cardiac, peritoneal and splenic 
macrophages from C57BL/6 mice. 
Gene expression profile of tissue-homeostatic genes (A), tissue remodeling (Mmp13, Timp3) 
and pro-angiogenic (Igf1, Lyve1, Stab1) genes (B) in CRMs, peritoneal macrophages and 
splenic macrophages. Data represent the mean ± SEM of 3 independent experiments with a 
pool of 5-10 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001.  
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We additionally compared the gene M2-like gene expression patterns obtained 
by Q-PCR between the three populations of macrophages by using hierarchical 
clustering analysis with Genesis (Sturn, Quackenbush et al, 2002). The analysis 
differentiated a group of genes highly enriched in CRMs compared to peritoneal and 
splenic cells that included Cd163, Cx3cr1, Mmp13, Timp3, Lyve1 and Stab1 (Figure 
6).  
        
 
These findings suggest that CRMs may have a unique tissue-homeostatic 
signature compared to other tissue-resident macrophages. The higher expression of 
several anti-inflammatory, pro-angiogenic and tissue remodeling genes by CRMs 
points out a role for these cells in immunomodulation, regulation of angiogenesis, 
and matrix remodeling. 
 
Figure 6 Gene specific signature of cardiac resident macrophages. 
Hierarchical clustering of genes detected in isolated macrophages by Q-PCR was 
performed by the high content analysis software Genesis upon normalization of 
data. Differentially expressed genes in CRMs compared to peritoneal (PT MP) and 
splenic(SP MP) macrophages were grouped in a cluster. Red indicates upregulated 
genes whereas green indicates downregulated genes. 
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1.2. Characterization of cardiac resident macrophages in MaFIA 
transgenic mice. 
  In addition to C57BL/6 mice, we performed cell tracking approaches to 
characterize CRMs. We used the MaFIA transgenic (Tg) mouse, that express the 
enhanced green fluorescent protein (GFP) under the control of the c-fms promoter 
(Csfr-1/Cd115) (Burnett 2004). In MaFIA mice, pro-inflammatory and anti-
inflammatory monocytes/macrophages can be respectively recognized as Ly6Chi / 
GFP+ and Ly6Clo / GFP+ cells (Burnett 2004). Based on this, we performed FACS 
and immunofluorescence analysis in order to identify CRMs in this model. 
  After extraction of cells from MaFIA mouse hearts, we performed FACS 
analysis. Leukocytes were identified as CD45+ cells (Figure 7A, left), and myeloid 
population as CD11b+ cells (Figure 7A, right). A population of Ly6Clo / GFP+ cells 
was found within the CD11b+ gate that accounted for ~60% of the total CD45+ cells 
(Figures 7B). Further FACS analysis showed that   Ly6Clo / GFP+ cells stained 
positive for F4/80, MerTK, CD64 and CD68 confirming their macrophage identity. In 
addition, positive labeling for the M2-like markers Mrc1 and Lyve1 was found in this 
population (Figure 7C). These results demonstrate that Ly6Clo / GFP+ cells represent 
CRMs in the MaFIA mouse heart under steady state conditions. 
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Figure 7 Identification of cardiac resident macrophages in MaFIA transgenic mice. 
Cardiac single cell suspensions from healthy hearts of MaFIA mice were analyzed by FACS. 
(A) CD45
+
 leukocytes were identified, (left) and CD11b
+
 myeloid cells were selected within 
the CD45
+
 gate (right). (B) Dot plot depicting Ly6C
lo
 
/ GFP
+
 
cells within the myeloid gate. (C) 
Histograms showing positive staining for F4/80, MerTK, CD64, CD68, Mrc1 and Lyve1 in 
Ly6C
lo
 
/ GFP
+ 
population. Images are representative of 3 independent experiments with 
mouse group sizes of 4-5 mice.  
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We further performed immunofluorescence analysis of MaFIA heart sections 
after staining with CD68, GFP, CD31 and Dapi. Confocal analysis revealed a 
population of CD68+ / GFP+ cells that were homogeneously distributed along the 
myocardium (Figure 8A). These cells exhibited typical macrophage elongated shape 
and were found close to CD31+ endothelial cells (Figure 8B and C). Small and big 
blood vessels were distinguished by their size, shape and positive labeling for CD31. 
CD68+ / GFP+ CRMs were found in close proximity to either small capillaries or big 
blood vessels (Figure 8C). In addition, immunostaining with Lyve1 and Mrc1 
revealed positive labeling for these markers by GFP+ cells (Figure 8D). 
Our FACS and confocal data indicate that macrophages are identified by their 
Csf1r expression in healthy heart and thus, can be recognized as GFP+ cells in 
MaFIA Tg mice. These cells exhibit perivascular localization and express typical M2-
like markers. 
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Figure 8 Confocal analysis of cardiac resident macrophages in MaFIA transgenic 
mice. 
(A) Cross sectional image of MaFIA mouse heart left ventricle stained for nuclei (blue), 
CD68 (red), CD31 (white) and GFP (green). (B) Magnified projection view of regions from 
(A) highlighted in white shows CD68
+ 
/ GFP
+ 
cells (white arrows) close to endothelial cells 
(yellow arrowheads). (C) 3D reconstruction of regions showing GFP
+ 
/ CD68
+
 macrophages 
(white arrows) in close proximity with either big
 
 
blood vessels (C1, C1´) or CD31
+ 
small 
capillaries (C2, C2´). Blood vessels and small capillaries are indicated by yellow 
arrowheads. (D) Micrographs of adult MaFIA mouse heart sections stained for CD68 (red), 
GFP (green) and Lyve1 (white) showing GFP
+ 
/ CD68
+
 / Lyve1
+
 macrophages (left, white 
arrows) and GFP
+ 
/ Lyve1
+
 / Mrc1
+
 macrophages (right, white arrows). Images are 
representative of at least 3 hearts.  
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1.3. Characterization of cardiac resident macrophages in 
CX3CR1
GFP/+ transgenic mice. 
  In a complementary approach we used the CX3CR1
GFP/+ Tg mouse, in which 
one allele of the Cx3cr1 gene, the receptor for the macrophage chemokine 
fractalkine/Cx3cl1, has been replaced by the reporter GFP (Jung, Aliberti et al, 2000). 
This model has allowed the identification of tissue-resident macrophages from a wide 
array of tissues (Jung, Aliberti et al, 2000; Davalos, Grutzendler et al, 2005; 
Nimmerjahn, Kirchhoff et al, 2005; Pinto, Paolicelli et al, 2012).  
  FACS analysis performed on CX3CR1
GFP/+ mouse hearts identified a 
population of Ly6Clo / GFP+ cells within the myeloid subset that accounted for ~64% 
of the total leukocytes (Figure 9A and B). Expression of F4/80, MerTK, CD64 and 
CD68 in Ly6Clo / GFP+ cells confirmed their macrophage identity. In addition, these 
cells stained positive for Mrc1 and Lyve1 (Figure 9C). These results indicate that 
Ly6Clo / GFP+ cells represent CRMs in the resting CX3CR1
 GFP/+ mouse heart. 
Confocal analysis revealed a population of CD68+ / GFP+ cells distributed 
throughout the myocardium (Figure 10A), that exhibited perivascular position 
(Figure 10B and C) and that  showed positive staining for Lyve1 and Mrc1 (Figure 
10D). 
These findings demonstrate that CRMs can be recognized as GFP+ cells in 
the CX3CR1
 GFP/+ Tg mouse and that these cells display similar features as those 
identified in C57BL/6 and MaFIA mice.   
Collectively, the data obtained in this objective reveal the existence of a 
cardiac macrophage population in the healthy myocardium that can be recognized by 
using different mouse models. These cells exhibit perivascular position and express 
genes associated to tissue-homeostatic and pro-angiogenic functions.  
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Figure 9 Identification of cardiac resident macrophages in CX3CR1
GFP/+
 transgenic 
mice. 
Cardiac single cell suspensions from healthy hearts of CX3CR1
GFP/+ 
mice were analyzed by 
FACS. (A) CD45
+
 leukocytes were identified, (left) and CD11b
+
 myeloid cells were selected 
within the CD45
+ 
gate (right). (B) Dot plot depicting Ly6C
lo
 
/ GFP
+ 
cells within the myeloid 
gate. (C) Histograms showing positive staining for F4/80, MerTK, CD64, CD68, Mrc1 and 
Lyve1 in Ly6C
lo
 
/ GFP
+ 
population. Images are representative of 3 independent experiments 
with mouse group sizes of at least 4 mice. 
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Figure 10 Confocal analysis of cardiac resident macrophages in CX3CR1 
GFP/+
 transgenic 
mice. 
(A) Cross sectional image of CX3CR1
GFP/+
 mouse heart left ventricle stained for nuclei (blue), 
CD68 (red), CD31 (white) and GFP (green). Left ventricle is indicated (LV). (B) Magnified 
projection view of regions from (A) highlighted in white shows CD68
+
 / GFP
+
 cells (red arrows) 
close to endothelial cells (white arrows). (C) 3D reconstruction of regions showing GFP
+ 
/ 
CD68
+
 macrophages (white arrows) in close proximity with either big
 
 
blood vessels (C1, C1´) 
or CD31
+ 
small capillaries (C2, C2´). Blood vessels and small capillaries are indicated by 
yellow arrowheads. (D) Micrographs of adult MaFIA mouse heart sections stained for CD68 
(red), GFP (green) and Lyve1 (white) showing GFP
+ 
/ CD68
+
 / Lyve1
+
 macrophages (left, white 
arrows) and GFP
+ 
/ Lyve1
+
 / Mrc1
+
 macrophages (right, white arrows). Images are 
representative of at least 3 hearts.   
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Objective 2. Study of distinct macrophage subsets and their 
contribution to cardiac healing/repair upon myocardial infarction.  
In this objective, we wanted to investigate whether distinct monocyte and 
macrophage subsets may contribute in specific ways to the inflammatory response 
and myocardial healing after MI. For that, we used two different mouse models of MI. 
The first method was the permanent ligation of the left anterior descending artery 
(LAD-ligation). This surgical procedure imitates the pathophisilogycal aspects 
occurring in infarction-related myocardial ischemia in humans (Kolk, Meyberg et al, 
2009). The second method was the cryo-infarction or cryoinjury of the myocardium. 
Cryoinjury produces a reproducible area of necrosis followed by an extensive 
inflammatory response and thus, is a useful model to study the myeloid cell 
populations found after injury (Jensen, Kosek et al, 1987; van Amerongen, Harmsen 
et al, 2008).   
 
2.1. Study of monocyte and macrophage response to myocardial 
infarction in C57BL/6 mice. 
2.1.1. Time course of monocyte and macrophage subsets after LAD-ligation or 
cryoinjury. 
 We first analyzed the dynamic and identity of the distinct monocyte and 
macrophage populations found after LAD-ligation. For that, we performed FACS 
analysis of cells isolated from either healthy or infarct tissues after staining with 
CD45, CD11b, F4/80 and Ly6C.      
We found that under steady state conditions, heart contained a leukocyte 
population mainly composed of F4/80+ / Ly6Clo CRMs. However, as soon as 3 days 
after MI, we found an abundant subset of F4/80+ / Ly6Chi (Ly6Chi) cells within the 
myocardium that accounted for ~50-60 % of the total leukocytes (Figures 11A and 
B). At this time, Ly6Chi cells coexisted with a minor population of F4/80+ / Ly6Clo 
(Ly6Clo) cells that represented the ~20% of the leukocytes. On day 7 after injury, as 
inflammation gave rise to resolution, the Ly6Chi subset decreased (~15-20% of total 
leukocytes) and the predominant population was composed of Ly6Clo cells that 
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represented the ~50-60% of leukocytes. At final stages after MI, as inflammation 
totally declined, the population of Ly6Clo cells was restored to similar levels to those 
found in the steady state (Figures 11A and B).  
The cell percentage among CD45+ cells is a relative quantification that does 
not reflect the total amount of cells actually present in the myocardium. Thus, we 
calculated the total number of monocytes and macrophages per milligram of heart 
tissue after LAD-ligation (Figure 11C). We observed that the kinetics of Ly6Chi cell 
number was similar to that found in the relative quantification. Accordingly, we found 
that the number of Ly6Chi cells in basal conditions was low (~0.04 x 107 cells/mg 
tissue), reached a maximum peak on day 3 (~0.8 x 107 cells/mg tissue), and 
decreased on day 30 (0.02 x 107 cells/mg tissue). In contrast, the number of Ly6Clo 
cells previous to injury was low (~0.4 x 107 cells/mg of tissue) but gradually increased 
after injury, reaching a maximum peak on day 7 (~0.9 x 107 cells/mg tissue) and 
dropping to initial numbers on 30 days after injury (~0.03 x 107 cells/mg tissue) 
(Figure 11C).  
In addition to the LAD-ligation model, we characterized the monocyte and 
macrophage response after cryoinjury. Interestingly, the kinetics of Ly6Clo and Ly6Chi 
cells was similar to that found after LAD-ligation (Figure 12A). Accordingly, the 
percentage of Ly6Clo and Ly6Chi cells after cryoinjury correlated with that observed 
after LAD-ligation (Figure 12B).  On the other hand, although the number of Ly6Chi 
cells on day 3 was slightly higher after cryoinjury (~1.3 x 107 cells/mg tissue) (Figure 
12C) than after LAD-ligation (~0.8 x 107 cells/mg tissue) (Figure 11C), this difference 
was not significant (data not shown).   
These results indicate that monocyte and macrophage subsets found after 
LAD-ligation or cryoinjury show similar kinetics and cell numbers. This suggests a 
homogeneous behavior of these cells in response to different types of cardiac injury.  
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Figure 11 Two distinct Ly6C
lo
 and Ly6C
hi
 subsets are found after LAD-ligation in C57BL/6 
mice. 
Cardiac single cell suspensions from healthy and infarcted hearts of C57BL/6 mice were 
analyzed by FACS. (A) Dot plots of infarcted hearts depicting Ly6C
lo
 (red squares) and Ly6C
hi
 
(blue squares) cell
 
subsets within the myeloid CD11b
+
 gate at specified times after LAD-ligation. 
(B) Relative percentages of Ly6C
lo
 
and Ly6C
hi
 cells within the CD45
+
 population before and after 
injury. (C) Total number of Ly6C
lo
 
and Ly6C
hi
 
cells per mg of tissue before and after LAD-ligation. 
Data represent the means ± SEM of 3 independent experiments with a pool of 10-15 mice per 
group. 
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Figure 12 Two distinct Ly6C
lo
 and Ly6C
hi
 subsets are found after cryoinjury in C57BL/6 
mice. 
Cardiac single cell suspensions from healthy and cryoinjured hearts of C57BL/6 mice were 
analyzed by FACS. (A) Dot plots of infarcted hearts depicting Ly6C
lo
 (red squares) and Ly6C
hi
 
(blue squares) cell
 
subsets within the myeloid CD11b
+
 gate at specified times after cryoinjury. 
(B) Relative percentages of Ly6C
lo
 
and Ly6C
hi
 cells within the CD45
+
 population before and 
after cryoinjury. (C) Total number of Ly6C
lo
 
and Ly6C
hi
 
cells per mg of tissue before and after 
cryoinjury. Data represent the means ± SEM of 3 independent experiments with a pool of 10-15 
mice per group. 
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2.1.2. Immunophenotype of Ly6Chi and Ly6Clo cells. 
We next explored the mononuclear identity of Ly6Chi and Ly6Clo subsets, to 
know whether these cells were actually monocytes or macrophages. For that, we 
labeled the cells with the macrophage specific markers MerTK, CD64 and CD68 as 
well as with the M2-like marker, Mrc1.  
In the LAD-ligation approach, we found that Ly6Clo cells expressed all the 
typical macrophage markers either at basal conditions or at different times after injury 
(Figure 13). This indicated that Ly6Clo cells retain macrophage identity over time 
following injury. In contrast, Ly6Chi cells found after MI exhibited an heterogeneous 
expression of macrophage markers. On day 3 after injury, we found two subsets of 
Ly6Chi cells with different expression levels of CD64 and CD68 (Figure 13). These 
results suggested the presence of two subsets of Ly6Chi cells; one of them would 
represent blood-recruited monocytes that are recognized by their low expression of 
CD64 and CD68; and the other one would represent cells under monocyte-
macrophage transition that express high levels of CD68 and CD64. However, at day 
3, the labeling with MerTK and Mrc1 only identified a population of Ly6Chi cells that 
expressed intermediate levels of these markers compared to Ly6Clo cells. This 
suggests that Ly6Chi cells (including those under monocyte-macrophage transition) 
might not have fully differentiated into macrophages at this time and thus, the 
delineation between monocytes and macrophages is not totally clear. Moreover, the 
small population of Ly6Chi cells found on day 7 displayed the same dichotomy in 
terms of CD68 expression and showed low expression of CD64, MerTK and Mrc1. 
Based on all these observations, we decided to define the Ly6Chi subset as 
“monocytes/macrophages”. Finally, at day 30 after MI, Ly6Clo cells found within the 
myocardium showed the same immune-phenotype than Ly6Clo CRMs found at 
steady state. These findings point to a restoration of the CRM population at very late 
stages following MI.  
In the cryoinjury model, the immunophenotype exhibited by Ly6Chi and Ly6Clo 
cells after injury was similar to that observed after LAD-ligation (Figure 14). These 
results reinforce the idea that the same monocyte and macrophage populations are 
involved in the inflammatory response associated to either LAD-ligation or cryoinjury. 
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Altogether, the present data demonstrate a biphasic monocyte and 
macrophage response to cardiac injury, characterized by different subsets of cells 
defined by their Ly6C expression. On the one hand, Ly6Clo cells are macrophages 
that are found not only in resting conditions (day 0) but also after injury. On the other 
hand, Ly6Chi cells are recruited upon injury and disappear as the inflammation is 
resolved. The surface marker labeling also suggests that the Ly6Chi population is 
composed of a mixture of both infiltrating monocytes and cells under monocyte-
macrophage transition that exhibit weak expression of typical macrophage markers.  
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Figure 13 Immunophenotype of Ly6C
lo
 and Ly6C
hi
 
subsets after LAD-
ligation in C57BL/6 mice. 
Ly6C
lo
 
and Ly6C
hi
 cells were analyzed for the expression of the indicated 
antibodies. Histograms depict staining for MerTK, CD64, Mrc1 and CD68 
expression in Ly6C
lo
 
and Ly6C
hi
 populations at specified times after LAD-
ligation. Controls represent cells labeled with the antibodies CD45, CD11b, 
F4/80 and Ly6C but not with the antibody of interest (MerTK, CD64, Mrc1 or 
CD68) in each case. Histograms are representative of 3 independent 
experiments with mouse group sizes of at least 4 mice. 
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Figure 14 Immunophenotype of Ly6C
lo
 and Ly6C
hi
 
subsets after cryoinjury 
in C57BL/6 mice. 
Ly6C
lo
 
and Ly6C
hi
 cells were analyzed for the expression of the indicated 
antibodies. Histograms depict staining for MerTK, CD64, Mrc1 and CD68 
expression in Ly6C
lo
 
and Ly6C
hi
 populations at specified times after cryoinjury. 
Controls represent cells labeled with the antibodies CD45, CD11b, F4/80 and 
Ly6C but not with the antibody of interest (MerTK, CD64, Mrc1 or CD68) in each 
case. Images are representative of 3 independent experiments with mouse group 
sizes of at least 4 mice. 
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2.1.3. Gene expression profile analysis of isolated Ly6Chi and Ly6Clo cells. 
Several markers have been associated with monocyte/macrophage phenotype 
transition in different in vivo models of inflammation. To gain insight into the distinct 
phenotype of monocytes and macrophages and to evaluate their specific functional 
properties during myocardial repair, we isolated Ly6Clo cells from days 3, 7 and 30 
and Ly6Chi cells from days 3 and 7 after cryoinjury or LAD-ligation. To examine their 
gene expression profile, a number of genes associated to the pro-inflammatory 
response (M1-like markers) as well as several M2-like genes were analyzed by Q-
PCR.  
On day 3 after LAD-ligation, we found that the pro-inflammatory genes Cox2, 
Il1b and Nos2 were significant upregulated in Ly6Chi cells compared to Ly6Clo 
macrophages (Figure 15A). Notably, at day 7, Ly6Chi cells displayed lower levels of 
all the pro-inflammatory genes suggesting a decrease in the inflammatory phenotype 
of these cells at this time (Figure 15A).  
In addition, the analysis confirmed that several M2-like genes (Cx3cr1, Cd163, 
Mrc1 and Retnla) were higher expressed in Ly6Clo cells than in Ly6Chi cells on day 3. 
Moreover, Ly6Clo cells showed highly expression of Cx3cr1, Cd163, Igf1, Mrc1, 
Retnla, Lyve1 and Stab1 compared to Ly6Chi cells on day 7 (Figure 15B). 
Interestingly, the majority of M2-like markers were significantly upregulated in Ly6Clo 
cells on day 30 compared to Ly6Clo cells isolated from days 3 and 7 after MI 
(Figures 15B and 16B). The pro-angiogenic marker Vegfa was upregulated after 
LAD-ligation in both Ly6Chi and Ly6Clo cells but was highly expressed in Ly6Chi cells 
on day 7 after injury.  
We next focused on the genes expressed in Ly6Chi and Ly6Clo subsets 
specifically on days 3 and 7 after LAD-ligation, and compared them by using 
hierarchical clustering analysis performed with Genesis. As shown in Figure 15C, 
this analysis identified two different clusters of genes. One of these clusters grouped 
the pro-inflammatory set of genes highly expressed in Ly6Chi cells, especially on day 
3. The other cluster contained the pool of M2-like genes that were found differentially 
expressed in Ly6Clo cells on days 3 and 7 after MI (Figure 15C). 
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In the cryoinjury model, we found significantly upregulation of the pro-
inflammatory genes Cox2, Il1b and Nos2 in Ly6Chi cells compared to Ly6Clo 
macrophages on day 3 (Figure 16A).  Although Il6 showed a tendency to be higher 
expressed in Ly6Chi cells than in Ly6Clo cells, this difference was not significant. 
In addition, most of the M2-like genes were highly expressed in Ly6Clo cells 
compared to Ly6Chi cells at both day 3 (Cd163, Igf1, Mrc1, Retnla, Lyve1, Stab1) and 
day 7 (Cd163, Cx3cr1, Retnla, Lyve1) after cryoinjury (Figure 16B). Moreover, Vegfa 
was upregulated after cryoinjury by Ly6Chi and Ly6Clo subsets, but no differential 
expression was found between both cell populations. 
The genesis clustering analysis identified two clusters of genes that except for 
Vegfa, coincided to those obtained in the LAD-ligation model. 
These observations demonstrate that Ly6Chi monocytes/macrophages are 
highly pro-inflammatory, pointing to a role for these cells as key players in the 
inflammatory response after MI. Moreover, at later stages after injury Ly6Chi cells 
might lose gradually their pro-inflammatory potential. In contrast, Ly6Clo 
macrophages exhibit a marked anti-inflammatory phenotype compared to Ly6Chi 
cells which is represented by their higher expression of M2-like and pro-angiogenic 
genes. Therefore, Ly6Clo cells may act as immunosupressors of inflammation, a 
process that is required for cardiac homeostasis restoration. Notably, the M2-like 
expression pattern exhibited by Ly6Clo cells was highly pronounced at very late 
stages following injury. These results strength the notion that Ly6Clo cells present 
within the myocardium at late stages after MI resemble CRMs that return once the 
homeostasis is restored.  
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Figure 15 Gene expression profile of FACS-isolated Ly6C
lo 
and Ly6C
hi 
cells after LAD-ligation 
from C57BL/6 mice. 
Q-PCR expression profiles of M1-like (A) and M2-like (B) genes in isolated Ly6C
lo
 and Ly6C
hi
 
populations from hearts at specified days after LAD-ligation. Data represent the mean ± SEM of 3 
independent experiments with a pool of 10-15 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001. 
(C) Results from Q-PCR of days 3 and 7 post injury were analyzed by the high content analysis 
software Genesis upon normalization of data. Heat map matrix identified two clusters of 
differentially expressed genes. Red indicates upregulated genes whereas green indicates 
downregulated genes. 
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Figure 16. Gene expression profile of FACS-isolated Ly6C
lo
 and Ly6C
hi
 
cells after cryoinjury from 
C57BL/6 mice. 
Q-PCR expression profiles of M1-like  (A) and M2-like (B) genes in isolated Ly6C
lo
 and Ly6C
hi
 
populations from hearts at specified days after cryoinjury.. Data represent the mean ± SEM of 3 
independent experiments with a pool of 10-15 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001. (C) 
Results from Q-PCR of days 3 and 7 post injury were analyzed by the high content analysis software 
Genesis upon normalization of data. Heat map matrix identified two clusters  of differentially expressed 
genes. Red indicates upregulated genes whereas green indicates downregulated genes. 
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2.2. Characterization of monocyte and macrophage subsets 
following cryoinjury in CX3CR1
GFP/+ mice. 
CX3CR1 
GFP/+ Tg mice have been also used to identify distinct subsets of 
monocytes/macrophages in circulation and in different mouse models of injury 
(Geissmann, Jung et al, 2003; Arnold, Henry et al, 2007; Nahrendorf, Swirski et al, 
2007). Accordingly, inflammatory and anti-inflammatory cells can be recognized as 
Ly6Chi / CX3CR1
lo and Ly6Clo / CX3CR1
hi subsets respectively in this model 
(Geissmann, Jung et al, 2003; Arnold, Henry et al, 2007). Based on that, we 
examined the distinct monocyte and macrophage populations at different times after 
cryoinjury in CX3CR1
GFP/+ mice. 
 
2.2.1. Time course of monocyte and macrophage subsets after cryoinjury. 
  Cells were collected from either non-injured (day 0) or injured myocardium and 
were analyzed according to their GFP and Ly6C expression by FACS. We found that 
two distinct subsets of monocytes/macrophages were sequentially present after 
injury (Figure 17A). Under steady state, heart tissue contained a population of 
CRMs, recognized as Ly6Clo / CX3CR1
hi cells that represented the ~61% of the 
leukocytes. On day 3 after injury, a subset of Ly6Chi / CX3CR1
lo cells accumulated in 
the heart, accounting for ~ 49% of leukocytes. This population decreased on days 7 
and 15, representing the ~ 5% of leukocytes at these times. In addition, 3 days after 
injury, we found a subset of Ly6Clo / CX3CR1
hi cells that represented the ~ 22% of 
leukocytes. These cells increased at day 7 (~57% of leukocytes) and showed a total 
recovery on day 15 post injury (~61% of leukocytes) (Figures 17A, B and C).  
In addition, the number of cells per milligram of tissue was calculated. We 
found a high number of Ly6Chi / CX3CR1
lo cells on day 3 (~1.5 x 106 cells/ mg tissue), 
that decreased on day 7 (~0.3 x 107 cells/mg tissue) and showed the lowest number 
on day 15 (~0.03 x 107 cells/mg tissue) after cryoinjury (Figure 17C). The number of 
Ly6Clo / CX3CR1
hi cells on day 0 was low (~0.6 x 107 cells/mg tissue). These cells 
increased on day 3 (~0.7 x 107 cells/mg of tissue), showed a peak on day 7 (~1.3 x 
107 cells/mg tissue) and dropped to initial numbers 15 days after injury (~0.7 x 107 
cells/mg tissue). 
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These data illustrate a biphasic monocyte/macrophage response to cryoinjury 
in which Ly6Chi and Ly6Clo cells can be additionally recognized by their differentially 
CX3CR1 expression. The percentage and number of Ly6C
lo / CX3CR1
hi and Ly6Chi / 
CX3CR1
lo subsets coincided with those showed by Ly6Clo and Ly6Chi cells in 
C57BL/6 mice. This indicates that the CX3CR1
GFP/+ model can be used to study the 
distinct subsets of monocytes and macrophages involved in the inflammatory 
response to MI. 
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Figure 17. Kinetics and gene expression profile of Ly6C
lo
 
/ CX3CR1
hi
 and Ly6C
hi
 
/ CX3CR1
lo 
subsets after cryoinjury in CX3CR1
GFP/+ 
mice. 
Cardiac single cell suspensions from healthy or cryoinjured hearts of CX3CR1
GFP/+
 
mice were analyzed 
by FACS. (A) Representative dot plots depicting Ly6C
lo 
/ CX3CR1
hi
 (red circles) and Ly6C
hi
 / CX3CR1
lo
 
(blue circles) cell
 
subsets within the CD11b
+
 gate at specified times after cryoinjury. (B) Relative 
percentages of cells within the CD45
+
 population before and after cryoinjury. (C) Total number of Ly6C
lo
 
/ CX3CR1
hi
 
and Ly6C
hi
 / CX3CR1
lo
 
cells per mg of tissue before and after cryoinjury. Data represent the 
means ± SEM of 3 independent experiments with a pool of 3-6 mice per group. (D,E) Q-PCR profile 
analysis of M1-like (D) and M2-like (E) genes expressed in Ly6C
lo 
/ CX3CR1
hi
 and in Ly6C
hi
 / CX3CR1
lo 
subsets on days 3 and 7 after cryoinjury. Data represent the mean ± SEM of 3 independent experiments 
with a pool of 10-15 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001. 
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2.2.2. Gene expression analysis of isolated Ly6Chi / CX3CR1lo and Ly6Clo / 
CX3CR1hi cells following cryoinjury. 
We next focus on examining the gene phenotype of monocyte and 
macrophage subsets found after cryoinjury in CX3CR1
GFP/+ mice. For that purpose, 
we isolated the most abundant cell populations found on days 3 and 7 that were 
represented by the Ly6Chi / CX3CR1
lo and the Ly6Clo / CX3CR1
hi subsets respectively. 
The same M1-like and M2-like genes assessed in the C57BL/6 mouse were 
analyzed in CX3CR1
GFP/+ mice by Q-PCR.  
The analysis showed that Ly6Chi / CX3CR1
lo isolated from 3 days-infarcted 
hearts expressed higher levels of the M1-like genes Cox2, Il6, and Nos2  than Ly6Clo 
/ CX3CR1
hi cells isolated from 7days-cryoinjured hearts (Figure 17D). Conversely, 
Ly6Clo / CX3CR1
hi cells found on day 7 highly expressed a considerable number of 
M2-like genes compared to Ly6Chi / CX3CR1
lo   cells (Figure 17E).  
These findings were in agreement with those obtained in the C57BL/6 mouse 
and thus, strength the notion that after MI, Ly6Chi cells are skewed to a more 
inflammatory or M1 polarization state, whereas Ly6Clo cells exhibit a tissue-
homeostatic signature.  
Interestingly, we observed that after injury, the expression of M2-like genes in 
Ly6Clo cells in both C57BL/6 and CX3CR1
GFP/+ mice was consistent with a previously 
defined “TEM-like signature” exhibited by Tie2-expressing monocytes/macrophages 
in tumors (Pucci, Venneri et al, 2009). TEM signature includes several anti-
inflammatory and pro-angiogenic markers such as Cd163, Cx3cr1, Mrc1, Lyve1, 
Stab1 that we found to be highly expressed in Ly6Clo cells after injury  This evidence 
prompted us to examine the existence of TEMs in the setting of MI. This idea is 
developed in the third objective of the thesis.  
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2.3. Comparative analysis of cardiac fibrosis and function in 
cryoinjury- and LAD-ligation- induced myocardial infarction. 
  In mammals, myocardial cell death due to infarction results in scar formation 
and little regenerative response (Zak 1974; Soonpaa and Field 1994). However, 
some studies in mice have reported cardiac recovery following cryoinjury suggesting 
the use of this model to study cardiac repair and regeneration after MI (van 
Amerongen, Harmsen et al, 2008). Based on that, we wanted to analyze the effects 
of cryoinjury on cardiac function and fibrosis development and compared them to 
those found after LAD-ligation. For that, we used echocardiography and histological 
studies at different time points after injury. 
  A total of 20 and 15 animals were subjected to LAD-ligation and cryoinjury 
respectively. In control groups, all animals survived. Total mortality associated to 
surgery (including the first 2 h post-procedure) in LAD-ligation and cryoinjury group 
was 15-20% and 5-10%, respectively. Total mortality during the follow-up period in 
LAD-ligation was around the 10% and 2% in cryoinjury. 
          In the echocardiography analysis, the 90% of animals that survived to LAD-
ligation displayed marked alterations in left ventricle (LV) systolic function on day 3 
post-surgery. In contrast, in the cryoinjured group only the 40-50% of animals that 
survived showed similar cardiac alterations when compared to their respective 
controls on day 3 post-injury (data not shown). We next selected those mice from 
both groups with systolic cardiac dysfunction and compared their left ventricular 
ejection fraction (LVEF) and LV chamber size. We found that in both approaches 
infarcted mice showed a significant decrease in LVEF when compared to their 
controls at the specified time points following injury (Figure 18A). However, this 
reduction was more pronounced in the case of animals subjected to LAD-ligation 
resulting significantly accentuated on 30 days post MI. Two-dimensional guided M-
mode revealed highly left ventricular dilatation in LAD-subjected mice compared to 
cryoinjured mice (Figure 18B). 
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Figure 18 In vivo echocardiography assessment of left ventricle function after 
cryoinjury or LAD ligation in C57BL/6 mice. 
(A) Left ventricle ejection fraction (LVEF) was measured by 2D echocardiography 
analysis using the area-length method from long-axis view in control mice (basal) and 
on days 3, 7 and 30 following cryoinjury or LAD-ligation. Data represent the mean ± 
SEM of  5-10 mice per group. Significant differences compared with controls are 
indicated as *P < 0.05, **P < 0.01, ***P < 0.001. Significant differences between 
cryoinjury and LAD-ligation models are indicated as 
#
P < 0.001. (B) Representative two 
dimensional and corresponding M-mode images of a long-axis view in control (basal) or 
30 days after cryoinjury or LAD-ligation. Cryoinjury results in modest left ventricle 
dilation (left, bottom), whereas LAD-ligation results in marked left ventricle dilation 
(right, bottom).  
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We next performed histological analysis of infarcted hearts to compare the 
structural effects and infarct size between LAD-ligation and cryoinjury models.  
On day 3 after LAD-ligation, hearts displayed an ischemic area with small 
coagulation and hemorrhage content (Figure 19A). Moreover, histological 
examination at this time revealed an inflammatory infiltrate in the infarcted region 
(Figure 19B). On day 7, a fibrotic scar was already formed which further developed 
into a big area of fibrosis that on day 30 occupied the vast majority of the left ventricle 
(Figure 19B).  
Figure 19 Histological analysis of heart sections after LAD-ligation in C57BL/6 mice. 
 (A) Mouse heart images collected from day 0 and days 3, 7 and 30 after LAD-ligation. The 
area surrounded by a red line indicates infarct area. (B) Masson’s trichrome stained cross 
sections of left ventricles from controls and infarcted hearts at days 3, 7 and 30 after injury. 
Magnified views of depicted insets are shown (bottom). Scale bars are shown in black lines. 
Images are representative of at least 3 hearts.   
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 In the cryoinjury study, 3 days-infarcted hearts displayed an extensive area of 
coagulation necrosis with hemorrhage (Figure 20A), as well as a dense inflammatory 
infiltrate (Figure 20B). On day 7, a visible scar was observed (Figure 20A) with less 
inflammatory content (Figure 20B). Finally, a transmural scar composed of 
collagenous fibers was formed on day 30 (Figure B). Furthermore, at this time, 
although wall thinning became apparent it was more moderate than after LAD-
ligation (Figures 19B and 20B).  
Figure 20 Histological analysis of heart sections after cryoinjury in C57BL/6 mice. 
 (A) Mouse heart images collected at day 0 and days 3, 7 and 30 after cryoinjury. The area 
surrounded by a red line indicates infarct area. (B) Masson’s trichrome stained cross sections of left 
ventricles from controls and infarcted hearts on days 3, 7 and 30 after cryoinjury. Magnified views of 
depicted insets are shown (bottom). Scale bars are shown in black lines. Images are representative 
of at least 3 hearts.  
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The histological observations together with the ecocardioghraphy analysis 
demonstrate that cryoinjury results in less worsening of the left ventricle function, 
modest scarring and small cardiac remodeling compared with infarcts produced by 
LAD-ligation.  
 
Objective 3 Identification and characterization of Tie2-expresing 
macrophages in the context of ischemic myocardium. 
TEMs are a subset of circulating and tumor-infiltrating 
monocytes/macrophages expressing the angiopoietin receptor Tie2 (De Palma, 
Venneri et al, 2005; Pucci, Venneri et al, 2009). Prior studies have demonstrated that 
TEMs can be found in both tumors and ischemic tissues (De Palma, Murdoch et al, 
2007; Hamm, Veschini et al, 2013; Patel, Smith et al, 2013). Our data revealed that 
Ly6Clo macrophages found after MI expressed some genes included within the 
previously described “TEM signature” (Pucci, Venneri et al, 2009). This observation 
led us to explore the existence of TEM-like macrophages in the context of MI. For 
that purpose, we used Tie2-GFP Tg mice, which express a reporter GFP under the 
control of the Tie2 promoter. 
 
3.1. Time course of TEM infiltration following myocardial infarction. 
To investigate whether TEMs were present in infarcted hearts, Tie2-GFP mice 
were subjected to LAD-ligation and heart samples were analyzed at different time 
points following injury.  
           FACS analysis of sham and infarcted hearts identified a subset of CD11b+ / 
Tie2+ cells within the leukocyte gate that was significantly higher in infarcts than in 
sham hearts. The percentage of CD11b+ / Tie2+ cells among leukocytes peaked on 
day 7 and declined on day 15 after injury (Figures 21A and B).  
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Figure 21 Recruitment of TEMs into myocardium after LAD-ligation. 
(A) FACS analysis at each time point after LAD-ligation and their corresponding controls (sham) 
in Tie2-GFP mice. CD45
+
 cells present in injured myocardium were analyzed for CD11b and 
Tie2 (GFP) expression. (B) Histograms showing the percentage of CD11b
+
 / Tie2
+
 cells among 
the CD45
+
 gate. Data represent the mean ± SEM of 3 independent experiments with a pool of 3-
4 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001. (C) CD11b
+
 / Tie2
+
 cells from infarcts on 
day 7 after LAD-ligation were analyzed for the expression of the indicated antibodies. 
Histograms for F4/80, MerTK, CD64, CD68, Mrc1 and Lyve1 expression detected within the 
CD11b
+
 / Tie2
+
 population. Controls represent cells labeled with the antibodies CD45, CD11b, 
GFP but not with the antibody of interest (F4/80, MerTK, CD64, CD68 Mrc1 or Lyve1) in each 
case. All images are representative histograms of 3 independent experiments with mouse group 
sizes of 3-4 mice.  
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Further FACS analysis of CD11b+ / Tie2+ cells on day 7 after injury revealed 
that these cells expressed the typical macrophage markers F4/80, MerTK, CD64 and 
CD68, and the M2-like markers Mrc1 and Lyve1 (Figure 22A). These results suggest 
that CD11b+ / Tie2+ cells present within the myocardium belong to the 
monocyte/macrophage lineage and thus, represent a TEM population. 
 
3.2. Localization of TEMs within the infarcted myocardium of Tie2-
GFP mice. 
To examine the localization of TEMs in the heart, confocal analysis was 
performed on 7-days infarcted hearts after staining with GFP, CD68 and Dapi. We 
found a population of TEMs, recognized as CD68+ / Tie2-GFP+ cells that were 
localized within the infarcted region (Figures 22A and B). In addition, we found a 
considerable number of CD68- / Tie2+ endothelial cells that likely represent 
neovessels appearing few days after MI. Notably, TEMs were in close proximity to 
CD68- / Tie2+ endothelial cells, exhibiting a predominant perivascular position (Figure 
22B). In addition, we examined the presence of TEMs within the non-injured /remote 
area (Figure 22A). We only detected CD68+ / Tie2- macrophages and endothelial 
cells (Figure 22C). These results indicate that TEMs are not present in non-injured 
regions. 
 In a complementary approach, we studied the presence of TEMs after 
cryoinjury. FACS analysis of sham operated and cryoinjured Tie2-GFP mice revealed 
the presence of a significant percentage of CD11b+ / Tie2+ cells in the injured 
myocardium compared to sham hearts. These cells were recognized as TEMs and 
showed a similar time course than TEMs found in the LAD-ligation model (Figures 
23A, B). 
Altogether, these data indicate that the ischemic myocardium recruits a 
population of TEMs that is more abundant on day 7 that can be localized close to 
endothelial cells within the infarcted region. 
 
 
RESULTS 
 
108 
 
 
Figure 22 Localization of TEMs within myocardium after 7 days post LAD-ligation in Tie2-GFP 
mice. 
(A) Cross section view of a 7 days-infarcted Tie2-GFP mouse heart stained for Dapi (blue), CD68 
(red) and GFP (green). Infarcted area (A) and remote area (B) are indicated (left). TEMs were found 
within the infarcted area (A1, A2) (right). (B) 3D reconstruction of magnified view from A1 and A2. 
TEMs were recognized as  CD68
+
 
/ Tie2
+
 cells (yellow arrowheads) and were found close to CD68
-
 
/ 
Tie2
+
 endothelial cells (white arrows) within the infarcted region. (C) 3D reconstruction of magnified 
view from remote area (B) depicts endothelial cells (white arrows) and CD68
+
 / Tie2
-
 macrophages 
(yellow arrows) White lines represent scale bars. Images are representative of at least 3 hearts.   
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Figure  23 Recruitment of TEMs into myocardium after cryoinjury in Tie2-GFP mice. 
(A) Representative examples of FACS analysis at each time point after cryoinjury and their 
corresponding controls (sham) from Tie2-GFP mouse hearts. CD45
+
 cells present in injured 
myocardium were analyzed for CD11b and Tie2 (GFP) expression. Images are 
representative of 3 independent experiments. (B) Histograms showing the percentage of 
CD11b
+
 / Tie2
+
 cells among CD45
+
 gate. Data represent the mean ± SEM of 3 independent 
experiments with a pool of 3-4 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001.  
A 
B 
A 
A1 
A2 
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3.3. Gene expression profile of TEMs versus Tie2- / Ly6Clo cells. 
  We next compared the gene expression profile between TEMs and the 
subpopulation of Ly6Clo / Tie2- macrophages found after MI. For that we isolated both 
populations from 7 days-infarcted Tie2-GFP hearts (Figure 24A) and performed RNA 
sequencing analysis (RNA-Seq). 
According to the adjusted p value < 0.05, the analysis revealed a set of 609 
differentially expressed genes (DEGs) in TEMs versus Ly6Clo / Tie2- macrophages 
(Figure 24B). Applying standard filter criteria (logFC -1.5 > logFC > 1.5) a total of 
220 genes were upregulated in TEM versus Ly6Clo / Tie2- macrophages. Similarly, 
64 genes were decreased in TEMs versus Ly6Clo / Tie2- macrophages. 
           
Figure 24 RNA-seq analysis of FACS-isolated TEMs 
versus Ly6C
lo
 / Tie2
- 
macrophages. 
 (A) Dot plots depicting FACS-sorting strategy of TEMs 
(CD11b
+
 / Tie2
+
) (blue square) and Ly6C
lo
 / Tie2
-
 cells 
(red square) within the CD45
+
 gate. (B) Heat map of 
differentially expressed genes with adjusted p value < 
0.05 in TEMs versus Ly6C
lo
 / Tie2
-
 cells from the 
myocardium on day 7 post-injury. Heat map displays 
data from each individually isolated TEMs and Ly6C
lo
 / 
Tie2
-
 populations. 3 replicates were used with a pool of 
9-10 mice per replicate. Red and green represent 
upregulated and downregulated genes in TEMs versus 
Ly6C
lo
 / Tie2
- 
macrophages respectively  
RESULTS 
 
111 
 
We next performed Gene Ontology (GO) analysis of DEGs (Harris, Clark et al, 
2004). Interestingly, TEMs showed an enrichment of the positively DEGs in biological 
processes such as cell adhesion, angiogenesis, cell motion and skeletal system 
development. In contrast, Ly6Clo / Tie2- cells showed enrichment in biological 
processes associated to immune response (Figure 25A). 
The gene expression profile revealed higher expression of Tie2 (Tk) in TEMs 
than in Ly6Clo / Tie2- macrophages indicating that both populations were correctly 
separated (Figure 25B and Table 4). Moreover, TEMs upregulated a number of 
typical endothelial cell genes such as Cdh5, Cdh13, Pecam1, Angpt2, Egfl7, Epas1, 
Robo4, Kdr, Flt1 and Flt2 compared to Ly6Clo / Tie2- macrophages (Figure 25B; 
Table 4). Remarkably, TEMs expressed lower levels of genes associated to the 
immune cell response than Ly6Clo / Tie2- macrophages. These genes included 
members of the toll like receptor superfamily such as Tlr1, Tlr2, Tlr3 and Tlr9 and the 
monocyte/macrophage derived cytokines Ccl12, Ccl7, Cxcl1 and Cxcl10. In addition, 
TEMs showed downregulation of some M2-like genes such as Lyve1, Cx3cr1, 
Cd163, Tgfb1, Retnla and Mrc1 compared to Ly6Clo / Tie2- macrophages. These 
results differed from those observed in tumors, where TEMs are characterized by 
their high expression of typical M2-like genes compared to tumor associated M2 
macrophages (Figure 25B and Table 5).   
  KEGG pathways analysis of DEGs by Babelomics (Medina, Carbonell et al, 
2010) in TEMs versus Ly6Clo / Tie2- cells revealed an enrichment of genes 
associated to cell adhesion, leukocyte trans-endothelial cell migration and focal 
adhesion, suggesting a direct contact between TEMs and endothelial cells through 
distinct cell surface receptors (Table 6). In addition, other pathways including ECM-
receptor interaction and hematopoietic cell lineage were enriched in TEMs compared 
to Ly6Clo / Tie2- macrophages. 
These data demonstrate that TEMs represent a distinct population from Ly6Clo 
/ Tie2- macrophages found after MI. Ly6Clo / Tie2- cells exhibit higher expression of 
classical anti-inflammatory genes than TEMs and are involved in biological 
processes associated to immune cell response. Conversely, TEMs present in 
infarcted myocardium express high levels of several endothelial cell-related genes 
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compared to Ly6Clo / Tie2- macrophages, and show enrichment in processes such as 
cell adhesion and angiogenesis. 
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Figure 25 GO Biological 
Processes terms in TEMs 
versus Ly6C
lo
 / Tie2
-
 
macrophages. 
 (A) Analysis of functional 
categories for the DEGs in 
TEMs versus Ly6C
lo
 / Tie2
-
 cells 
ordered by -log of adjusted p-
value. Z-score ranges from 
higher (green) to lower (red) 
enriched biological processes in 
TEMs. (B) List of selected DEGs 
identified by RNA-seq with red 
indicating up-regulated genes 
and green indicating down-
regulated genes. Color codes 
indicate the biological function of 
the genes. 
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Kegg pathway genes adj_pvalue 
Cell adhesion Jam2,Cdh5,Pecam1,Ptprm,Cd34 5.07088E-3 
Leukocyte transedothelial cell migration Jam2,Cdh5,Cxcl12,Pecam1 2.34392E-2 
Focal adhesion Kdr,Flt1,Itga1,Col4a1,Col4a2,Cav1,Spp1 5.39428E-4 
ECM-Receptor interaction Itga1,Col4a1,Cd36,Col4a2,Spp1 5.61211E-4 
Hematopoietic cell lineage Itga1,Il7r,Cd36,Anpep,Cd34 6.91751E-4 
Table 4 KEGG pathways analysis of TEMs versus Ly6C
lo
 / Tie2
-
 macrophages. 
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Table 5 Differentially expressed genes in TEMs versus Ly6C
lo 
/ Tie2
-
 macrophages. 
List of selected genes among the DEGs that were upregulated in TEMs versus Ly6C
lo
 / Tie2
-
 cells. 
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Table 6 Differentially expressed genes in Ly6C
lo
 / Tie2
-
 macrophages versus TEMs. 
List of selected genes among the DEGs that were upregulated in Ly6C
lo
 / Tie2
-
cells versus 
TEMs. 
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Characterization of cardiac resident macrophage populations. 
A number of tissue-resident macrophages have been extensively described 
and their immunophenotype and tissue function have been fully characterized 
(Gautier, Shay et al, 2012; Davies, Jenkins et al, 2013). However, such rigorous 
analysis has not being performed in the heart so far. In this work, we demonstrate 
that the adult mammalian heart contains a population of cardiac resident 
macrophages (CRMs) which are homogeneously distributed along the myocardium. 
In the steady state, CRMs are F4/80+ cells and express low amounts of the 
inflammatory lymphocyte antigen 6c (Ly6C) Proteins previously predicted to 
distinguish macrophages from other cell types, such as MerTK (the kinase involved 
in efferocytosis), CD64 (the high-affinity Fcγ receptor I), CD68 (macrosialin) and 
CD115 (c-Fms or CSF1R) are expressed in CRMs as demonstrated by our FACS-
based immunophenotype analysis. Staining of CD64 and MerTK has been proposed 
to serve as a starting point for the identification of macrophages in tissues that can 
be used powerfully in addition to F4/80 staining (Gautier, Shay et al, 2012). The 
identification of CD64 and MerTK among CRMs, suggests a possible role for these 
cells in innate immunity, efferocytosis and the clearance of debris. Accordingly to 
recent work, MHCII staining revealed the existence of two subsets of CRMs 
distinguished by their expression of high or low amounts of this marker (Epelman, 
Lavine et al, 2014). MHCIIhi macrophages have been proposed to have a role in 
immunosurveillance, by processing and presenting antigens to T cells, whereas 
MHCIIlo macrophages may contribute to local homeostasis by phagocytizing dying 
cardiomyocytes (Epelman, Lavine et al, 2014). Together, these data suggest that 
CRMs, as well as other tissue-resident macrophages may develop typical 
macrophage functions in the heart, acting as immune sentinels in the frontline of 
defense. 
In our gene expression profile analysis, we found that CRMs, if compared to 
peritoneal and splenic resident macrophages, differentially express a number of M2-
like genes (Cd163, Cx3cr1, Lyve1,Timp3, Mrc1) as well as the collangenolytic 
enzyme Mmp13. These findings suggest that CRMs may have a distinctive gene 
expression profile compared to other tissue-resident macrophage populations that 
might be determined by the cardiac microenviroment.  
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The finding that CRMs express scavenger receptors such as Cd163 and Mrc1 
indicates that these cells may contribute to cardiac homeostasis by clearance of 
tissue debris. CD163, a scavenger receptor for hemoglobin-haptoglobin complexes, 
may mediate the clearance of free hemoglobin from the myocardium by CRMs, 
offering protection against hemoglobin-mediated oxidative tissue damage (Fabriek, 
van Bruggen et al, 2009). Mrc1, (mannose receptor, CD206), is a C-type lectin 
expressed predominantly by most M2 macrophages (Azad, Rajaram et al, 2014). 
Mrc1 expression in CRMs may be required for endocytosis and phagocytosis, 
necessary for scavenging unwanted glycoproteins from cardiac tissue (Azad, 
Rajaram et al, 2014).  
In addition, we observed that CRMs express Timp3 (tissue inhibitor of 
metalloproteinases-3), which has emerged as a key mediator of inflammation that 
moderates the differentiation of macrophages into pro-inflammatory (M1) phenotype 
in several tissues (Menghini, Casagrande et al, 2012; Gill, Gharib et al, 2013). 
Likewise, TIMP3 expression in CRMs may contribute to maintain the anti-
inflammatory profile of these cells in the steady state. Furthermore, CRMs express 
Mmp13, which has been found to be required for the regression of hepatic fibrosis 
(Fallowfield, Mizuno et al, 2007), thus suggesting that CRMs might be endowed with 
anti-fibrotic and tissue remodeling functions.  
The CX3CR1
GFP/+ mouse has emerged as a suitable model to characterize 
tissue macrophages in several organs (Medina-Contreras, Geem et al, 2011). 
CX3CR1, the receptor for the chemokine fractalkine/CX3CL1 has anti-inflammatory 
functions and plays a central role in macrophage homeostasis by promoting cell 
survival (Landsman, Bar-On et al, 2009; Medina-Contreras, Geem et al, 2011). We 
found that CRMs differentially express Cx3cr1 compared to splenic and peritoneal 
macrophages, suggesting that CX3CL1 signaling though CX3CR1 may be essential 
for CRM survival in the steady state. Moreover, consistent to previous work, our 
FACS and confocal experiments demonstrate that CRMs can be identified and 
distinguished from other myeloid cells by their expression of CX3CR1 (Pinto, 
Paolicelli et al, 2012).  
Tissue-resident macrophages from different organs share both common and 
unique gene expression patterns (Gautier, Shay et al, 2012). Recent transcriptional 
profiling studies suggest that cardiac macrophages share similar gene expression 
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profiles with other tissue-resident macrophage populations such as lung 
macrophages, microglia and peritoneal macrophages (Epelman, Lavine et al, 2014). 
Despite this, it is clear that tissue-resident macrophages are highly heterogeneous 
exhibiting different phenotypes as a consequence of their tissue-specific localization 
and function. Accordingly, CRMs likely have a unique phenotype and possess highly 
specialized properties which are determined by the cardiac environment.  
Recently, the existence of four subsets of cardiac macrophages with different 
expression of surface markers (i.e. MHCII, Ly6C) and autofluorescence has been 
described (Epelman, Lavine et al, 2014). In this groundbreaking paper has been 
shown that the majority of these cardiac macrophage populations are independent 
from the blood monocyte influx and represent an embryonically yolk sac derived 
macrophage lineage (Epelman, Lavine et al, 2014). Despite these findings, the 
mechanisms controlling macrophage proliferation throughout life are still largely 
unknown. CSF-1R is a type III integral membrane protein tyrosine kinase encoded by 
the c-fms proto-oncogene (csf1r) (Dai, Ryan et al, 2002; Sweet and Hume 2003; 
Chitu and Stanley 2006). Signaling through CSF1R is required for the proliferation, 
differentiation, and survival of tissue-resident macrophages in several organs (Dai, 
Ryan et al, 2002; Jenkins, Ruckerl et al, 2011; Hume and MacDonald 2012; Davies, 
Rosas et al, 2013; Hashimoto, Chow et al, 2013). However, CRM populations 
expressing CSF-1R in the resting myocardium have not been investigated so far. 
Here, we show that it is possible to identify CRMs by their CSF-1R expression, to this 
extent we took advantage of the MaFIA Tg mouse. These results suggest that CRMs 
may depend on CSF1R expression and its ligand, CSF-1 to proliferate and self-
renew in the heart.  
Macrophage and endothelial cell interactions are important for vascular 
network formation in developing organs (Sunderkotter, Steinbrink et al, 1994; Fantin, 
Vieira et al, 2010) and in disease (De Palma, Murdoch et al, 2007; Venneri, De 
Palma et al, 2007; Mazzieri, Pucci et al, 2011). Prior studies have reported a close 
proximity between macrophages and endothelial cells in the heart (Azzawi, Hasleton 
et al, 1997; Pinto, Paolicelli et al, 2012). However, the association between these two 
cell types has not been exhaustively described.  
Our confocal analysis refines prior studies and provides a detailed view of 
CRM distribution in respect to the vasculature. Here, we demonstrate that CRMs 
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show a preferential perivascular localization being located in close proximity to either 
big or small cardiac blood vessels. Furthermore, CRMs displayed enrichment in pro-
angiogenic genes such as Stab1 (Stabilin) and Lyve1 (Lymphatic Vessel Endothelial 
Hyaluronic Acid Receptor). STAB1+ macrophages contribute to angiogenesis in 
developing organs (Pucci, Venneri et al, 2009), and in adult tissues (Kodelja, Muller 
et al, 1997; Goerdt, Politz et al, 1999; Schledzewski, Falkowski et al, 2006). 
Moreover, in the adipose tissue, expression of LYVE1 by macrophages is crucial for 
hemangiogenesis (Cho, Koh et al, 2007). In addition, LYVE1+ macrophages 
intimately associate with the developing lymphatic vasculature providing pro-
lymphangiogenic molecules in the dermal microenviroment (Pucci, Venneri et al, 
2009; Gordon, Rao et al, 2010). In line with these studies, expression of Stab1 and 
Lyve1 by CRMs suggests a role for these cells in the regulation of angiogenesis and 
lymphoangiogenesis in the heart. In addition, we found that CRMs also expressed 
Igf1 (Insulin growth factor 1), which is an important regulator of growth, survival, and 
macrophages differentiation in many tissues (Musaro, Giacinti et al, 2007; Pelosi, 
Giacinti et al, 2007; Santini, Tsao et al, 2007; Semenova, Koegel et al, 2008) and has 
been reported to have pro-angiogenic functions (Piecewicz, Pandey et al, 2012). 
Together, these results demonstrate that CRMs and endothelial cells interact and 
strongly suggest that this interaction could be necessary for coronary vasculature 
maintenance and heart homeostasis. We propose that CRMs and endothelial cells 
could be receptive to reciprocal para/juxta-crine signaling in which CRMs may have a 
potential role in maintaining vessels structure, in regulating capillary density and in 
helping reparative functions by promoting neo-vessels maturation. Overall, this 
interaction might be crucial for the appropriate regulation of microvessel density and 
stability thus regulating the proper supply of O2 and nutrients to the myocardium. 
In summary, the present work provides a framework for understanding the 
macrophage biology in the steady state heart. However, the elucidation of CRM 
functional roles in cardiac homeostasis would require CRM-specific ablation 
strategies, which are currently unavailable. Selective elimination of CRMs would help 
to determine whether these cells may influence the metabolism, contraction or 
survival of cardiomyocytes as well as the regulation of angiogenesis in the steady 
state and/or disease (Frantz and Nahrendorf 2014). 
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Two monocyte and macrophage subsets with distinct functional 
phenotypes are found after myocardial infarction.  
Following disruption of cardiac homeostasis by either LAD-ligation or 
cryoinjury, we found that two myeloid subsets distinguished by their Ly6C 
expression, are sequentially present within the injured myocardium.  
The traditional view has been that once recruited into the inflamed tissue, 
monocytes differentiate into macrophages (Murray and Wynn 2011; Mantovani, 
Biswas et al, 2013). However, previous studies performed by Narhendorf and 
coworkers showed a sequential recruitment of Ly6Chi and Ly6Clo monocytes into the 
heart in response to MI (Nahrendorf, Swirski et al, 2007).  In the same study, the 
authors demonstrate that Ly6Chi and Ly6Clo monocytes are involved in pro-
inflammatory and anti-inflammatory functions respectively and argues against in situ 
Ly6Chi → Ly6Clo conversion (Nahrendorf, Swirski et al, 2007). This study led to the 
idea that extravasated Ly6Chi and Ly6Clo monocytes may not necessarily differentiate 
into macrophages but might fulfill these specialized functions in the heart as short-
lived, reprogrammed monocytes (Nahrendorf, Swirski et al, 2007; Swirski, 
Nahrendorf et al, 2009).  
Here we show that Ly6Chi cells found early after injury comprise a mixture of 
both monocytes and monocyte-derived macrophages, as demonstrated by the 
heterogeneity found in CD64 and CD68 expression within this population. Therefore, 
in contrast to Nahrendorf’s previous work, we consider that in the early response 
after MI, a number of Ly6Chi monocytes may give rise to Ly6Chi macrophages 
resulting in the co-existence of both monocytes and macrophages. Nevertheless, 
Ly6Chi cells are likely not fully differentiated, as they express low levels of all the 
macrophage markers. 
 Furthermore, our data suggest that Ly6Clo cells present both in resting 
conditions (day 0) and after injury are macrophages, as demonstrated by their 
expression of typical macrophage markers (MerTK, CD64, CD68) and the M2-like 
marker Mrc1. These findings are in agreement with a recent study reporting that 
Ly6Clo cells dominating the second phase of cardiac healing are macrophages that 
derived from Ly6Chi monocytes (Hilgendorf, Gerhardt et al, 2014). According to this, 
the increased number of Ly6Clo cells that we found on day 7 post-MI might be 
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attributed to the local conversion of Ly6Chi monocytes to Ly6Clo macrophages. This 
idea is consistent with the phenotype switch from Ly6Chi monocytes to Ly6Clo 
macrophages previously described for skeletal muscle regeneration (Arnold, Henry et 
al, 2007). However, it is probably that Ly6Clo macrophages also arise via 
differentiation of bone marrow- or splenic- derived Ly6Clo monocytes (Swirski, 
Nahrendorf et al, 2009; Leuschner, Rauch et al, 2012) or via in situ activation and 
expansion of Ly6Clo CRMs. These possibilities might not be exclusive and further 
studies are needed to dissect the exact lineage relationship between monocytes and 
macrophages in the heart. Moreover, it is unclear whether monocytes and 
macrophages coexisting within the infarct contribute equally to the inflammatory 
response, or have specific functions. These questions have been addressed in this 
study by further transcriptional profile analysis allowing us to discover highly specific 
cell surface markers that clearly separate monocyte from macrophage populations. 
 
Ly6Clo and Ly6Chi subsets display distinct functional profiles. 
Expression profiling of isolated Ly6Chi and Ly6Clo subsets from infarcts 
revealed notable phenotype heterogeneity between both populations reflecting their 
distinct functional properties in cardiac healing and repair. Our data point to a role for 
Ly6Chi monocytes/macrophages in the inflammatory response as demonstrated by 
their expression of pro-inflammatory genes such as Cox2, Il1b, Il6 and iNos. This 
phenotype is evident soon after injury (day 3) and declines with time likely as a 
consequence of inflammation resolution. In addition, our results show an anti-
inflammatory phenotype of Ly6Clo macrophages as evidenced by their expression of 
several M2-like markers such as Cx3cr1, Cd163, Igf1, Lyve1, Retnla and Mrc1. This 
phenotype is maintained over time after injury and it is likely necessary for 
inflammation resolution and efficient wound healing. Ly6Clo cells have been reported 
to release vascular endothelial growth factor (VEGFA), suggesting a pro-angiogenic 
function of these cells after MI (Nahrendorf, Swirski et al, 2007). In our studies, both, 
Ly6Chi and Ly6Clo cells expressed Vegfa after cryoinjury or LAD-ligation. These 
results indicate that Ly6Chi and Ly6Clo cells might share VEGF-dependent pro-
angiogenic functions after MI. Nevertheless, high expression of angiogenesis-related 
markers such as Lyve1 and Stab1 in Ly6Clo cells compared to Ly6Chi cells after MI, 
suggest an enhanced pro-angiogenic function of Ly6Clo macrophages. Accordingly, 
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prior work reports that anti-inflammatory STAB1+ M2 macrophages support healing 
by secretion of angiogenic factors in different pathologies (Goerdt, Politz et al, 1999) 
(Szekanecz, Haines et al, 1994; Djemadji-Oudjiel, Goerdt et al, 1996; Schledzewski, 
Falkowski et al, 2006). Furthermore, it has been reported that LYVE1+ macrophages 
may exert a physical role in the formation of lymphatic vessels under inflammatory 
conditions (Maruyama, Ii et al, 2005). In addition, other studies suggest that LYVE1+ / 
STAB1+ specialized macrophages may transiently perform lymphatic endothelial 
functions or pave the way for lymph-angiogenesis in tumors metastasis 
(Schledzewski, Falkowski et al, 2006). In line with these findings, our results show a 
higher expression of these markers in Ly6Clo macrophages than in Ly6Chi cells, and 
thus, support the notion that Ly6Clo macrophages have an enhanced pro-angiogenic 
role in the ischemic myocardium.  
Interestingly, the profile exhibited by Ly6Clo cells resulted more pronounced at 
the end point of cardiac repair process, and shared some similarities with those 
previously found in CRMs.  These findings suggest that Ly6Clo macrophages 
involved in the healing response after injury possess tissue-homeostatic properties, 
similar to those exhibited by macrophages in resting conditions. Such properties 
might be necessary for restoring and maintaining the cardiac homeostasis. We have 
not explored the contribution of CRMs to the healing response after MI, due to the 
lack of specific markers that distinguish CRMs from recruited Ly6Clo macrophages. 
The identification of new genes specific to each population will allow the generation 
of new tracking and depletion approaches to unravel their individual function in 
response to MI. 
 
Ly6Chi and Ly6Clo cells can be identified by their CX3CR1 
expression.  
Earlier studies have reported the presence of Ly6Chi / CX3CR1
lo and Ly6Clo / 
CX3CR1
hi monocytes/macrophages in inflamed or injured tissues that exert pro-
inflammatory and anti-inflammatory functions respectively (Geissmann, Jung et al, 
2003; Ginhoux, Tacke et al, 2006; Arnold, Henry et al, 2007; Swirski, Libby et al, 
2007). Taking advantage of CX3CR1
GFP/+ Tg mice, we demonstrate that Ly6Chi / 
CX3CR1
lo and Ly6Clo / CX3CR1
hi subsets are sequentially present within the 
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myocardium upon injury. Furthermore, the time course data obtained with this model 
resemble the one previously obtained in C57BL/6 mice. These findings indicates that 
Ly6Chi and Ly6Clo cells can be distinguished by their CX3CR1 expression. 
Previous studies have shown that Ly6Chi / CX3CR1
lo exert pro-inflammatory 
actions in injured skeletal muscle, whereas anti-inflammatory Ly6Clo / CX3CR1
hi 
macrophages promote muscle repair and myogenesis (Arnold, Henry et al, 2007). 
According to this, our gene expression analysis revealed an accentuated pro-
inflammatory phenotype of isolated Ly6Chi / CX3CR1
lo cells, and an anti-inflammatory 
profile of Ly6Clo / CX3CR1
hi cells after cryoinjury.  These findings are consistent with 
those obtained in C57BL/6 mice and thus, reinforce the idea that Ly6Chi and Ly6Clo 
display distinct functional properties in cardiac healing and repair following injury.  
 
Comparision of cryoinjury and LAD-ligation models of myocardial 
infarction. 
The inflammatory response following MI is determinative for tissue healing 
(Frangogiannis, Smith et al, 2002). Therefore, accurate knowledge of inflammatory 
populations involved in the process of the MI model applied is fundamental for 
experimental use. Although in our study Ly6Chi cell infiltration on day 3 tended to be 
higher after cryoinjury than after LAD-ligation, this difference was not significant. 
These observations indicate that recruitment of inflammatory cells is similar in both 
approaches. In addition, the kinetics and gene expression profile of Ly6Chi and 
Ly6Clo subsets practically coincided after cryoinjury or LAD-ligation, suggesting a 
similar monocyte/macrophage response to cardiac damage in the two models. 
Despite the similarities in immune cell response observed between cryoinjury 
and LAD-ligation, we found that these models produce distinct functional effects in 
the heart. Indeed, cryoinjury failed to produce LV systolic alterations in the 50% of 
the animals suggesting that this method cannot guarantee the loss of cardiac 
function. Moreover, those mice with alterations in LV systolic function after cryoinjury, 
exhibited a more modest loss of LV contractility, less remodeling and no signs of left 
ventricle dilation after 4 weeks compared to LAD-ligation. Consistent with previous 
studies, our results suggest that cryoinjury produce smaller infarcts as well as 
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moderate left ventricle remodeling compared to LAD-ligation (van den Bos, Mees et 
al, 2005).  
In addition, histology of the hearts at earlier stages after injury revealed that 
the cellular pattern of healing cryolesions was similar to that seen after LAD-ligation. 
An inflammatory infiltration was observed  3 days post injury that was later replaced 
by collagen deposition. Nevertheless, at the end point of the study (day 30), a more 
extensive area of fibrotic scar and higher left ventricle dilatation were found in hearts 
subjected to LAD-ligation than in cryoinjured hearts. These findings indicate that 
cryoinjury leads to less pathological remodeling than LAD-ligation.  
Cryoinjury produces uniform infarcts since the length of the epicardial 
cryoinfarct borders correlates closely with the size of the probe used (van den Bos, 
Mees et al, 2005). The cryolesion results in the necrosis of cardiac cells without 
concomitant ischemia (Kolk, Meyberg et al, 2009). Furthermore, the freezing process 
leads to an injury that probably results from the mechanical forces induced by 
formation of ice crystals both in the intracellular and extracellular spaces and inside 
the vasculature (Mazur 1970). Nevertheless, myocardial cells that are located closer 
to the endothelium might be not exposed to such extreme cooling temperatures as 
the epicardial cells. This could explain the smaller infarct size and less affection of 
left ventricle function observed after cryoinjured compared to LAD-ligated hearts. 
Interestingly, previous studies have reported relative larger areas of 
neovascularization surrounding necrotic myocardium in cryoinjury models (van 
Amerongen, Harmsen et al, 2008) that provide reperfusion of the infarcted area 
(Reffelmann, Hale et al, 2003). We did not measured angiogenesis after injury. 
However, we cannot discard that cryoinjury might lead to an enhanced 
neovascularization process that contribute to a better recovery of cardiac function 
and less pathological fibrosis. This could also explain the functional and histological 
differences observed between the two models of MI.  
The induction of MI by LAD-ligation in mice was initially described 20 years 
ago (Zolotareva and Kogan 1978) and to date, it represents the standard model for 
experimental MI. However, LAD-ligation often gives rise to apical aneurysmatic 
infarcts of variable size (van den Bos, Mees et al, 2005). This led some authors to 
develop experimental myocardial injury models using simple cryoinjury in order to 
obtain standardization of the size, depth, and location of the wound (Roell, Lu et al, 
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2002; Brede, Roell et al, 2003). Based on our results, we think that cryoinjury could 
serve as a model for the study of immune cell populations involved in cardiac repair. 
However, since cryoinjury leads to smaller infarcts and less pronounced adverse 
remodeling, it would be more difficult to obtain strong differences in infarct 
remodeling between an interventional and control group, which may lead to the need 
of larger experimental groups. 
 
Identification and characterization of Tie2-expresing macrophages 
in the infarcted myocardium. 
TEMs are present in a wide variety of human and mouse tumors (De Palma, 
Murdoch et al, 2007; Pucci, Venneri et al, 2009) and in ischemic skeletal muscle 
(Bacci, Capobianco et al, 2009; Takeda, Costa et al, 2011; Hamm, Veschini et al, 
2013; Patel, Smith et al, 2013), where they have been shown to exert pro-angiogenic 
and pro-arterogenic functions. However, the existence of TEM-like populations in the 
context of ischemic heart failure has remained unexplored so far.  
 In this study, we demonstrate for the first time that TEMs are recruited into the 
ischemic myocardium in response to MI. These cells express macrophage markers 
and represent a small population (around 5%) of the total leukocyte pool found after 
injury. 
Extensive bioinformatics analysis of our database obtained by RNA-
sequencing demonstrate that TEMs display enhanced expression of genes typical of 
the endothelial cell lineage. Indeed, Cdh5, Pecam1, Angpt2, Epas1, Robo4, were 
found to be upregulated, and a number of typical M2-like genes such as Lyve1, 
Cx3cr1, Cd163, Tgfb1 and Mmp13, were downregulated in TEMs if compared to 
Ly6Clo / Tie2- macrophages. These results are in contrast to a previous work showing 
that TEMs express a typical M2-like signature and that they lack endothelial cell 
marker expression (Pucci, Venneri et al, 2009). However, we found that TEMs also 
express monocyte and macrophage markers such as Ly6C, MertK, Cd14, Cd68 and 
Cd36 (Table 5) supporting the notion that TEMs found after cardiac injury belong to 
the monocyte/macrophage lineage. According to this idea, the existence of 
monocytes/macrophages expressing endothelial genes have been previously 
described (Rehman, Li et al, 2003). Pro-angiogenic Tie2+ macrophages expressing 
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specific endothelial cell markers are found in solid tumors, where they have been 
distinguished from endothelial cells and inflammatory macrophages (McKenney, 
Weiss et al, 2001; Pucci, Venneri et al, 2009; Kim, Kang et al, 2013). Notably, a 
recent work shows that circulating monocytes can be converted on site into pro-
angiogenic and pro-arteriogenic professional cells expressing several endothelial cell 
markers through a VEGF-induced reprogramming mechanism (Avraham-Davidi, Ely 
et al, 2012). In line with these results, we propose that TEMs recruited into the 
infarcted myocardium may represent a population of macrophages exhibiting 
properties typical of endothelial cells and distinct from those found in TEMs derived 
from tumors or ischemic skeletal muscle. 
Hypoxia is a major driver of angiogenesis, and macrophages found in hypoxic 
areas are particularly associated with necrotic tissue and express several pro-
angiogenic genes (Murdoch, Muthana et al, 2008). Previous studies have reported 
that TEMs accumulate in hypoxic areas, and that they are mainly located around the 
blood vessels providing paracrine support during vascular maturation (De Palma, 
Venneri et al, 2005; Hamm, Veschini et al, 2013). We propose that the relative 
proximity of TEMs to endothelial cells in infarcted regions may provide survival and 
growth signals to endothelial cells during reparative angiogenesis and thus TEMs 
might be required for the re-vascularization and re-oxygenation of the ischemic 
myocardium. Accordingly, we confirmed that recruited TEMs express higher levels of 
genes involved in angiogenesis such as Angpt2, Cxcl12, Epas1, Robo4, Ctsb, Kdr, 
Flt1 and Flt4 than Ly6Clo / Tie2- macrophages.  
The endothelial Per-Arnt-Sim Domain Protein 1, (Epas1/Hif2α) is a 
transcription factor, member of the HIF family, that is induced under hypoxia (Lewis, 
De Palma et al, 2007). Epas1 is highly expressed in endothelial cells where it 
mediates the expression of hypoxia-regulated genes activating the expression of 
Tie2 (Lewis, De Palma et al, 2007). Interestingly, previous studies have shown that 
tumor macrophages express Epas1 in human bladder cancer, where they promote 
angiogenesis and tumor progression (Koga, Kageyama et al, 2004). These findings 
suggest that the ischemic myocardium microenviroment may induces the expression 
of Epas1 in TEMs leading to the activation of pro-angiogenic genes involved in the 
neovascularization process.  
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Macrophages have been reported to produce VEGF under hypoxic conditions. 
In fact, targeted ablation of the Vegfa gene in myeloid cells results in the inhibition of 
the angiogenic program (Stockmann, Doedens et al, 2008). The pro-angiogenic 
factors Vegfa, Vegfb and Vegfc were among the group of non-differentially expressed 
genes in TEMs versus Ly6Clo / Tie2- cells. However, Flt1 (Vegfr1), Flk1/Kdr (Vegfr2) 
and Flt4 (Vegfr3) were highly expressed in TEMs. These observations indicate that 
release of VEGF by endothelial cells or by other cell types in the ischemic 
myocardium may bind to VEGFRs on TEMs, mediating a signal transduction that 
activates the pro-angiogenic program in these cells.  
Other genes differentially expressed in TEMs compared to Ly6Clo / Tie2- 
macrophages were Cxcl12 (encoding for the stromal cell-derived factor-1, SDF1) and 
Angpt2 (Angiopoietin-2). It has been previously shown that release of SDF1 by 
ischemic or injured tissues into the circulation regulates the recruitment of pro-
angiogenic CXCR4+ bone marrow cells and endothelial cell progenitors (EPCs) 
(Petit, Jin et al, 2007). Likewise, TEM-specific CXCL12 expression might have a role 
in the recruitment of bone marrow derived pro-angiogenic precursors into the 
infarcted myocardium, supporting revascularization. Moreover, Angiopoietin 2 
(ANG2) a ligand for Tie2, is produced by angiogenic vessels and is a 
chemoattractant for TEMs (Mazzieri, Pucci et al, 2011). Hypoxia induces Tie2 
expression on TEMs and, together with ANG2, activates their pro-angiogenic 
program (Lewis, De Palma et al, 2007). Accordingly, Angpt2 expression in TEMs 
within the infarcted myocardium may also promote blood vessel formation by 
enhancing their pro-angiogenic activity through an autocrine mechanism.  
Collectively, our results demonstrate that TEMs express several hypoxia-
related pro-angiogenic genes, indicating a potential function of these cells in 
promoting re-vascularization of the ischemic myocardium. 
Following ischemic injury, angiogenesis leads to an expanded microvascular 
network adjacent to the ischemic zone that provides additional blood flow to relieve 
the ischemia and facilitate tissue repair (Peirce and Skalak 2003; Annex 2013). In 
this context, growing neo-vessels might navigate through tissue stroma as they 
locate and grow towards other vessel elements (Annex 2013; Hoying, Utzinger et al, 
2014). Increasing evidences suggest that the vascular and the nervous systems 
share signaling pathways controlling axon and vascular pattering and guidance 
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(Gelfand, Hong et al, 2009). Semaphorins, a large group of proteins originally 
identified as axon guidance molecules, and their receptors, neuropilins and plexins, 
have recently been implicated in vascular development and angiogenesis (Gelfand, 
Hong et al, 2009; Casazza, Laoui et al, 2013). Interestingly, we found that TEMs 
over-express genes associated to cell motion such as Semaphorin6a (Sema6a) and 
Plexina2 (Plxna2). SEMA6A, is a transmembrane protein that binds to membrane-
bound PLEXINA2 and PLEXIN4A. SEMA6A and its receptors have been extensively 
characterized for their roles in neuronal development, where they regulate cellular 
migration and axon guidance (Gelfand, Hong et al, 2009). Moreover, SEMA6A has 
been shown to be a critical mediator of endothelial cell survival and a selective 
regulator of VEGF/VEGFR2 signaling in angiogenesis (Segarra, Ohnuki et al, 2012). 
Altogether, our findings suggest that expression of Sema6a and Plxna in TEMs might 
act as a guidance cue for endothelial cell migration within the infarcted region, thus 
promoting neo-vascular network formation.   
Notably, we found that TEMs also exhibit enhanced expression of genes 
associated with cell-to-cell adhesion and leukocyte trans-endothelial cell migration. 
Studies in the developing embryo show that Tie2+ macrophages support the 
formation of blood vessels by physically promoting fusion of sprouting endothelial tip 
cells via direct cell-to-cell contacts (Fantin, Vieira et al, 2010). These observations 
suggest that while extravasating into the myocardium, TEMs may activate endothelial 
cells by cell-to-cell interactions, mediated by surface molecules such as CDH5 and 
CD31. 
Considering our data, it is tempting to speculate that following migration into 
the infarcted region, TEMs could activate a pro-angiogenic gene program in 
response to hypoxia. In this context, TEMs might activate endothelial cells either by 
the release of pro-angiogenic factors, or by direct TEMs/endothelial cells interactions. 
Both mechanisms might induce endothelial cell survival, guide angiogenesis and 
promote vascular remodeling and maturation.  
EPCs have been identified as bone marrow-derived endothelial precursor cells 
that contribute to neo-vascularization (Balaji, King et al, 2013). EPCs mobilize from 
bone marrow in response to hypoxia and SDF1 induced by trauma or vascular injury. 
Once at the site of tissue repair, EPCs contribute to new vessel formation by their 
direct incorporation into neo-formed vessels, differentiation into mature endothelial 
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cells, and/or production of paracrine signals (Balaji, King et al, 2013). Based on the 
notion that Tie2 expression was specific of endothelial cells, in the past, TEMs were 
interpreted as EPCs, even though they expressed hematopoietic/myeloid markers 
(Modarai, Burnand et al, 2005). Nevertheless, a number of studies have now clearly 
shown that Tie2+ mononuclear cells found in tumors belong to the myeloid lineage 
(De Palma, Venneri et al, 2005; De Palma, Murdoch et al, 2007) discarding the idea 
of an EPC origin of TEMs. 
There is no consensus in the specific surface marker that definitely 
distinguishes EPCs. However, investigators usually characterize them by including 
markers of stemness and hematopoietic lineage such as CD34, c-kit, or Sca-1 (in 
mice) and CD34 and CD133 (in humans) in combination with markers demonstrating 
endothelial commitment (KDR / FLK1) (Balaji, King et al, 2013). In our experiments, 
TEMs displayed enhanced expression of Cd34 and Flk1 compared to Ly6Clo / Tie2- 
macrophages but did not express c-Kit or Sca-1. In addition, the expression of the 
macrophage and monocyte specific markers MerTK, Cd68 and Ly6Cin TEMs 
indicates the mononuclear nature of these cells and thus, suggests that TEMs do not 
belong to the EPC lineage. 
In our study, TEMs displayed downregulation of several genes associated to 
the resolution of inflammation such as Cx3cr1, Cd163, Lyve1, Retnla, Cd209g, Mrc1 
and Clec4a2 compared to Ly6Clo / Tie2- macrophages.  (Figure 25 and Table 6). 
Furthermore, TEMs express lower levels of Tgfb1, (Transforming Growth Factor β) 
than Ly6Clo / Tie2- macrophages, which is involved in extracellular matrix 
reconstruction through fibroblast activation and collagen deposition (Jaffer, Sosnovik 
et al, 2006). Collectively, these results indicate that TEMs and Ly6Clo / Tie2- 
macrophages likely contribute in a different manner to cardiac healing and repair. In 
this regard, our data suggest that in response to cardiac injury, Ly6Clo / Tie2- 
macrophages develop immuno-modulatory functions aimed at resolving inflammation 
and favoring scar formation. In contrast, TEMs would represent a cell population 
expressing pro-angiogenic factors that promote the formation of new blood vessels 
thus allowing the revascularization of the ischemic myocardium.  
In conclusion, our data provide the first demonstration of the involvement of 
TEMs in ischemia associated to LAD-ligation. Considering the high incidence and 
mortality caused by MI in the developed countries, this study is highly significant and 
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endowed with an enormous potential of discovery. Indeed, future studies in the field 
could open new avenues to exploit TEMs as therapeutic targets or as effectors for 
the treatment of MI, its progression and outcome. 
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1. In homeostatic conditions, the heart contains a population of cardiac resident 
macrophages that can be recognized by cell tracking approaches in both CX3CR1
gfp/+ 
and MaFIA mice.  
 
2. Cardiac resident macrophages are located in close proximity to the coronary 
vasculature, and express several anti-inflammatory, pro-angiogenic and tissue 
remodeling genes suggesting a role for these cells in inmuno-modulation, regulation 
of angiogenesis and matrix remodeling.  
 
3. Induction of myocardial infarction by either cryoinjury or LAD-ligation results in 
an immune response comprised of two monocyte and macrophage subsets 
distinguished by their levels of Ly6C expression, that appear within the myocardium 
in a sequential manner.  
 
4.  Ly6Chi cells found early after injury represent monocytes and macrophages with 
pro-inflammatory properties, whereas Ly6Clo cells present at later times after injury 
are macrophages displaying an anti-inflammatory and pro-angiogenic profile.  
 
5. Tie2-expressing macrophages (TEMs) are recruited into the myocardium in 
response to myocardial infarction and represent a cell population distinct from the 
Ly6Clo macrophage subset. 
 
6. TEMs express several highly pro-angiogenic and endotelial cell-like markers 
and exhibit a preferential perivascular location. These observations suggest a role for 
TEMs in the cardiac angiogenic process necessary for the revascularization and 
recovery of the ischemic myocardium. 
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7. Cryoinjury and LAD-ligation are suitable models to study immune cell 
response associated to myocardial infarction. However, cryoinjury has limitations 
since it produces smaller infarcts, reduced fibrotic scar and less worsening of the 
cardiac function compared to LAD-ligation.  
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1. En situación de homeostasis, el corazón alberga una población de 
macrófagos residentes cardíacos que pueden ser reconocidos por su expresión de 
GFP en los modelos de ratón transgénicos CX3CR1
gfp/+ y MaFIA.  
 
2.  Los macrófagos residentes cardíacos muestran una localización cercana a la 
vasculatura coronaria así como un patrón de expresión típico anti-inflamatorio que 
incluye genes implicados en angiogénesis y remodelado tisular. Esto sugiere un 
papel importante de los macrófagos residentes cardíacos en los procesos de 
inmunorregulación, angiogénesis y remodelación de la matriz extracelular en el 
corazón.   
 
3. La inducción del infarto de miocardio por criolesión o por ligación permanente 
de la arteria coronaria da lugar a una respuesta inmunitaria caracterizada por la 
presencia secuencial de dos subpoblaciones de monocitos y macrófagos que se 
diferencian entre sí por su mayor o menor expresión del marcador de superficie 
Ly6C. 
 
4. La subpoblación celular que expresa niveles elevados de Ly6C  (Ly6Chi) está 
presente en el miocardio en fases tempranas tras el infarto y se compone de 
monocitos y macrófagos con fenotipo pro-inflamatorio. La subpoblación celular 
distinguida por su menor nivel de expresión de Ly6C (Ly6Clo) se encuentra presente 
en el corazón en fases más tardías y exhibe un patrón de expresión anti-inflamatorio 
y pro-angiogénico.  
 
5. En respuesta al infarto de miocardio, tiene lugar el reclutamiento de 
macrófagos Tie2+ (TEMs) en el corazón, que representan una población distinta de 
los macrófagos Ly6Clo.  
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6. Los macrófagos Tie2+ expresan numerosos genes pro-angiogénicos así como 
marcadores típicos de células endoteliales y exhiben una localización preferencial en 
zonas perivasculares. Esto sugiere que los macrófagos Tie2+ pueden estar 
implicados en el proceso de angiogénesis cardíaca necesario para la 
revascularización y recuperación del miocardio isquémico. 
 
7. La criolesión  y la ligación permanente coronaria constituyen modelos  útiles 
para la caracterización de las poblaciones mieloides implicadas en la respuesta 
inmunitaria que tiene lugar tras el infarto. No obstante, la criolesión produce infartos 
de menor tamaño, una menor pérdida de función cardíaca así como una reducida 
lesión fibrótica comparado con el modelo de ligación permanente coronaria. 
 
   
143 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
   
144 
 
BIBLIOGRAPHY 
 
145 
 
 
Al-Shahrour, F., R. Diaz-Uriarte and J. Dopazo (2004). "FatiGO: a web tool for finding 
significant associations of Gene Ontology terms with groups of genes." 
Bioinformatics 20(4): 578-580. 
Annex, B. H. (2013). "Therapeutic angiogenesis for critical limb ischaemia." Nature reviews. 
Cardiology 10(7): 387-396. 
Arnold, L., A. Henry, F. Poron, Y. Baba-Amer, N. van Rooijen, A. Plonquet, R. K. Gherardi and 
B. Chazaud (2007). "Inflammatory monocytes recruited after skeletal muscle injury 
switch into antiinflammatory macrophages to support myogenesis." The Journal of 
experimental medicine 204(5): 1057-1069. 
Auffray, C., D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. Cumano, G. 
Lauvau and F. Geissmann (2007). "Monitoring of blood vessels and tissues by a 
population of monocytes with patrolling behavior." Science 317(5838): 666-670. 
Auffray, C., D. K. Fogg, E. Narni-Mancinelli, B. Senechal, C. Trouillet, N. Saederup, J. Leemput, 
K. Bigot, L. Campisi, M. Abitbol, T. Molina, I. Charo, D. A. Hume, A. Cumano, G. 
Lauvau and F. Geissmann (2009). "CX3CR1+ CD115+ CD135+ common 
macrophage/DC precursors and the role of CX3CR1 in their response to 
inflammation." The Journal of experimental medicine 206(3): 595-606. 
Augustin, H. G., G. Y. Koh, G. Thurston and K. Alitalo (2009). "Control of vascular 
morphogenesis and homeostasis through the angiopoietin-Tie system." Nature 
reviews. Molecular cell biology 10(3): 165-177. 
Aurora, A. B., E. R. Porrello, W. Tan, A. I. Mahmoud, J. A. Hill, R. Bassel-Duby, H. A. Sadek and 
E. N. Olson (2014). "Macrophages are required for neonatal heart regeneration." 
The Journal of clinical investigation 124(3): 1382-1392. 
Avraham-Davidi, I., Y. Ely, V. N. Pham, D. Castranova, M. Grunspan, G. Malkinson, L. Gibbs-
Bar, O. Mayseless, G. Allmog, B. Lo, C. M. Warren, T. T. Chen, J. Ungos, K. Kidd, K. 
Shaw, I. Rogachev, W. Wan, P. M. Murphy, S. A. Farber, L. Carmel, G. S. Shelness, M. 
L. Iruela-Arispe, B. M. Weinstein and K. Yaniv (2012). "ApoB-containing lipoproteins 
regulate angiogenesis by modulating expression of VEGF receptor 1." Nature 
medicine 18(6): 967-973. 
Azad, A. K., M. V. Rajaram and L. S. Schlesinger (2014). "Exploitation of the Macrophage 
Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics." 
Journal of cytology & molecular biology 1(1). 
Azzawi, M., P. S. Hasleton, S. W. Kan, V. F. Hillier, A. Quigley and I. V. Hutchinson (1997). 
"Distribution of myocardial macrophages in the normal human heart." Journal of 
anatomy 191 ( Pt 3): 417-423. 
Azzawi, M., S. W. Kan, V. Hillier, N. Yonan, I. V. Hutchinson and P. S. Hasleton (2005). "The 
distribution of cardiac macrophages in myocardial ischaemia and cardiomyopathy." 
Histopathology 46(3): 314-319. 
Bacci, M., A. Capobianco, A. Monno, L. Cottone, F. Di Puppo, B. Camisa, M. Mariani, C. 
Brignole, M. Ponzoni, S. Ferrari, P. Panina-Bordignon, A. A. Manfredi and P. Rovere-
Querini (2009). "Macrophages are alternatively activated in patients with 
endometriosis and required for growth and vascularization of lesions in a mouse 
model of disease." The American journal of pathology 175(2): 547-556. 
Balaji, S., A. King, T. M. Crombleholme and S. G. Keswani (2013). "The Role of Endothelial 
Progenitor Cells in Postnatal Vasculogenesis: Implications for Therapeutic 
Neovascularization and Wound Healing." Advances in wound care 2(6): 283-295. 
BIBLIOGRAPHY 
 
146 
 
Bertrand, J. Y., A. Jalil, M. Klaine, S. Jung, A. Cumano and I. Godin (2005). "Three pathways to 
mature macrophages in the early mouse yolk sac." Blood 106(9): 3004-3011. 
Biswas, S. K. and A. Mantovani (2010). "Macrophage plasticity and interaction with 
lymphocyte subsets: cancer as a paradigm." Nature immunology 11(10): 889-896. 
Bolli, R., A. R. Chugh, D. D'Amario, J. H. Loughran, M. F. Stoddard, S. Ikram, G. M. Beache, S. 
G. Wagner, A. Leri, T. Hosoda, F. Sanada, J. B. Elmore, P. Goichberg, D. Cappetta, N. 
K. Solankhi, I. Fahsah, D. G. Rokosh, M. S. Slaughter, J. Kajstura and P. Anversa 
(2011). "Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): 
initial results of a randomised phase 1 trial." Lancet 378(9806): 1847-1857. 
Bouchentouf, M., P. Paradis, K. A. Forner, J. Cuerquis, M. N. Boivin, J. Zheng, M. R. Boulassel, 
J. P. Routy, E. L. Schiffrin and J. Galipeau (2010). "Monocyte derivatives promote 
angiogenesis and myocyte survival in a model of myocardial infarction." Cell 
transplantation 19(4): 369-386. 
Braunwald, E., J. E. Muller, R. A. Kloner and P. R. Maroko (1983). "Role of beta-adrenergic 
blockade in the therapy of patients with myocardial infarction." The American 
journal of medicine 74(1): 113-123. 
Brede, M., W. Roell, O. Ritter, F. Wiesmann, R. Jahns, A. Haase, B. K. Fleischmann and L. Hein 
(2003). "Cardiac hypertrophy is associated with decreased eNOS expression in 
angiotensin AT2 receptor-deficient mice." Hypertension 42(6): 1177-1182. 
Brutsaert, D. L. (2003). "Cardiac endothelial-myocardial signaling: its role in cardiac growth, 
contractile performance, and rhythmicity." Physiological reviews 83(1): 59-115. 
Burnett, S. H. (2004). "Conditional macrophage ablation in transgenic mice expressing a Fas-
based suicide gene." Journal of leukocyte biology 75(4): 612-623. 
Burnett, S. H., E. J. Kershen, J. Zhang, L. Zeng, S. C. Straley, A. M. Kaplan and D. A. Cohen 
(2004). "Conditional macrophage ablation in transgenic mice expressing a Fas-based 
suicide gene." Journal of leukocyte biology 75(4): 612-623. 
Cailhier, J. F., M. Partolina, S. Vuthoori, S. Wu, K. Ko, S. Watson, J. Savill, J. Hughes and R. A. 
Lang (2005). "Conditional macrophage ablation demonstrates that resident 
macrophages initiate acute peritoneal inflammation." Journal of immunology 
174(4): 2336-2342. 
Casazza, A., D. Laoui, M. Wenes, S. Rizzolio, N. Bassani, M. Mambretti, S. Deschoemaeker, J. 
A. Van Ginderachter, L. Tamagnone and M. Mazzone (2013). "Impeding macrophage 
entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits 
angiogenesis and restores antitumor immunity." Cancer cell 24(6): 695-709. 
Coffelt, S. B., A. O. Tal, A. Scholz, M. De Palma, S. Patel, C. Urbich, S. K. Biswas, C. Murdoch, 
K. H. Plate, Y. Reiss and C. E. Lewis (2010). "Angiopoietin-2 regulates gene expression 
in TIE2-expressing monocytes and augments their inherent proangiogenic 
functions." Cancer research 70(13): 5270-5280. 
Cruz-Adalia, A., L. J. Jimenez-Borreguero, M. Ramirez-Huesca, I. Chico-Calero, O. Barreiro, E. 
Lopez-Conesa, M. Fresno, F. Sanchez-Madrid and P. Martin (2010). "CD69 limits the 
severity of cardiomyopathy after autoimmune myocarditis." Circulation 122(14): 
1396-1404. 
Chien, K. R., I. J. Domian and K. K. Parker (2008). "Cardiogenesis and the complex biology of 
regenerative cardiovascular medicine." Science 322(5907): 1494-1497. 
Chinetti-Gbaguidi, G. and B. Staels (2011). "Macrophage polarization in metabolic disorders: 
functions and regulation." Current opinion in lipidology 22(5): 365-372. 
Chitu, V. and E. R. Stanley (2006). "Colony-stimulating factor-1 in immunity and 
inflammation." Current opinion in immunology 18(1): 39-48. 
BIBLIOGRAPHY 
 
147 
 
Cho, C. H., Y. J. Koh, J. Han, H. K. Sung, H. Jong Lee, T. Morisada, R. A. Schwendener, R. A. 
Brekken, G. Kang, Y. Oike, T. S. Choi, T. Suda, O. J. Yoo and G. Y. Koh (2007). 
"Angiogenic role of LYVE-1-positive macrophages in adipose tissue." Circulation 
research 100(4): e47-57. 
Chorro, L., A. Sarde, M. Li, K. J. Woollard, P. Chambon, B. Malissen, A. Kissenpfennig, J. B. 
Barbaroux, R. Groves and F. Geissmann (2009). "Langerhans cell (LC) proliferation 
mediates neonatal development, homeostasis, and inflammation-associated 
expansion of the epidermal LC network." The Journal of experimental medicine 
206(13): 3089-3100. 
Dai, X. M., G. R. Ryan, A. J. Hapel, M. G. Dominguez, R. G. Russell, S. Kapp, V. Sylvestre and E. 
R. Stanley (2002). "Targeted disruption of the mouse colony-stimulating factor 1 
receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, 
increased primitive progenitor cell frequencies, and reproductive defects." Blood 
99(1): 111-120. 
Daly, C., A. Eichten, C. Castanaro, E. Pasnikowski, A. Adler, A. S. Lalani, N. Papadopoulos, A. 
H. Kyle, A. I. Minchinton, G. D. Yancopoulos and G. Thurston (2013). "Angiopoietin-2 
functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF 
inhibition." Cancer research 73(1): 108-118. 
Davalos, D., J. Grutzendler, G. Yang, J. V. Kim, Y. Zuo, S. Jung, D. R. Littman, M. L. Dustin and 
W. B. Gan (2005). "ATP mediates rapid microglial response to local brain injury in 
vivo." Nature neuroscience 8(6): 752-758. 
Davies, L. C., S. J. Jenkins, J. E. Allen and P. R. Taylor (2013). "Tissue-resident macrophages." 
Nature immunology 14(10): 986-995. 
Davies, L. C., M. Rosas, S. J. Jenkins, C. T. Liao, M. J. Scurr, F. Brombacher, D. J. Fraser, J. E. 
Allen, S. A. Jones and P. R. Taylor (2013). "Distinct bone marrow-derived and tissue-
resident macrophage lineages proliferate at key stages during inflammation." 
Nature communications 4: 1886. 
Dayan, V., G. Yannarelli, F. Billia, P. Filomeno, X. H. Wang, J. E. Davies and A. Keating (2011). 
"Mesenchymal stromal cells mediate a switch to alternatively activated 
monocytes/macrophages after acute myocardial infarction." Basic research in 
cardiology 106(6): 1299-1310. 
De Palma, M., C. Murdoch, M. A. Venneri, L. Naldini and C. E. Lewis (2007). "Tie2-expressing 
monocytes: regulation of tumor angiogenesis and therapeutic implications." Trends 
in immunology 28(12): 519-524. 
De Palma, M., M. A. Venneri, R. Galli, L. Sergi Sergi, L. S. Politi, M. Sampaolesi and L. Naldini 
(2005). "Tie2 identifies a hematopoietic lineage of proangiogenic monocytes 
required for tumor vessel formation and a mesenchymal population of pericyte 
progenitors." Cancer cell 8(3): 211-226. 
Djemadji-Oudjiel, N., S. Goerdt, V. Kodelja, M. Schmuth and C. E. Orfanos (1996). 
"Immunohistochemical identification of type II alternatively activated dendritic 
macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis." Archives of 
dermatological research 288(12): 757-764. 
Dunay, I. R., R. A. Damatta, B. Fux, R. Presti, S. Greco, M. Colonna and L. D. Sibley (2008). 
"Gr1(+) inflammatory monocytes are required for mucosal resistance to the 
pathogen Toxoplasma gondii." Immunity 29(2): 306-317. 
Epelman, S., K. J. Lavine, A. E. Beaudin, D. K. Sojka, J. A. Carrero, B. Calderon, T. Brija, E. L. 
Gautier, S. Ivanov, A. T. Satpathy, J. D. Schilling, R. Schwendener, I. Sergin, B. Razani, 
E. C. Forsberg, W. M. Yokoyama, E. R. Unanue, M. Colonna, G. J. Randolph and D. L. 
Mann (2014). "Embryonic and adult-derived resident cardiac macrophages are 
BIBLIOGRAPHY 
 
148 
 
maintained through distinct mechanisms at steady state and during inflammation." 
Immunity 40(1): 91-104. 
Fabriek, B. O., R. van Bruggen, D. M. Deng, A. J. Ligtenberg, K. Nazmi, K. Schornagel, R. P. 
Vloet, C. D. Dijkstra and T. K. van den Berg (2009). "The macrophage scavenger 
receptor CD163 functions as an innate immune sensor for bacteria." Blood 113(4): 
887-892. 
Fallowfield, J. A., M. Mizuno, T. J. Kendall, C. M. Constandinou, R. C. Benyon, J. S. Duffield 
and J. P. Iredale (2007). "Scar-associated macrophages are a major source of hepatic 
matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis." 
Journal of immunology 178(8): 5288-5295. 
Fantin, A., J. M. Vieira, G. Gestri, L. Denti, Q. Schwarz, S. Prykhozhij, F. Peri, S. W. Wilson and 
C. Ruhrberg (2010). "Tissue macrophages act as cellular chaperones for vascular 
anastomosis downstream of VEGF-mediated endothelial tip cell induction." Blood 
116(5): 829-840. 
Fishbein, M. C., D. Maclean and P. R. Maroko (1978). "The histopathologic evolution of 
myocardial infarction." Chest 73(6): 843-849. 
Frangogiannis, N. G. (2012). "Regulation of the inflammatory response in cardiac repair." 
Circulation research 110(1): 159-173. 
Frangogiannis, N. G., C. W. Smith and M. L. Entman (2002). "The inflammatory response in 
myocardial infarction." Cardiovascular research 53(1): 31-47. 
Frantz, S., U. Hofmann, D. Fraccarollo, A. Schafer, S. Kranepuhl, I. Hagedorn, B. Nieswandt, 
M. Nahrendorf, H. Wagner, B. Bayer, C. Pachel, M. P. Schon, S. Kneitz, T. Bobinger, F. 
Weidemann, G. Ertl and J. Bauersachs (2013). "Monocytes/macrophages prevent 
healing defects and left ventricular thrombus formation after myocardial infarction." 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 27(3): 871-881. 
Frantz, S. and M. Nahrendorf (2014). "Cardiac macrophages and their role in ischaemic heart 
disease." Cardiovascular research. 
Gautier, E. L., T. Shay, J. Miller, M. Greter, C. Jakubzick, S. Ivanov, J. Helft, A. Chow, K. G. 
Elpek, S. Gordonov, A. R. Mazloom, A. Ma'ayan, W. J. Chua, T. H. Hansen, S. J. Turley, 
M. Merad and G. J. Randolph (2012). "Gene-expression profiles and transcriptional 
regulatory pathways that underlie the identity and diversity of mouse tissue 
macrophages." Nature immunology 13(11): 1118-1128. 
Gaziano, T. A. (2005). "Cardiovascular disease in the developing world and its cost-effective 
management." Circulation 112(23): 3547-3553. 
Geissmann, F., S. Jung and D. R. Littman (2003). "Blood monocytes consist of two principal 
subsets with distinct migratory properties." Immunity 19(1): 71-82. 
Geissmann, F., M. G. Manz, S. Jung, M. H. Sieweke, M. Merad and K. Ley (2010). 
"Development of monocytes, macrophages, and dendritic cells." Science 327(5966): 
656-661. 
Gelfand, M. V., S. Hong and C. Gu (2009). "Guidance from above: common cues direct 
distinct signaling outcomes in vascular and neural patterning." Trends in cell biology 
19(3): 99-110. 
Getts, D. R., R. L. Terry, M. T. Getts, M. Muller, S. Rana, B. Shrestha, J. Radford, N. Van 
Rooijen, I. L. Campbell and N. J. King (2008). "Ly6c+ "inflammatory monocytes" are 
microglial precursors recruited in a pathogenic manner in West Nile virus 
encephalitis." The Journal of experimental medicine 205(10): 2319-2337. 
Gill, S. E., S. A. Gharib, E. M. Bench, S. W. Sussman, R. T. Wang, C. Rims, T. P. Birkland, Y. 
Wang, A. M. Manicone, J. K. McGuire and W. C. Parks (2013). "Tissue inhibitor of 
BIBLIOGRAPHY 
 
149 
 
metalloproteinases-3 moderates the proinflammatory status of macrophages." 
American journal of respiratory cell and molecular biology 49(5): 768-777. 
Ginhoux, F., M. Greter, M. Leboeuf, S. Nandi, P. See, S. Gokhan, M. F. Mehler, S. J. Conway, 
L. G. Ng, E. R. Stanley, I. M. Samokhvalov and M. Merad (2010). "Fate mapping 
analysis reveals that adult microglia derive from primitive macrophages." Science 
330(6005): 841-845. 
Ginhoux, F., F. Tacke, V. Angeli, M. Bogunovic, M. Loubeau, X. M. Dai, E. R. Stanley, G. J. 
Randolph and M. Merad (2006). "Langerhans cells arise from monocytes in vivo." 
Nature immunology 7(3): 265-273. 
Godwin, J. W., A. R. Pinto and N. A. Rosenthal (2013). "Macrophages are required for adult 
salamander limb regeneration." Proceedings of the National Academy of Sciences of 
the United States of America 110(23): 9415-9420. 
Goerdt, S., O. Politz, K. Schledzewski, R. Birk, A. Gratchev, P. Guillot, N. Hakiy, C. D. Klemke, 
E. Dippel, V. Kodelja and C. E. Orfanos (1999). "Alternative versus classical activation 
of macrophages." Pathobiology : journal of immunopathology, molecular and 
cellular biology 67(5-6): 222-226. 
Gordon, E. J., S. Rao, J. W. Pollard, S. L. Nutt, R. A. Lang and N. L. Harvey (2010). 
"Macrophages define dermal lymphatic vessel calibre during development by 
regulating lymphatic endothelial cell proliferation." Development 137(22): 3899-
3910. 
Hamm, A., L. Veschini, Y. Takeda, S. Costa, E. Delamarre, M. L. Squadrito, A. T. Henze, M. 
Wenes, J. Serneels, F. Pucci, C. Roncal, A. Anisimov, K. Alitalo, M. De Palma and M. 
Mazzone (2013). "PHD2 regulates arteriogenic macrophages through TIE2 
signalling." EMBO molecular medicine 5(6): 843-857. 
Harel-Adar, T., T. Ben Mordechai, Y. Amsalem, M. S. Feinberg, J. Leor and S. Cohen (2011). 
"Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes 
improves infarct repair." Proceedings of the National Academy of Sciences of the 
United States of America 108(5): 1827-1832. 
Harris, M. A., J. Clark, A. Ireland, J. Lomax, M. Ashburner, R. Foulger, K. Eilbeck, S. Lewis, B. 
Marshall, C. Mungall, J. Richter, G. M. Rubin, J. A. Blake, C. Bult, M. Dolan, H. 
Drabkin, J. T. Eppig, D. P. Hill, L. Ni, M. Ringwald, R. Balakrishnan, J. M. Cherry, K. R. 
Christie, M. C. Costanzo, S. S. Dwight, S. Engel, D. G. Fisk, J. E. Hirschman, E. L. Hong, 
R. S. Nash, A. Sethuraman, C. L. Theesfeld, D. Botstein, K. Dolinski, B. Feierbach, T. 
Berardini, S. Mundodi, S. Y. Rhee, R. Apweiler, D. Barrell, E. Camon, E. Dimmer, V. 
Lee, R. Chisholm, P. Gaudet, W. Kibbe, R. Kishore, E. M. Schwarz, P. Sternberg, M. 
Gwinn, L. Hannick, J. Wortman, M. Berriman, V. Wood, N. de la Cruz, P. Tonellato, P. 
Jaiswal, T. Seigfried and R. White (2004). "The Gene Ontology (GO) database and 
informatics resource." Nucleic acids research 32(Database issue): D258-261. 
Hashimoto, D., A. Chow, C. Noizat, P. Teo, M. B. Beasley, M. Leboeuf, C. D. Becker, P. See, J. 
Price, D. Lucas, M. Greter, A. Mortha, S. W. Boyer, E. C. Forsberg, M. Tanaka, N. van 
Rooijen, A. Garcia-Sastre, E. R. Stanley, F. Ginhoux, P. S. Frenette and M. Merad 
(2013). "Tissue-resident macrophages self-maintain locally throughout adult life with 
minimal contribution from circulating monocytes." Immunity 38(4): 792-804. 
He, H., J. Xu, C. M. Warren, D. Duan, X. Li, L. Wu and M. L. Iruela-Arispe (2012). "Endothelial 
cells provide an instructive niche for the differentiation and functional polarization 
of M2-like macrophages." Blood 120(15): 3152-3162. 
Hellermann, J. P., S. J. Jacobsen, M. M. Redfield, G. S. Reeder, S. A. Weston and V. L. Roger 
(2005). "Heart failure after myocardial infarction: clinical presentation and survival." 
European journal of heart failure 7(1): 119-125. 
BIBLIOGRAPHY 
 
150 
 
Hellermann, J. P., S. J. Jacobsen, G. S. Reeder, F. Lopez-Jimenez, S. A. Weston and V. L. Roger 
(2003). "Heart failure after myocardial infarction: prevalence of preserved left 
ventricular systolic function in the community." American heart journal 145(4): 742-
748. 
Hilgendorf, I., L. Gerhardt, T. C. Tan, C. Winter, T. A. Holderried, B. G. Chousterman, Y. 
Iwamoto, R. Liao, A. Zirlik, M. Scherrer-Crosbie, C. C. Hedrick, P. Libby, M. 
Nahrendorf, R. Weissleder and F. K. Swirski (2014). "Ly-6Chigh Monocytes Depend 
on Nr4a1 to Balance both Inflammatory and Reparative Phases in the Infarcted 
Myocardium." Circulation research. 
Hoying, J. B., U. Utzinger and J. A. Weiss (2014). "Formation of microvascular networks: role 
of stromal interactions directing angiogenic growth." Microcirculation. 
Hume, D. A. and K. P. MacDonald (2012). "Therapeutic applications of macrophage colony-
stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling." 
Blood 119(8): 1810-1820. 
Jackson, K. A., S. M. Majka, H. Wang, J. Pocius, C. J. Hartley, M. W. Majesky, M. L. Entman, L. 
H. Michael, K. K. Hirschi and M. A. Goodell (2001). "Regeneration of ischemic cardiac 
muscle and vascular endothelium by adult stem cells." The Journal of clinical 
investigation 107(11): 1395-1402. 
Jaffer, F. A., D. E. Sosnovik, M. Nahrendorf and R. Weissleder (2006). "Molecular imaging of 
myocardial infarction." Journal of molecular and cellular cardiology 41(6): 921-933. 
Jenkins, S. J., D. Ruckerl, P. C. Cook, L. H. Jones, F. D. Finkelman, N. van Rooijen, A. S. 
MacDonald and J. E. Allen (2011). "Local macrophage proliferation, rather than 
recruitment from the blood, is a signature of TH2 inflammation." Science 332(6035): 
1284-1288. 
Jensen, J. A., J. C. Kosek, T. K. Hunt, W. H. Goodson, 3rd and D. C. Miller (1987). "Cardiac 
cryolesions as an experimental model of myocardial wound healing." Annals of 
surgery 206(6): 798-803. 
Jung, S., J. Aliberti, P. Graemmel, M. J. Sunshine, G. W. Kreutzberg, A. Sher and D. R. Littman 
(2000). "Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and 
green fluorescent protein reporter gene insertion." Molecular and cellular biology 
20(11): 4106-4114. 
Kanehisa, M., S. Goto, S. Kawashima, Y. Okuno and M. Hattori (2004). "The KEGG resource 
for deciphering the genome." Nucleic acids research 32(Database issue): D277-280. 
Kim, O. H., G. H. Kang, H. Noh, J. Y. Cha, H. J. Lee, J. H. Yoon, M. Mamura, J. S. Nam, D. H. 
Lee, Y. A. Kim, Y. J. Park, H. Kim and B. C. Oh (2013). "Proangiogenic TIE2(+)/CD31 (+) 
macrophages are the predominant population of tumor-associated macrophages 
infiltrating metastatic lymph nodes." Molecules and cells 36(5): 432-438. 
Klimchenko, O., A. Di Stefano, B. Geoerger, S. Hamidi, P. Opolon, T. Robert, M. Routhier, J. 
El-Benna, A. L. Delezoide, S. Boukour, B. Lescure, E. Solary, W. Vainchenker and F. 
Norol (2011). "Monocytic cells derived from human embryonic stem cells and fetal 
liver share common differentiation pathways and homeostatic functions." Blood 
117(11): 3065-3075. 
Kodelja, V., C. Muller, S. Tenorio, C. Schebesch, C. E. Orfanos and S. Goerdt (1997). 
"Differences in angiogenic potential of classically vs alternatively activated 
macrophages." Immunobiology 197(5): 478-493. 
Koga, F., Y. Kageyama, S. Kawakami, Y. Fujii, N. Hyochi, N. Ando, T. Takizawa, K. Saito, A. 
Iwai, H. Masuda and K. Kihara (2004). "Prognostic significance of endothelial Per-
Arnt-sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of 
BIBLIOGRAPHY 
 
151 
 
tumor associated macrophages in invasive bladder cancer." The Journal of urology 
171(3): 1080-1084. 
Kolk, M. V., D. Meyberg, T. Deuse, K. R. Tang-Quan, R. C. Robbins, H. Reichenspurner and S. 
Schrepfer (2009). "LAD-ligation: a murine model of myocardial infarction." Journal of 
visualized experiments : JoVE(32). 
Krausgruber, T., K. Blazek, T. Smallie, S. Alzabin, H. Lockstone, N. Sahgal, T. Hussell, M. 
Feldmann and I. A. Udalova (2011). "IRF5 promotes inflammatory macrophage 
polarization and TH1-TH17 responses." Nature immunology 12(3): 231-238. 
Krausz, S., S. Garcia, C. A. Ambarus, D. de Launay, M. Foster, B. Naiman, W. Iverson, J. R. 
Connor, M. A. Sleeman, A. J. Coyle, J. Hamann, D. Baeten, P. P. Tak and K. A. 
Reedquist (2012). "Angiopoietin-2 promotes inflammatory activation of human 
macrophages and is essential for murine experimental arthritis." Annals of the 
rheumatic diseases 71(8): 1402-1410. 
Kreider, T., R. M. Anthony, J. F. Urban, Jr. and W. C. Gause (2007). "Alternatively activated 
macrophages in helminth infections." Current opinion in immunology 19(4): 448-
453. 
Lambert, J. M., E. F. Lopez and M. L. Lindsey (2008). "Macrophage roles following myocardial 
infarction." International journal of cardiology 130(2): 147-158. 
Landsman, L., L. Bar-On, A. Zernecke, K. W. Kim, R. Krauthgamer, E. Shagdarsuren, S. A. Lira, 
I. L. Weissman, C. Weber and S. Jung (2009). "CX3CR1 is required for monocyte 
homeostasis and atherogenesis by promoting cell survival." Blood 113(4): 963-972. 
Lasala, G. P. and J. J. Minguell (2009). "Bone marrow-derived stem/progenitor cells: their use 
in clinical studies for the treatment of myocardial infarction." Heart, lung & 
circulation 18(3): 171-180. 
Leor, J., L. Rozen, A. Zuloff-Shani, M. S. Feinberg, Y. Amsalem, I. M. Barbash, E. Kachel, R. 
Holbova, Y. Mardor, D. Daniels, A. Ocherashvilli, A. Orenstein and D. Danon (2006). 
"Ex vivo activated human macrophages improve healing, remodeling, and function 
of the infarcted heart." Circulation 114(1 Suppl): I94-100. 
Leuschner, F., P. J. Rauch, T. Ueno, R. Gorbatov, B. Marinelli, W. W. Lee, P. Dutta, Y. Wei, C. 
Robbins, Y. Iwamoto, B. Sena, A. Chudnovskiy, P. Panizzi, E. Keliher, J. M. Higgins, P. 
Libby, M. A. Moskowitz, M. J. Pittet, F. K. Swirski, R. Weissleder and M. Nahrendorf 
(2012). "Rapid monocyte kinetics in acute myocardial infarction are sustained by 
extramedullary monocytopoiesis." The Journal of experimental medicine 209(1): 
123-137. 
Lewis, C. E., M. De Palma and L. Naldini (2007). "Tie2-expressing monocytes and tumor 
angiogenesis: regulation by hypoxia and angiopoietin-2." Cancer research 67(18): 
8429-8432. 
Li, B. and C. N. Dewey (2011). "RSEM: accurate transcript quantification from RNA-Seq data 
with or without a reference genome." BMC bioinformatics 12: 323. 
Lucas, D., C. Scheiermann, A. Chow, Y. Kunisaki, I. Bruns, C. Barrick, L. Tessarollo and P. S. 
Frenette (2013). "Chemotherapy-induced bone marrow nerve injury impairs 
hematopoietic regeneration." Nature medicine 19(6): 695-703. 
Lucas, T., A. Waisman, R. Ranjan, J. Roes, T. Krieg, W. Muller, A. Roers and S. A. Eming 
(2010). "Differential roles of macrophages in diverse phases of skin repair." Journal 
of immunology 184(7): 3964-3977. 
Mantovani, A., S. K. Biswas, M. R. Galdiero, A. Sica and M. Locati (2013). "Macrophage 
plasticity and polarization in tissue repair and remodelling." The Journal of 
pathology 229(2): 176-185. 
BIBLIOGRAPHY 
 
152 
 
Mantovani, A., A. Sica and M. Locati (2005). "Macrophage polarization comes of age." 
Immunity 23(4): 344-346. 
Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi and M. Locati (2004). "The 
chemokine system in diverse forms of macrophage activation and polarization." 
Trends in immunology 25(12): 677-686. 
Martinez, F. O., A. Sica, A. Mantovani and M. Locati (2008). "Macrophage activation and 
polarization." Frontiers in bioscience : a journal and virtual library 13: 453-461. 
Maruyama, K., M. Ii, C. Cursiefen, D. G. Jackson, H. Keino, M. Tomita, N. Van Rooijen, H. 
Takenaka, P. A. D'Amore, J. Stein-Streilein, D. W. Losordo and J. W. Streilein (2005). 
"Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive 
macrophages." The Journal of clinical investigation 115(9): 2363-2372. 
Matsubara, T., T. Kanto, S. Kuroda, S. Yoshio, K. Higashitani, N. Kakita, M. Miyazaki, M. 
Sakakibara, N. Hiramatsu, A. Kasahara, Y. Tomimaru, A. Tomokuni, H. Nagano, N. 
Hayashi and T. Takehara (2013). "TIE2-expressing monocytes as a diagnostic marker 
for hepatocellular carcinoma correlates with angiogenesis." Hepatology 57(4): 1416-
1425. 
Maus, U. A., M. A. Koay, T. Delbeck, M. Mack, M. Ermert, L. Ermert, T. S. Blackwell, J. W. 
Christman, D. Schlondorff, W. Seeger and J. Lohmeyer (2002). "Role of resident 
alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice." 
American journal of physiology. Lung cellular and molecular physiology 282(6): 
L1245-1252. 
Mazur, P. (1970). "Cryobiology: the freezing of biological systems." Science 168(3934): 939-
949. 
Mazzieri, R., F. Pucci, D. Moi, E. Zonari, A. Ranghetti, A. Berti, L. S. Politi, B. Gentner, J. L. 
Brown, L. Naldini and M. De Palma (2011). "Targeting the ANG2/TIE2 axis inhibits 
tumor growth and metastasis by impairing angiogenesis and disabling rebounds of 
proangiogenic myeloid cells." Cancer cell 19(4): 512-526. 
McKenney, J. K., S. W. Weiss and A. L. Folpe (2001). "CD31 expression in intratumoral 
macrophages: a potential diagnostic pitfall." The American journal of surgical 
pathology 25(9): 1167-1173. 
Medina-Contreras, O., D. Geem, O. Laur, I. R. Williams, S. A. Lira, A. Nusrat, C. A. Parkos and 
T. L. Denning (2011). "CX3CR1 regulates intestinal macrophage homeostasis, 
bacterial translocation, and colitogenic Th17 responses in mice." The Journal of 
clinical investigation 121(12): 4787-4795. 
Medina, I., J. Carbonell, L. Pulido, S. C. Madeira, S. Goetz, A. Conesa, J. Tarraga, A. Pascual-
Montano, R. Nogales-Cadenas, J. Santoyo, F. Garcia, M. Marba, D. Montaner and J. 
Dopazo (2010). "Babelomics: an integrative platform for the analysis of 
transcriptomics, proteomics and genomic data with advanced functional profiling." 
Nucleic acids research 38(Web Server issue): W210-213. 
Menghini, R., V. Casagrande, S. Menini, A. Marino, V. Marzano, M. L. Hribal, P. Gentileschi, 
D. Lauro, O. Schillaci, G. Pugliese, P. Sbraccia, A. Urbani, R. Lauro and M. Federici 
(2012). "TIMP3 overexpression in macrophages protects from insulin resistance, 
adipose inflammation, and nonalcoholic fatty liver disease in mice." Diabetes 61(2): 
454-462. 
Meyer, G. P., K. C. Wollert, J. Lotz, J. Steffens, P. Lippolt, S. Fichtner, H. Hecker, A. Schaefer, 
L. Arseniev, B. Hertenstein, A. Ganser and H. Drexler (2006). "Intracoronary bone 
marrow cell transfer after myocardial infarction: eighteen months' follow-up data 
from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-
elevation infarct regeneration) trial." Circulation 113(10): 1287-1294. 
BIBLIOGRAPHY 
 
153 
 
Mirza, R., L. A. DiPietro and T. J. Koh (2009). "Selective and specific macrophage ablation is 
detrimental to wound healing in mice." The American journal of pathology 175(6): 
2454-2462. 
Modarai, B., K. G. Burnand, B. Sawyer and A. Smith (2005). "Endothelial progenitor cells are 
recruited into resolving venous thrombi." Circulation 111(20): 2645-2653. 
Morimoto, H., M. Takahashi, A. Izawa, H. Ise, M. Hongo, P. E. Kolattukudy and U. Ikeda 
(2006). "Cardiac overexpression of monocyte chemoattractant protein-1 in 
transgenic mice prevents cardiac dysfunction and remodeling after myocardial 
infarction." Circulation research 99(8): 891-899. 
Mosser, D. M. and J. P. Edwards (2008). "Exploring the full spectrum of macrophage 
activation." Nature reviews. Immunology 8(12): 958-969. 
Motoike, T., S. Loughna, E. Perens, B. L. Roman, W. Liao, T. C. Chau, C. D. Richardson, T. 
Kawate, J. Kuno, B. M. Weinstein, D. Y. Stainier and T. N. Sato (2000). "Universal GFP 
reporter for the study of vascular development." Genesis 28(2): 75-81. 
Moyer, A. L. and K. R. Wagner (2011). "Regeneration versus fibrosis in skeletal muscle." 
Current opinion in rheumatology 23(6): 568-573. 
Murdoch, C., M. Muthana, S. B. Coffelt and C. E. Lewis (2008). "The role of myeloid cells in 
the promotion of tumour angiogenesis." Nature reviews. Cancer 8(8): 618-631. 
Murray, P. J. and T. A. Wynn (2011). "Protective and pathogenic functions of macrophage 
subsets." Nature reviews. Immunology 11(11): 723-737. 
Musaro, A., C. Giacinti, L. Pelosi, G. Dobrowolny, L. Barberi, C. Nardis, D. Coletti, B. M. 
Scicchitano, S. Adamo and M. Molinaro (2007). "Stem cell-mediated muscle 
regeneration and repair in aging and neuromuscular diseases." European journal of 
histochemistry : EJH 51 Suppl 1: 35-43. 
Nahrendorf, M., M. J. Pittet and F. K. Swirski (2010). "Monocytes: protagonists of infarct 
inflammation and repair after myocardial infarction." Circulation 121(22): 2437-
2445. 
Nahrendorf, M. and F. K. Swirski (2013). "Monocyte and macrophage heterogeneity in the 
heart." Circulation research 112(12): 1624-1633. 
Nahrendorf, M., F. K. Swirski, E. Aikawa, L. Stangenberg, T. Wurdinger, J. L. Figueiredo, P. 
Libby, R. Weissleder and M. J. Pittet (2007). "The healing myocardium sequentially 
mobilizes two monocyte subsets with divergent and complementary functions." The 
Journal of experimental medicine 204(12): 3037-3047. 
Naik, S. H., P. Sathe, H. Y. Park, D. Metcalf, A. I. Proietto, A. Dakic, S. Carotta, M. O'Keeffe, M. 
Bahlo, A. Papenfuss, J. Y. Kwak, L. Wu and K. Shortman (2007). "Development of 
plasmacytoid and conventional dendritic cell subtypes from single precursor cells 
derived in vitro and in vivo." Nature immunology 8(11): 1217-1226. 
Nimmerjahn, A., F. Kirchhoff and F. Helmchen (2005). "Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo." Science 308(5726): 1314-1318. 
Novak, M. L. and T. J. Koh (2013). "Macrophage phenotypes during tissue repair." Journal of 
leukocyte biology 93(6): 875-881. 
Novak, M. L. and T. J. Koh (2013). "Phenotypic transitions of macrophages orchestrate tissue 
repair." The American journal of pathology 183(5): 1352-1363. 
Ohmori, Y. and T. A. Hamilton (1997). "IL-4-induced STAT6 suppresses IFN-gamma-
stimulated STAT1-dependent transcription in mouse macrophages." Journal of 
immunology 159(11): 5474-5482. 
Onai, N., A. Obata-Onai, M. A. Schmid, T. Ohteki, D. Jarrossay and M. G. Manz (2007). 
"Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional 
BIBLIOGRAPHY 
 
154 
 
dendritic cell progenitors in mouse bone marrow." Nature immunology 8(11): 1207-
1216. 
Orlic, D., J. Kajstura, S. Chimenti, F. Limana, I. Jakoniuk, F. Quaini, B. Nadal-Ginard, D. M. 
Bodine, A. Leri and P. Anversa (2001). "Mobilized bone marrow cells repair the 
infarcted heart, improving function and survival." Proceedings of the National 
Academy of Sciences of the United States of America 98(18): 10344-10349. 
Panizzi, P., F. K. Swirski, J. L. Figueiredo, P. Waterman, D. E. Sosnovik, E. Aikawa, P. Libby, M. 
Pittet, R. Weissleder and M. Nahrendorf (2010). "Impaired infarct healing in 
atherosclerotic mice with Ly-6C(hi) monocytosis." Journal of the American College of 
Cardiology 55(15): 1629-1638. 
Patel, A. S., A. Smith, S. Nucera, D. Biziato, P. Saha, R. Q. Attia, J. Humphries, K. Mattock, S. P. 
Grover, O. T. Lyons, L. G. Guidotti, R. Siow, A. Ivetic, S. Egginton, M. Waltham, L. 
Naldini, M. De Palma and B. Modarai (2013). "TIE2-expressing 
monocytes/macrophages regulate revascularization of the ischemic limb." EMBO 
molecular medicine 5(6): 858-869. 
Peirce, S. M. and T. C. Skalak (2003). "Microvascular remodeling: a complex continuum 
spanning angiogenesis to arteriogenesis." Microcirculation 10(1): 99-111. 
Pelosi, L., C. Giacinti, C. Nardis, G. Borsellino, E. Rizzuto, C. Nicoletti, F. Wannenes, L. 
Battistini, N. Rosenthal, M. Molinaro and A. Musaro (2007). "Local expression of IGF-
1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines 
and chemokines." FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 21(7): 1393-1402. 
Petit, I., D. Jin and S. Rafii (2007). "The SDF-1-CXCR4 signaling pathway: a molecular hub 
modulating neo-angiogenesis." Trends in immunology 28(7): 299-307. 
Pfeffer, M. A. and E. Braunwald (1990). "Ventricular remodeling after myocardial infarction. 
Experimental observations and clinical implications." Circulation 81(4): 1161-1172. 
Piecewicz, S. M., A. Pandey, B. Roy, S. H. Xiang, B. R. Zetter and S. Sengupta (2012). "Insulin-
like growth factors promote vasculogenesis in embryonic stem cells." PloS one 7(2): 
e32191. 
Pinto, A. R., R. Paolicelli, E. Salimova, J. Gospocic, E. Slonimsky, D. Bilbao-Cortes, J. W. 
Godwin and N. A. Rosenthal (2012). "An abundant tissue macrophage population in 
the adult murine heart with a distinct alternatively-activated macrophage profile." 
PloS one 7(5): e36814. 
Pollard, J. W. (2009). "Trophic macrophages in development and disease." Nature reviews. 
Immunology 9(4): 259-270. 
Porrello, E. R., A. I. Mahmoud, E. Simpson, J. A. Hill, J. A. Richardson, E. N. Olson and H. A. 
Sadek (2011). "Transient regenerative potential of the neonatal mouse heart." 
Science 331(6020): 1078-1080. 
Pucci, F., M. A. Venneri, D. Biziato, A. Nonis, D. Moi, A. Sica, C. Di Serio, L. Naldini and M. De 
Palma (2009). "A distinguishing gene signature shared by tumor-infiltrating Tie2-
expressing monocytes, blood "resident" monocytes, and embryonic macrophages 
suggests common functions and developmental relationships." Blood 114(4): 901-
914. 
Rae, F., K. Woods, T. Sasmono, N. Campanale, D. Taylor, D. A. Ovchinnikov, S. M. Grimmond, 
D. A. Hume, S. D. Ricardo and M. H. Little (2007). "Characterisation and trophic 
functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP 
transgene reporter." Developmental biology 308(1): 232-246. 
BIBLIOGRAPHY 
 
155 
 
Reffelmann, T., S. L. Hale, J. S. Dow and R. A. Kloner (2003). "No-reflow phenomenon persists 
long-term after ischemia/reperfusion in the rat and predicts infarct expansion." 
Circulation 108(23): 2911-2917. 
Rehman, J., J. Li, C. M. Orschell and K. L. March (2003). "Peripheral blood "endothelial 
progenitor cells" are derived from monocyte/macrophages and secrete angiogenic 
growth factors." Circulation 107(8): 1164-1169. 
Ren, G., L. H. Michael, M. L. Entman and N. G. Frangogiannis (2002). "Morphological 
Characteristics of the Microvasculature in Healing Myocardial Infarcts." Journal of 
Histochemistry & Cytochemistry 50(1): 71-79. 
Roell, W., Z. J. Lu, W. Bloch, S. Siedner, K. Tiemann, Y. Xia, E. Stoecker, M. Fleischmann, H. 
Bohlen, R. Stehle, E. Kolossov, G. Brem, K. Addicks, G. Pfitzer, A. Welz, J. Hescheler 
and B. K. Fleischmann (2002). "Cellular cardiomyoplasty improves survival after 
myocardial injury." Circulation 105(20): 2435-2441. 
Ruckh, J. M., J. W. Zhao, J. L. Shadrach, P. van Wijngaarden, T. N. Rao, A. J. Wagers and R. J. 
Franklin (2012). "Rejuvenation of regeneration in the aging central nervous system." 
Cell stem cell 10(1): 96-103. 
Sabin, F. R. (1925). "The Opportunity of Anatomy." Science 61(1585): 499-507. 
Salto-Tellez, M., S. Yung Lim, R. M. El-Oakley, T. P. Tang, A. L. ZA and S. K. Lim (2004). 
"Myocardial infarction in the C57BL/6J mouse: a quantifiable and highly 
reproducible experimental model." Cardiovascular pathology : the official journal of 
the Society for Cardiovascular Pathology 13(2): 91-97. 
Santini, M. P., L. Tsao, L. Monassier, C. Theodoropoulos, J. Carter, E. Lara-Pezzi, E. Slonimsky, 
E. Salimova, P. Delafontaine, Y. H. Song, M. Bergmann, C. Freund, K. Suzuki and N. 
Rosenthal (2007). "Enhancing repair of the mammalian heart." Circulation research 
100(12): 1732-1740. 
Satoh, T., O. Takeuchi, A. Vandenbon, K. Yasuda, Y. Tanaka, Y. Kumagai, T. Miyake, K. 
Matsushita, T. Okazaki, T. Saitoh, K. Honma, T. Matsuyama, K. Yui, T. Tsujimura, D. 
M. Standley, K. Nakanishi, K. Nakai and S. Akira (2010). "The Jmjd3-Irf4 axis regulates 
M2 macrophage polarization and host responses against helminth infection." Nature 
immunology 11(10): 936-944. 
Schlaeger, T. M., S. Bartunkova, J. A. Lawitts, G. Teichmann, W. Risau, U. Deutsch and T. N. 
Sato (1997). "Uniform vascular-endothelial-cell-specific gene expression in both 
embryonic and adult transgenic mice." Proceedings of the National Academy of 
Sciences of the United States of America 94(7): 3058-3063. 
Schledzewski, K., M. Falkowski, G. Moldenhauer, P. Metharom, J. Kzhyshkowska, R. Ganss, A. 
Demory, B. Falkowska-Hansen, H. Kurzen, S. Ugurel, G. Geginat, B. Arnold and S. 
Goerdt (2006). "Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is 
expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and 
wound healing tissue in vivo and in bone marrow cultures in vitro: implications for 
the assessment of lymphangiogenesis." The Journal of pathology 209(1): 67-77. 
Schulz, C., E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, M. 
Prinz, B. Wu, S. E. Jacobsen, J. W. Pollard, J. Frampton, K. J. Liu and F. Geissmann 
(2012). "A lineage of myeloid cells independent of Myb and hematopoietic stem 
cells." Science 336(6077): 86-90. 
Segarra, M., H. Ohnuki, D. Maric, O. Salvucci, X. Hou, A. Kumar, X. Li and G. Tosato (2012). 
"Semaphorin 6A regulates angiogenesis by modulating VEGF signaling." Blood 
120(19): 4104-4115. 
Semenova, E., H. Koegel, S. Hasse, J. E. Klatte, E. Slonimsky, D. Bilbao, R. Paus, S. Werner and 
N. Rosenthal (2008). "Overexpression of mIGF-1 in keratinocytes improves wound 
BIBLIOGRAPHY 
 
156 
 
healing and accelerates hair follicle formation and cycling in mice." The American 
journal of pathology 173(5): 1295-1310. 
Serbina, N. V. and E. G. Pamer (2006). "Monocyte emigration from bone marrow during 
bacterial infection requires signals mediated by chemokine receptor CCR2." Nature 
immunology 7(3): 311-317. 
Shahrara, S., M. V. Volin, M. A. Connors, G. K. Haines and A. E. Koch (2002). "Differential 
expression of the angiogenic Tie receptor family in arthritic and normal synovial 
tissue." Arthritis research 4(3): 201-208. 
Sica, A. and A. Mantovani (2012). "Macrophage plasticity and polarization: in vivo veritas." 
The Journal of clinical investigation 122(3): 787-795. 
Song, K., Y. J. Nam, X. Luo, X. Qi, W. Tan, G. N. Huang, A. Acharya, C. L. Smith, M. D. Tallquist, 
E. G. Neilson, J. A. Hill, R. Bassel-Duby and E. N. Olson (2012). "Heart repair by 
reprogramming non-myocytes with cardiac transcription factors." Nature 485(7400): 
599-604. 
Soonpaa, M. H. and L. J. Field (1994). "Assessment of cardiomyocyte DNA synthesis during 
hypertrophy in adult mice." The American journal of physiology 266(4 Pt 2): H1439-
1445. 
Stanley, E. R. (2009). "Lineage commitment: cytokines instruct, at last!" Cell stem cell 5(3): 
234-236. 
Stockmann, C., A. Doedens, A. Weidemann, N. Zhang, N. Takeda, J. I. Greenberg, D. A. 
Cheresh and R. S. Johnson (2008). "Deletion of vascular endothelial growth factor in 
myeloid cells accelerates tumorigenesis." Nature 456(7223): 814-818. 
Sturn, A., J. Quackenbush and Z. Trajanoski (2002). "Genesis: cluster analysis of microarray 
data." Bioinformatics 18(1): 207-208. 
Sunderkotter, C., K. Steinbrink, M. Goebeler, R. Bhardwaj and C. Sorg (1994). "Macrophages 
and angiogenesis." Journal of leukocyte biology 55(3): 410-422. 
Sweet, M. J. and D. A. Hume (2003). "CSF-1 as a regulator of macrophage activation and 
immune responses." Archivum immunologiae et therapiae experimentalis 51(3): 
169-177. 
Swirski, F. K., P. Libby, E. Aikawa, P. Alcaide, F. W. Luscinskas, R. Weissleder and M. J. Pittet 
(2007). "Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis 
and give rise to macrophages in atheromata." The Journal of clinical investigation 
117(1): 195-205. 
Swirski, F. K., M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J. L. 
Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E. Aikawa, T. R. Mempel, P. 
Libby, R. Weissleder and M. J. Pittet (2009). "Identification of splenic reservoir 
monocytes and their deployment to inflammatory sites." Science 325(5940): 612-
616. 
Szekanecz, Z., G. K. Haines, T. R. Lin, L. A. Harlow, S. Goerdt, G. Rayan and A. E. Koch (1994). 
"Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and 
ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible 
pathogenetic and clinical significance in rheumatoid arthritis." Arthritis and 
rheumatism 37(2): 221-231. 
Takeda, Y., S. Costa, E. Delamarre, C. Roncal, R. Leite de Oliveira, M. L. Squadrito, V. 
Finisguerra, S. Deschoemaeker, F. Bruyere, M. Wenes, A. Hamm, J. Serneels, J. 
Magat, T. Bhattacharyya, A. Anisimov, B. F. Jordan, K. Alitalo, P. Maxwell, B. Gallez, 
Z. W. Zhuang, Y. Saito, M. Simons, M. De Palma and M. Mazzone (2011). 
"Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing 
arteriogenesis." Nature 479(7371): 122-126. 
BIBLIOGRAPHY 
 
157 
 
Titos, E., B. Rius, A. Gonzalez-Periz, C. Lopez-Vicario, E. Moran-Salvador, M. Martinez-
Clemente, V. Arroyo and J. Claria (2011). "Resolvin D1 and its precursor 
docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting 
macrophage polarization toward an M2-like phenotype." Journal of immunology 
187(10): 5408-5418. 
Tongers, J., D. W. Losordo and U. Landmesser (2011). "Stem and progenitor cell-based 
therapy in ischaemic heart disease: promise, uncertainties, and challenges." 
European heart journal 32(10): 1197-1206. 
Uderhardt, S., M. Herrmann, O. V. Oskolkova, S. Aschermann, W. Bicker, N. Ipseiz, K. Sarter, 
B. Frey, T. Rothe, R. Voll, F. Nimmerjahn, V. N. Bochkov, G. Schett and G. Kronke 
(2012). "12/15-lipoxygenase orchestrates the clearance of apoptotic cells and 
maintains immunologic tolerance." Immunity 36(5): 834-846. 
van Amerongen, M. J., M. C. Harmsen, A. H. Petersen, E. R. Popa and M. J. van Luyn (2008). 
"Cryoinjury: a model of myocardial regeneration." Cardiovascular pathology : the 
official journal of the Society for Cardiovascular Pathology 17(1): 23-31. 
van Amerongen, M. J., M. C. Harmsen, N. van Rooijen, A. H. Petersen and M. J. van Luyn 
(2007). "Macrophage depletion impairs wound healing and increases left ventricular 
remodeling after myocardial injury in mice." The American journal of pathology 
170(3): 818-829. 
van den Bos, E. J., B. M. Mees, M. C. de Waard, R. de Crom and D. J. Duncker (2005). "A 
novel model of cryoinjury-induced myocardial infarction in the mouse: a comparison 
with coronary artery ligation." American journal of physiology. Heart and circulatory 
physiology 289(3): H1291-1300. 
van der Laan, A. M., E. N. Ter Horst, R. Delewi, M. P. Begieneman, P. A. Krijnen, A. Hirsch, M. 
Lavaei, M. Nahrendorf, A. J. Horrevoets, H. W. Niessen and J. J. Piek (2014). 
"Monocyte subset accumulation in the human heart following acute myocardial 
infarction and the role of the spleen as monocyte reservoir." European heart journal 
35(6): 376-385. 
van Furth, R. and Z. A. Cohn (1968). "The origin and kinetics of mononuclear phagocytes." 
The Journal of experimental medicine 128(3): 415-435. 
van Furth, R., Z. A. Cohn, J. G. Hirsch, J. H. Humphrey, W. G. Spector and H. L. Langevoort 
(1972). "The mononuclear phagocyte system: a new classification of macrophages, 
monocytes, and their precursor cells." Bulletin of the World Health Organization 
46(6): 845-852. 
van Furth, R., Z. A. Cohn, J. G. Hirsch, J. H. Humphrey, W. G. Spector and H. L. Langevoort 
(1972). "[Mononuclear phagocytic system: new classification of macrophages, 
monocytes and of their cell line]." Bulletin of the World Health Organization 47(5): 
651-658. 
Venneri, M. A., M. De Palma, M. Ponzoni, F. Pucci, C. Scielzo, E. Zonari, R. Mazzieri, C. 
Doglioni and L. Naldini (2007). "Identification of proangiogenic TIE2-expressing 
monocytes (TEMs) in human peripheral blood and cancer." Blood 109(12): 5276-
5285. 
Willenborg, S., T. Lucas, G. van Loo, J. A. Knipper, T. Krieg, I. Haase, B. Brachvogel, M. 
Hammerschmidt, A. Nagy, N. Ferrara, M. Pasparakis and S. A. Eming (2012). "CCR2 
recruits an inflammatory macrophage subpopulation critical for angiogenesis in 
tissue repair." Blood 120(3): 613-625. 
Wynn, T. A., A. Chawla and J. W. Pollard (2013). "Macrophage biology in development, 
homeostasis and disease." Nature 496(7446): 445-455. 
BIBLIOGRAPHY 
 
158 
 
Yasaka, T., N. M. Mantich, L. A. Boxer and R. L. Baehner (1981). "Functions of human 
monocyte and lymphocyte subsets obtained by countercurrent centrifugal 
elutriation: differing functional capacities of human monocyte subsets." Journal of 
immunology 127(4): 1515-1518. 
Yona, S., K. W. Kim, Y. Wolf, A. Mildner, D. Varol, M. Breker, D. Strauss-Ayali, S. Viukov, M. 
Guilliams, A. Misharin, D. A. Hume, H. Perlman, B. Malissen, E. Zelzer and S. Jung 
(2013). "Fate mapping reveals origins and dynamics of monocytes and tissue 
macrophages under homeostasis." Immunity 38(1): 79-91. 
Zak, R. (1974). "Development and proliferative capacity of cardiac muscle cells." Circulation 
research 35(2): suppl II:17-26. 
Zigmond, E., C. Varol, J. Farache, E. Elmaliah, A. T. Satpathy, G. Friedlander, M. Mack, N. 
Shpigel, I. G. Boneca, K. M. Murphy, G. Shakhar, Z. Halpern and S. Jung (2012). "Ly6C 
hi monocytes in the inflamed colon give rise to proinflammatory effector cells and 
migratory antigen-presenting cells." Immunity 37(6): 1076-1090. 
Zolotareva, A. G. and M. E. Kogan (1978). "Production of experimental occlusive myocardial 
infarction in mice." Cor et vasa 20(4): 308-314. 
 
 
 
 
 
 
 
 159 
 
 
 
 
APPENDIX 
  APPENDIX 
 
161 
 
During the research period, the phD candidate has contributed to the following 
publications: 
 
Núñez V, Alameda D, Rico D, Mota R, Gonzalo P, Cedenilla M, Fischer T, Boscá L, 
Glass CK, Arroyo AG, Ricote M. (2010) "Retinoid X receptor alpha controls innate 
inflammatory responses through the up-regulation of chemokine expression". 
Proceedings of the National Academy of Sciences of the United States of America.  
107(23): 10626-10631.   
 
Rőszer T, Menéndez-Gutiérrez MP, Cedenilla M, Ricote M. "Retinoid X receptors in 
macrophage biology". (2013). Trends in endocrinology and metabolism: TEM 24(9): 
460-468. 
 
Thomas Moore-Morris, Nuno Guimarães-Camboa, Indroneal Banerjee, Alexander C.  
Zambon, Tatiana Kisseleva, Aurélie Velayoudon, William B. Stallcup, Yusu Gu, 
Nancy D. Dalton, Marta Cedenilla, Rafael Gomez-Amaro, Bin Zhou, David A. 
Brenner, Kir L. Peterson, Ju Chen & Sylvia M. Evans “Resident fibroblasts are 
principal contributors to   cardiac fibrosis with pressure overload”.  In press in Journal 
of Clinical Investigation. 
 
 
 162 
 
 
 
